% $ biblatex auxiliary file $
% $ biblatex bbl format version 2.4 $
% Do not modify the above lines!
%
% This is an auxiliary file used by the 'biblatex' package.
% This file may safely be deleted. It will be recreated by
% biber as required.
%
\begingroup
\makeatletter
\@ifundefined{ver@biblatex.sty}
  {\@latex@error
     {Missing 'biblatex' package}
     {The bibliography requires the 'biblatex' package.}
      \aftergroup\endinput}
  {}
\endgroup


\refsection{0}
  \sortlist{nyt}{nyt}
    \entry{AbdAlla2001}{article}{}
      \name{labelname}{4}{}{%
        {{uniquename=0,hash=befdfaf0962bce2b9d0ea0005554d07f}{AbdAlla}{A\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a2e92ca9be0684b149e01ea9cb3692c3}{Lother}{L\bibinitperiod}{H}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bdada136abc94d25fb7c2945bcee9b11}{Massiery}{M\bibinitperiod}{A}{A\bibinitperiod}{el}{e\bibinitperiod}{}{}}%
        {{uniquename=0,hash=18f2640ac0ff604fd9719aacbc70ec98}{Quitterer}{Q\bibinitperiod}{U}{U\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{uniquename=0,hash=befdfaf0962bce2b9d0ea0005554d07f}{AbdAlla}{A\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a2e92ca9be0684b149e01ea9cb3692c3}{Lother}{L\bibinitperiod}{H}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bdada136abc94d25fb7c2945bcee9b11}{Massiery}{M\bibinitperiod}{A}{A\bibinitperiod}{el}{e\bibinitperiod}{}{}}%
        {{uniquename=0,hash=18f2640ac0ff604fd9719aacbc70ec98}{Quitterer}{Q\bibinitperiod}{U}{U\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3dcec34ff9989623e81fcb3f6b67e25b}
      \strng{fullhash}{eea8c3679d8a8b63864c38ea583b32d8}
      \field{sortinit}{A}
      \field{sortinithash}{c8a29dea43e9d2645817723335a4dbe8}
      \field{labelyear}{2001}
      \field{labelmonth}{09}
      \field{datelabelsource}{}
      \field{labeltitle}{{Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness.}}
      \field{abstract}{Several examples of functional G-protein-coupled receptor heterodimers have been identified. However, it is not known whether receptor heterodimerization is involved in the pathogenesis of human disorders. Here we show that in preeclamptic hypertensive women, a significant increase in heterodimerization occurs between the AT(1)-receptor for the vasopressor angiotensin II and the B(2)-receptor for the vasodepressor bradykinin. AT(1)-B(2)-receptor heterodimerization in preeclampsia correlated with a 4-5-fold increase in B(2)-receptor protein levels. Expression of the AT(1)-B(2) heterodimer increased the responsiveness to angiotensin II and conferred resistance in AT(1)-receptors to inactivation by reactive oxygen species raised in normotensive and preeclamptic pregnancies. We suggest that AT(1)-B(2) heterodimers contribute to angiotensin II hypersensitivity in preeclampsia. Moreover, we identify preeclampsia as the first disorder associated with altered G-protein-coupled receptor heterodimerization.}
      \field{issn}{1078-8956}
      \field{journaltitle}{Nat Med}
      \field{month}{09}
      \field{number}{9}
      \field{title}{{Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness.}}
      \field{volume}{7}
      \field{year}{2001}
      \field{pages}{1003\bibrangedash 9}
      \verb{doi}
      \verb 10.1038/nm0901-1003
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/11533702
      \endverb
      \keyw{Adult,Angiotensin II,Angiotensin II: metabolism,Angiotensin II: pharmacology,Blood Platelets,Blood Platelets: drug effects,Blood Platelets: metabolism,Blood Vessels,Blood Vessels: drug effects,Blood Vessels: metabolism,Case-Control Studies,Cells,Cultured,Dimerization,Female,GTP-Binding Proteins,GTP-Binding Proteins: metabolism,Humans,Omentum,Omentum: blood supply,Omentum: drug effects,Omentum: metabolism,Pre-Eclampsia,Pre-Eclampsia: drug therapy,Pre-Eclampsia: metabolism,Pregnancy,Reactive Oxygen Species,Reactive Oxygen Species: metabolism,Receptor,Angiotensin,Type 1,Receptor,Angiotensin,Type 2,Receptor,Bradykinin B2,Receptors,Angiotensin,Receptors,Angiotensin: drug effects,Receptors,Angiotensin: metabolism,Receptors,Bradykinin,Receptors,Bradykinin: drug effects,Receptors,Bradykinin: metabolism,Signal Transduction}
    \endentry
    \entry{Abraham2004}{article}{}
      \name{labelname}{5}{}{%
        {{uniquename=0,hash=7fe5f11a1a98a9282e46021642930579}{Abraham}{A\bibinitperiod}{Getu}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=23fea64199e4fb69cc301374abd23fdf}{Kneuer}{K\bibinitperiod}{Carsten}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e2843e0a39a296af7215bff3b0844423}{Ehrhardt}{E\bibinitperiod}{Carsten}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=fff951024a69ef645601e304917c62c2}{Honscha}{H\bibinitperiod}{Walther}{W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=444805ad3b6c098ca8c914894fd2bd3d}{Ungemach}{U\bibinitperiod}{Fritz\bibnamedelima R}{F\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{uniquename=0,hash=7fe5f11a1a98a9282e46021642930579}{Abraham}{A\bibinitperiod}{Getu}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=23fea64199e4fb69cc301374abd23fdf}{Kneuer}{K\bibinitperiod}{Carsten}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e2843e0a39a296af7215bff3b0844423}{Ehrhardt}{E\bibinitperiod}{Carsten}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=fff951024a69ef645601e304917c62c2}{Honscha}{H\bibinitperiod}{Walther}{W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=444805ad3b6c098ca8c914894fd2bd3d}{Ungemach}{U\bibinitperiod}{Fritz\bibnamedelima R}{F\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{d9b56f0e124cee8379611a501c8e65e7}
      \strng{fullhash}{9666433cb46609bce40b53a6334618ec}
      \field{sortinit}{A}
      \field{sortinithash}{c8a29dea43e9d2645817723335a4dbe8}
      \field{labelyear}{2004}
      \field{labelmonth}{05}
      \field{datelabelsource}{}
      \field{labeltitle}{{Expression of functional beta2-adrenergic receptors in the lung epithelial cell lines 16HBE14o(-), Calu-3 and A549.}}
      \field{abstract}{Adrenergic drugs acting through the beta(2)-adrenoceptor (beta(2)-AR) adenylate cyclase (AC) signal transduction system elicit a variety of responses within the mammalian airway epithelium; however, its composition of multiple phenotypically differentiated cell types complicates the understanding of the regulation cascades within this tissue. The present study evaluates beta(2)-AR mRNA level, number, subtype and the cyclic adenosine-3',5'-monophosphate (cyclic AMP) response to isoproterenol (iso) in the human airway epithelial cell lines 16HBE14o(-), Calu-3 and A549, using reverse transcriptase polymerase chain reaction (RT-PCR), radioligand binding studies, [(3)H]-radioimmunoassay and immunocytochemical staining. After 4-5 days in culture, all three cell types produced beta(2)-AR mRNA and protein at a magnitude of gene expression levels Calu-3>or=16HBE14o(-)>A549, whereas control cells Cos-1 and Caco-2 were negative. The beta(2)-AR adenylate cyclase system was highly expressed and functional in the human airway epithelial cells Calu-3 and 16HBE14o(-). The mean beta(2)-AR density (B(max)), equilibrium dissociation constant (K(D)), and the percentage of beta-AR subtypes assessed by radioligand binding were approximately 9908+/-1127 and 6423+/-895 binding sites/cell, 32+/-2.7 pM and 25+/-1.1 pM, and approximately 100{\%} in Calu-3 and 16HBE14o(-)cells, respectively. However, in the alveolar cell type A549 the cell surface beta(2)-AR was virtually undetectable by (-)-[(125)I]-iodocyanopindolol (ICYP) binding. Stimulation of cultured cells with (-)-isoproterenol enhanced the basal cyclic AMP accumulation only in Calu-3 and 16HBE14o(-) cells, which was blocked by the beta(2)-selective antagonist ICI 118,551, but not by the beta(1)-selective antagonist CGP 20712A, confirming functional coupling of the beta(2)-AR to adenylate cyclase in these cells. Immunocytochemical staining localised the receptor on the cell membrane and the cytoplasm in Calu-3 and 16HBE14o(-) cells, while it was confined to the cytoplasm only in A549 cells. In conclusion, the beta(2)-AR expression and its functional coupling to adenylyl cyclase was very high in the human airway epithelial cells Calu-3 and 16HBE14o(-), but not in A549, suggesting that the cell lines Calu-3 and 16HBE14o(-) present suitable models to study function and regulation of the beta-adrenoceptor signalling in the respiratory system.}
      \field{issn}{0006-3002}
      \field{journaltitle}{Biochim Biophys Acta}
      \field{month}{05}
      \field{number}{2-3}
      \field{title}{{Expression of functional beta2-adrenergic receptors in the lung epithelial cell lines 16HBE14o(-), Calu-3 and A549.}}
      \field{volume}{1691}
      \field{year}{2004}
      \field{pages}{169\bibrangedash 79}
      \verb{doi}
      \verb 10.1016/j.bbamcr.2004.02.002
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2004/Abraham et al/Abraham et al. - 2004 - Expression of functional beta2-adrenergic receptors in the lung epithelial cell lines 16HBE14o(-), Calu-3 and A5.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/15110997
      \endverb
      \keyw{Adenylate Cyclase,Adenylate Cyclase: metabolism,Adrenergic beta-Agonists,Adrenergic beta-Agonists: metabolism,Adrenergic beta-Antagonists,Adrenergic beta-Antagonists: metabolism,Animals,Cell Line,Cyclic AMP,Cyclic AMP: metabolism,Dose-Response Relationship,Drug,Epithelial Cells,Epithelial Cells: cytology,Epithelial Cells: metabolism,Humans,Iodocyanopindolol,Iodocyanopindolol: metabolism,Isoproterenol,Isoproterenol: metabolism,Lung,Lung: cytology,Lung: metabolism,Protein Isoforms,Protein Isoforms: genetics,Protein Isoforms: metabolism,Radioligand Assay,Receptors,Adrenergic,beta-2,Receptors,Adrenergic,beta-2: genetics,Receptors,Adrenergic,beta-2: metabolism}
    \endentry
    \entry{Ahles2011}{article}{}
      \name{labelname}{5}{}{%
        {{uniquename=0,hash=30f5bce5a067a09644d7a7f741c77cc9}{Ahles}{A\bibinitperiod}{Andrea}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d167f7a91ee7324160c05fe146f2cae3}{Rochais}{R\bibinitperiod}{Francesca}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=54fb9c3761e724a81a31f27e35e29d68}{Frambach}{F\bibinitperiod}{Torsten}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f39e29f598b25bb1d3ead141b888bdd0}{B{ü}nemann}{B\bibinitperiod}{Moritz}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=acaea11c14b745fade9d24235dd48bae}{Engelhardt}{E\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{uniquename=0,hash=30f5bce5a067a09644d7a7f741c77cc9}{Ahles}{A\bibinitperiod}{Andrea}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d167f7a91ee7324160c05fe146f2cae3}{Rochais}{R\bibinitperiod}{Francesca}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=54fb9c3761e724a81a31f27e35e29d68}{Frambach}{F\bibinitperiod}{Torsten}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f39e29f598b25bb1d3ead141b888bdd0}{B{ü}nemann}{B\bibinitperiod}{Moritz}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=acaea11c14b745fade9d24235dd48bae}{Engelhardt}{E\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{5707c5b37190a9d4c271539c5feb077a}
      \strng{fullhash}{a63b800e7de2780618b16bd270075415}
      \field{sortinit}{A}
      \field{sortinithash}{c8a29dea43e9d2645817723335a4dbe8}
      \field{labelyear}{2011}
      \field{labelmonth}{08}
      \field{datelabelsource}{}
      \field{labeltitle}{{A polymorphism-specific "memory" mechanism in the $\beta$(2)-adrenergic receptor.}}
      \field{abstract}{Signaling through G protein (heterotrimeric guanosine triphosphate-binding protein)-coupled receptors is affected by polymorphisms in receptor-encoding genes. Using fluorescence resonance energy transfer, we found that the $\beta$(2)-adrenergic receptor ($\beta$(2)AR) responded to repeated activation with altered activation kinetics. Polymorphic variants of the $\beta$(2)AR displayed divergent changes of $\beta$(2)AR activation kinetics that closely mimicked their different efficacies to generate cyclic adenosine 3',5'-monophosphate. More efficacious variants became faster in their activation kinetics, whereas less efficacious variants became slower, compared to their initial activation. These differences depended on phosphorylation of the receptor by G protein-coupled receptor kinases. Our findings suggest an intrinsic, polymorphism-specific property of the $\beta$(2)AR that alters activation kinetics upon continued stimulation and that may account for individual drug responses.}
      \field{issn}{1937-9145}
      \field{journaltitle}{Sci Signal}
      \field{month}{08}
      \field{number}{185}
      \field{title}{{A polymorphism-specific "memory" mechanism in the $\beta$(2)-adrenergic receptor.}}
      \field{volume}{4}
      \field{year}{2011}
      \field{pages}{ra53}
      \verb{doi}
      \verb 10.1126/scisignal.2001681
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2011/Ahles et al/Ahles et al. - 2011 - A polymorphism-specific memory mechanism in the $\beta$(2)-adrenergic receptor.pdf:pdf
      \endverb
      \verb{url}
      \verb http://stke.sciencemag.org/cgi/doi/10.1126/scisignal.2001681%20http://www.ncbi.nlm.nih.gov/pubmed/21868359
      \endverb
    \endentry
    \entry{Albizu2010}{article}{}
      \name{labelname}{19}{}{%
        {{uniquename=0,hash=d0c53dc31e957130274b15205768df98}{Albizu}{A\bibinitperiod}{Laura}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6c3b851874e0dcad28edb2db00d78d7f}{Cottet}{C\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f9d7adf43d2920a0c4a24ca38ae56761}{Kralikova}{K\bibinitperiod}{Michaela}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9edc6b8c9047344bebe1c42e68819fe2}{Stoev}{S\bibinitperiod}{Stoytcho}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=84620f81c65f21110259928d45b6d6d3}{Seyer}{S\bibinitperiod}{Ren{é}}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b97fc98363be580247e5c6576487a574}{Brabet}{B\bibinitperiod}{Isabelle}{I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b8e5d1a171939e8cda64e24c38e6c849}{Roux}{R\bibinitperiod}{Thomas}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9501218f1053c238e5c2da3a94f50383}{Bazin}{B\bibinitperiod}{Herv{é}}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6c342792fc270b296facafd4add2ee26}{Bourrier}{B\bibinitperiod}{Emmanuel}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=72fb7cd45e5626359e483f4760c86fb5}{Lamarque}{L\bibinitperiod}{Laurent}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4f7c56f85db286a868a76861c29e7ded}{Breton}{B\bibinitperiod}{Christophe}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4dfff3a27c88189c7289b3c001aa16cd}{Rives}{R\bibinitperiod}{Marie-Laure}{M\bibinithyphendelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5d96b4aa35f381de98ce66170ea22e1e}{Newman}{N\bibinitperiod}{Amy}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=25bb0130ad97cdddfd7d211a4fefd388}{Javitch}{J\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2256344e7e48a51afd66ddff0072d45b}{Trinquet}{T\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=88eb2cbe649d13506cf674c5ad0ef3be}{Manning}{M\bibinitperiod}{Maurice}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3ed411e8b5ac2a31843c53f8ca1350a7}{Mouillac}{M\bibinitperiod}{Bernard}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b176a802ab7b11c217ab95a7ad84d820}{Durroux}{D\bibinitperiod}{Thierry}{T\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{19}{}{%
        {{uniquename=0,hash=d0c53dc31e957130274b15205768df98}{Albizu}{A\bibinitperiod}{Laura}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6c3b851874e0dcad28edb2db00d78d7f}{Cottet}{C\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f9d7adf43d2920a0c4a24ca38ae56761}{Kralikova}{K\bibinitperiod}{Michaela}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9edc6b8c9047344bebe1c42e68819fe2}{Stoev}{S\bibinitperiod}{Stoytcho}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=84620f81c65f21110259928d45b6d6d3}{Seyer}{S\bibinitperiod}{Ren{é}}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b97fc98363be580247e5c6576487a574}{Brabet}{B\bibinitperiod}{Isabelle}{I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b8e5d1a171939e8cda64e24c38e6c849}{Roux}{R\bibinitperiod}{Thomas}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9501218f1053c238e5c2da3a94f50383}{Bazin}{B\bibinitperiod}{Herv{é}}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6c342792fc270b296facafd4add2ee26}{Bourrier}{B\bibinitperiod}{Emmanuel}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=72fb7cd45e5626359e483f4760c86fb5}{Lamarque}{L\bibinitperiod}{Laurent}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4f7c56f85db286a868a76861c29e7ded}{Breton}{B\bibinitperiod}{Christophe}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4dfff3a27c88189c7289b3c001aa16cd}{Rives}{R\bibinitperiod}{Marie-Laure}{M\bibinithyphendelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5d96b4aa35f381de98ce66170ea22e1e}{Newman}{N\bibinitperiod}{Amy}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=25bb0130ad97cdddfd7d211a4fefd388}{Javitch}{J\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2256344e7e48a51afd66ddff0072d45b}{Trinquet}{T\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=88eb2cbe649d13506cf674c5ad0ef3be}{Manning}{M\bibinitperiod}{Maurice}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3ed411e8b5ac2a31843c53f8ca1350a7}{Mouillac}{M\bibinitperiod}{Bernard}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b176a802ab7b11c217ab95a7ad84d820}{Durroux}{D\bibinitperiod}{Thierry}{T\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{d763eaccc333dd4184b6b0e6300d3ac9}
      \strng{fullhash}{423b5bc80db08f4f40888f1406c20e96}
      \field{sortinit}{A}
      \field{sortinithash}{c8a29dea43e9d2645817723335a4dbe8}
      \field{labelyear}{2010}
      \field{labelmonth}{08}
      \field{datelabelsource}{}
      \field{labeltitle}{{Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.}}
      \field{abstract}{G protein-coupled receptor (GPCR) oligomers have been proposed to play critical roles in cell signaling, but confirmation of their existence in a native context remains elusive, as no direct interactions between receptors have been reported. To demonstrate their presence in native tissues, we developed a time-resolved FRET strategy that is based on receptor labeling with selective fluorescent ligands. Specific FRET signals were observed with four different receptors expressed in cell lines, consistent with their dimeric or oligomeric nature in these transfected cells. More notably, the comparison between FRET signals measured with sets of fluorescent agonists and antagonists was consistent with an asymmetric relationship of the two protomers in an activated GPCR dimer. Finally, we applied the strategy to native tissues and succeeded in demonstrating the presence of oxytocin receptor dimers and/or oligomers in mammary gland.}
      \field{issn}{1552-4469}
      \field{journaltitle}{Nat Chem Biol}
      \field{month}{08}
      \field{number}{8}
      \field{title}{{Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.}}
      \field{volume}{6}
      \field{year}{2010}
      \field{pages}{587\bibrangedash 94}
      \verb{doi}
      \verb 10.1038/nchembio.396
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2010/Albizu et al/Albizu et al. - 2010 - Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.pdf:pdf;:Users/ska/Documents/thesis/literature/2010/Albizu et al/Albizu et al. - 2010 - Time-resolved FRET between GPCR ligands reveals oligomers in native tissues(2).pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/20622858
      \endverb
      \keyw{Algorithms,Animal,Animal: metabolism,Animals,COS Cells,Cell Line,Cercopithecus aethiops,Dimerization,Dopamine D2,Dopamine D2: agonists,Dopamine D2: antagonists {\&} inhibitors,Dopamine D2: metabolism,Female,Fluorescence Resonance Energy Transfer,Fluorescence Resonance Energy Transfer: methods,Fluorescent Dyes,G-Protein-Coupled,G-Protein-Coupled: agonists,G-Protein-Coupled: antagonists {\&} inhibi,G-Protein-Coupled: metabolism,Ligands,Mammary Glands,Models,Molecular,Oligopeptides,Oligopeptides: chemistry,Oligopeptides: metabolism,Oxytocin,Oxytocin: agonists,Oxytocin: antagonists {\&} inhibitors,Oxytocin: metabolism,Radioligand Assay,Rats,Receptors,Vasopressin,Vasopressin: agonists,Vasopressin: antagonists {\&} inhibitors,Vasopressin: metabolism}
    \endentry
    \entry{Angers2000}{article}{}
      \name{labelname}{7}{}{%
        {{uniquename=0,hash=11c1a1bf16ccbbfee146c513022fcc03}{Angers}{A\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=101ff2692e3e71f8361d212424da7c7f}{Salahpour}{S\bibinitperiod}{a}{a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=32220a8adc0e38cf77b8cbbfd36ff161}{Joly}{J\bibinitperiod}{E}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bf35841456d3bffa359d0bf34a9f73ca}{Hilairet}{H\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=730f9e1ee6833a174a8935a03979ed6d}{Chelsky}{C\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=eddb4011ee87a01590b9fb261d3294af}{Dennis}{D\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c65aaf3405b44a897e3073f4c531aed7}{Bouvier}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{uniquename=0,hash=11c1a1bf16ccbbfee146c513022fcc03}{Angers}{A\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=101ff2692e3e71f8361d212424da7c7f}{Salahpour}{S\bibinitperiod}{a}{a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=32220a8adc0e38cf77b8cbbfd36ff161}{Joly}{J\bibinitperiod}{E}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bf35841456d3bffa359d0bf34a9f73ca}{Hilairet}{H\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=730f9e1ee6833a174a8935a03979ed6d}{Chelsky}{C\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=eddb4011ee87a01590b9fb261d3294af}{Dennis}{D\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c65aaf3405b44a897e3073f4c531aed7}{Bouvier}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8f7e874d8ab4b49c4260c5fdde3ca414}
      \strng{fullhash}{93681d971d36f49ae5621da92cfa0fe5}
      \field{sortinit}{A}
      \field{sortinithash}{c8a29dea43e9d2645817723335a4dbe8}
      \field{labelyear}{2000}
      \field{labelmonth}{03}
      \field{datelabelsource}{}
      \field{labeltitle}{{Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET).}}
      \field{abstract}{Heptahelical receptors that interact with heterotrimeric G proteins represent the largest family of proteins involved in signal transduction across biological membranes. Although these receptors generally were believed to be monomeric entities, a growing body of evidence suggests that they may form functionally relevant dimers. However, a definitive demonstration of the existence of G protein-coupled receptor (GPCR) dimers at the surface of living cells is still lacking. Here, using bioluminescence resonance energy transfer (BRET), as a protein-protein interaction assay in whole cells, we unambiguously demonstrate that the human beta(2)-adrenergic receptor (beta(2)AR) forms constitutive homodimers when expressed in HEK-293 cells. Receptor stimulation with the hydrophilic agonist isoproterenol led to an increase in the transfer of energy between beta(2)AR molecules genetically fused to the BRET donor (Renilla luciferase) and acceptor (green fluorescent protein), respectively, indicating that the agonist interacts with receptor dimers at the cell surface. Inhibition of receptor internalization did not prevent agonist-promoted BRET, demonstrating that it did not result from clustering of receptors within endosomes. The notion that receptor dimers exist at the cell surface was confirmed further by the observation that BS3, a cell-impermeable cross-linking agent, increased BRET between beta(2)AR molecules. The selectivity of the constitutive interaction was documented by demonstrating that no BRET occurred between the beta(2)AR and two other unrelated GPCR. In contrast, the well characterized agonist-dependent interaction between the beta(2)AR and the regulatory protein beta-arrestin could be monitored by BRET. Taken together, the data demonstrate that GPCR exist as functional dimers in vivo and that BRET-based assays can be used to study both constitutive and hormone-promoted selective protein-protein interactions.}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proc Natl Acad Sci U S A}
      \field{month}{03}
      \field{number}{7}
      \field{title}{{Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET).}}
      \field{volume}{97}
      \field{year}{2000}
      \field{pages}{3684\bibrangedash 9}
      \verb{doi}
      \verb 10.1073/pnas.060590697
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2000/Angers et al/Angers et al. - 2000 - Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy trans.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=16300%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
      \keyw{Animals,Arrestins,Arrestins: metabolism,Cell Line,Cell Membrane,Cell Membrane: metabolism,Dimerization,Energy Transfer,Genetic Vectors,Humans,Luminescent Measurements,Protein Binding,Rats,Receptors,Adrenergic,beta-2,Receptors,Adrenergic,beta-2: chemistry,Receptors,Adrenergic,beta-2: genetics,Receptors,Adrenergic,beta-2: metabolism,Recombinant Fusion Proteins,Recombinant Fusion Proteins: chemistry,Recombinant Fusion Proteins: genetics,Recombinant Fusion Proteins: metabolism}
    \endentry
    \entry{Burford2014}{misc}{}
      \name{labelname}{7}{}{%
        {{uniquename=0,hash=1c7f7cd2847f8695d4dd03b3e6a15b41}{Burford}{B\bibinitperiod}{Neil\bibnamedelima T}{N\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b0e50d0b782f9815ebdb911573d49cdf}{Wehrman}{W\bibinitperiod}{Tom}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1a5577789c36428ca2dea67757dd5087}{Bassoni}{B\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=36a81363727209d46e3f4b25efc57324}{O'Connell}{O\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=df6ed51414597ff3ce382a0bbf01538f}{Banks}{B\bibinitperiod}{Martyn}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ea7349be151fa420c4890073aadc1f6f}{Zhang}{Z\bibinitperiod}{Litao}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=da0bd7a4f39a035b88a58350358a7484}{Alt}{A\bibinitperiod}{Andrew}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{uniquename=0,hash=1c7f7cd2847f8695d4dd03b3e6a15b41}{Burford}{B\bibinitperiod}{Neil\bibnamedelima T}{N\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b0e50d0b782f9815ebdb911573d49cdf}{Wehrman}{W\bibinitperiod}{Tom}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1a5577789c36428ca2dea67757dd5087}{Bassoni}{B\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=36a81363727209d46e3f4b25efc57324}{O'Connell}{O\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=df6ed51414597ff3ce382a0bbf01538f}{Banks}{B\bibinitperiod}{Martyn}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ea7349be151fa420c4890073aadc1f6f}{Zhang}{Z\bibinitperiod}{Litao}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=da0bd7a4f39a035b88a58350358a7484}{Alt}{A\bibinitperiod}{Andrew}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{22cec0f07a129397f9d78c4183d107ca}
      \strng{fullhash}{b7dbe9a5670c7f035d347b0b133d1997}
      \field{sortinit}{B}
      \field{sortinithash}{1a3a21dbed09540af12d49a0b14f4751}
      \field{labelyear}{2014}
      \field{labelmonth}{10}
      \field{datelabelsource}{}
      \field{labeltitle}{{Identification of Selective Agonists and Positive Allosteric Modulators for $\mu$- and $\delta$-Opioid Receptors from a Single High-Throughput Screen.}}
      \field{abstract}{Hetero-oligomeric complexes of G protein-coupled receptors (GPCRs) may represent novel therapeutic targets exhibiting different pharmacology and tissue- or cell-specific site of action compared with receptor monomers or homo-oligomers. An ideal tool for validating this concept pharmacologically would be a hetero-oligomer selective ligand. We set out to develop and execute a 1536-well high-throughput screen of over 1 million compounds to detect potential hetero-oligomer selective ligands using a $\beta$-arrestin recruitment assay in U2OS cells coexpressing recombinant µ- and $\delta$-opioid receptors. Hetero-oligomer selective ligands may bind to orthosteric or allosteric sites, and we might anticipate that the formation of hetero-oligomers may provide novel allosteric binding pockets for ligand binding. Therefore, our goal was to execute the screen in such a way as to identify positive allosteric modulators (PAMs) as well as agonists for µ, $\delta$, and hetero-oligomeric receptors. While no hetero-oligomer selective ligands were identified (based on our selection criteria), this single screen did identify numerous µ- and $\delta$-selective agonists and PAMs as well as nonselective agonists and PAMs. To our knowledge, these are the first µ- and $\delta$-opioid receptor PAMs described in the literature.}
      \field{booktitle}{J Biomol Screen}
      \field{issn}{1552-454X}
      \field{month}{10}
      \field{number}{9}
      \field{title}{{Identification of Selective Agonists and Positive Allosteric Modulators for $\mu$- and $\delta$-Opioid Receptors from a Single High-Throughput Screen.}}
      \field{volume}{19}
      \field{year}{2014}
      \field{pages}{1255\bibrangedash 1265}
      \verb{doi}
      \verb 10.1177/1087057114542975
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2014/Burford et al/Burford et al. - 2014 - Identification of Selective Agonists and Positive Allosteric Modulators for $\mu$- and $\delta$-Opioid Receptors from a S.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/25047277%20http://jbx.sagepub.com/cgi/doi/10.1177/1087057114542975
      \endverb
      \keyw{gpcr,high-throughput screen,opioid receptor,positive allosteric modulator,$\beta$ -arrestin}
    \endentry
    \entry{Calebiro2013}{article}{}
      \name{labelname}{9}{}{%
        {{uniquename=0,hash=fc24ae3c5afab3285f7d66b966b52017}{Calebiro}{C\bibinitperiod}{Davide}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9a626fdaf2c85a10a04f9e8bcb048763}{Rieken}{R\bibinitperiod}{Finn}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4e1ffd42da1bca2a6e7b9853401d3aad}{Wagner}{W\bibinitperiod}{Julia}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=726176e22d37828c452f8c5cb8c9c942}{Sungkaworn}{S\bibinitperiod}{Titiwat}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e2709161f8851160110892248516d588}{Zabel}{Z\bibinitperiod}{Ulrike}{U\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=486770f3e6716a6beff966d17af7d32b}{Borzi}{B\bibinitperiod}{Alfio}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a94e31231f050ca8e2cd57d23213054f}{Cocucci}{C\bibinitperiod}{Emanuele}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ae2ec2044902581c1376ce0c9328524b}{Z{ü}rn}{Z\bibinitperiod}{Alexander}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{uniquename=0,hash=fc24ae3c5afab3285f7d66b966b52017}{Calebiro}{C\bibinitperiod}{Davide}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9a626fdaf2c85a10a04f9e8bcb048763}{Rieken}{R\bibinitperiod}{Finn}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4e1ffd42da1bca2a6e7b9853401d3aad}{Wagner}{W\bibinitperiod}{Julia}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=726176e22d37828c452f8c5cb8c9c942}{Sungkaworn}{S\bibinitperiod}{Titiwat}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e2709161f8851160110892248516d588}{Zabel}{Z\bibinitperiod}{Ulrike}{U\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=486770f3e6716a6beff966d17af7d32b}{Borzi}{B\bibinitperiod}{Alfio}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a94e31231f050ca8e2cd57d23213054f}{Cocucci}{C\bibinitperiod}{Emanuele}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ae2ec2044902581c1376ce0c9328524b}{Z{ü}rn}{Z\bibinitperiod}{Alexander}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{82c0f3d50a9823654b326ec34a8e72a5}
      \strng{fullhash}{1d94c0c76d7873018aa68c0bedd4a221}
      \field{sortinit}{C}
      \field{sortinithash}{dd0e4ddd17488a6ebf12cd6de2f2c237}
      \field{labelyear}{2013}
      \field{datelabelsource}{}
      \field{labeltitle}{{Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization.}}
      \field{abstract}{G-protein-coupled receptors (GPCRs) constitute the largest family of receptors and major pharmacological targets. Whereas many GPCRs have been shown to form di-/oligomers, the size and stability of such complexes under physiological conditions are largely unknown. Here, we used direct receptor labeling with SNAP-tags and total internal reflection fluorescence microscopy to dynamically monitor single receptors on intact cells and thus compare the spatial arrangement, mobility, and supramolecular organization of three prototypical GPCRs: the $\beta$(1)-adrenergic receptor ($\beta$(1)AR), the $\beta$(2)-adrenergic receptor ($\beta$(2)AR), and the $\gamma$-aminobutyric acid (GABA(B)) receptor. These GPCRs showed very different degrees of di-/oligomerization, lowest for $\beta$(1)ARs (monomers/dimers) and highest for GABA(B) receptors (prevalently dimers/tetramers of heterodimers). The size of receptor complexes increased with receptor density as a result of transient receptor-receptor interactions. Whereas $\beta$(1)-/$\beta$(2)ARs were apparently freely diffusing on the cell surface, GABA(B) receptors were prevalently organized into ordered arrays, via interaction with the actin cytoskeleton. Agonist stimulation did not alter receptor di-/oligomerization, but increased the mobility of GABA(B) receptor complexes. These data provide a spatiotemporal characterization of $\beta$(1)-/$\beta$(2)ARs and GABA(B) receptors at single-molecule resolution. The results suggest that GPCRs are present on the cell surface in a dynamic equilibrium, with constant formation and dissociation of new receptor complexes that can be targeted, in a ligand-regulated manner, to different cell-surface microdomains.}
      \field{eprinttype}{arXiv}
      \field{isbn}{1205798110}
      \field{issn}{1091-6490}
      \field{journaltitle}{Proc Natl Acad Sci U S A}
      \field{number}{2}
      \field{title}{{Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization.}}
      \field{volume}{110}
      \field{year}{2013}
      \field{pages}{743\bibrangedash 8}
      \verb{doi}
      \verb 10.1073/pnas.1205798110
      \endverb
      \verb{eprint}
      \verb arXiv:1408.1149
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2013/Calebiro et al/Calebiro et al. - 2013 - Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct d.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3545784%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
      \keyw{Algorithms,Animals,Bicyclo Compounds,Heterocyclic,CHO Cells,Carbocyanines,Cricetinae,Cricetulus,Cyclic AMP,Cyclic AMP: metabolism,HEK293 Cells,Humans,Lipids,Microscopy,Fluorescence,Models,Chemical,Molecular Dynamics Simulation,Multiprotein Complexes,Multiprotein Complexes: chemistry,Plasmids,Plasmids: genetics,Radioligand Assay,Receptors,Adrenergic,beta-1,Receptors,Adrenergic,beta-1: chemistry,Receptors,Adrenergic,beta-2,Receptors,Adrenergic,beta-2: chemistry,Receptors,GABA,Receptors,GABA: chemistry,Thiazolidines}
    \endentry
    \entry{Cherezov2007}{article}{}
      \name{labelname}{11}{}{%
        {{uniquename=0,hash=1a3634310c3b2b06eb166770ab5dda0e}{Cherezov}{C\bibinitperiod}{Vadim}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0828d953129b55f1f04d368185bc4a7d}{Rosenbaum}{R\bibinitperiod}{Daniel\bibnamedelima M}{D\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ca3775064a137451b30b4c99003f4a53}{Hanson}{H\bibinitperiod}{Michael\bibnamedelima a}{M\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a3b965d18a54a31cb9e31c3c946397ab}{Rasmussen}{R\bibinitperiod}{S{ø}ren\bibnamedelimb G\bibnamedelima F}{S\bibinitperiod\bibinitdelim G\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a17351cabe32fd8450fc95c8c3f42f30}{Thian}{T\bibinitperiod}{Foon\bibnamedelima Sun}{F\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2bcba851193b37d5c2cddd70bf1f8763}{Kobilka}{K\bibinitperiod}{Tong\bibnamedelima Sun}{T\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=262005b69cd9f862ac5a6bbeefb45c14}{Choi}{C\bibinitperiod}{Hee-Jung}{H\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=10005bd943c85a857a98af23cad2c865}{Kuhn}{K\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ba52c7efafd2c12a9a0fd5ab9ad79bbd}{Weis}{W\bibinitperiod}{William\bibnamedelima I}{W\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=decc5062cdeca8b403aad00dc8d4ce14}{Kobilka}{K\bibinitperiod}{Brian\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5e870ddd905b49881f1c106759b7acfc}{Stevens}{S\bibinitperiod}{Raymond\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{uniquename=0,hash=1a3634310c3b2b06eb166770ab5dda0e}{Cherezov}{C\bibinitperiod}{Vadim}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0828d953129b55f1f04d368185bc4a7d}{Rosenbaum}{R\bibinitperiod}{Daniel\bibnamedelima M}{D\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ca3775064a137451b30b4c99003f4a53}{Hanson}{H\bibinitperiod}{Michael\bibnamedelima a}{M\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a3b965d18a54a31cb9e31c3c946397ab}{Rasmussen}{R\bibinitperiod}{S{ø}ren\bibnamedelimb G\bibnamedelima F}{S\bibinitperiod\bibinitdelim G\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a17351cabe32fd8450fc95c8c3f42f30}{Thian}{T\bibinitperiod}{Foon\bibnamedelima Sun}{F\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2bcba851193b37d5c2cddd70bf1f8763}{Kobilka}{K\bibinitperiod}{Tong\bibnamedelima Sun}{T\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=262005b69cd9f862ac5a6bbeefb45c14}{Choi}{C\bibinitperiod}{Hee-Jung}{H\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=10005bd943c85a857a98af23cad2c865}{Kuhn}{K\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ba52c7efafd2c12a9a0fd5ab9ad79bbd}{Weis}{W\bibinitperiod}{William\bibnamedelima I}{W\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=decc5062cdeca8b403aad00dc8d4ce14}{Kobilka}{K\bibinitperiod}{Brian\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5e870ddd905b49881f1c106759b7acfc}{Stevens}{S\bibinitperiod}{Raymond\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{def005f6b6e73b6545fbe03dfa484e8f}
      \strng{fullhash}{201365a24cbe5c169626e935f0b14b4b}
      \field{sortinit}{C}
      \field{sortinithash}{dd0e4ddd17488a6ebf12cd6de2f2c237}
      \field{labelyear}{2007}
      \field{labelmonth}{11}
      \field{datelabelsource}{}
      \field{labeltitle}{{High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.}}
      \field{abstract}{Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane. We report the crystal structure of a human beta2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resolution. The structure provides a high-resolution view of a human G protein-coupled receptor bound to a diffusible ligand. Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop. Cholesterol, a necessary component for crystallization, mediates an intriguing parallel association of receptor molecules in the crystal lattice. Although the location of carazolol in the beta2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.}
      \field{issn}{1095-9203}
      \field{journaltitle}{Science}
      \field{month}{11}
      \field{number}{5854}
      \field{title}{{High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.}}
      \field{volume}{318}
      \field{year}{2007}
      \field{pages}{1258\bibrangedash 65}
      \verb{doi}
      \verb 10.1126/science.1150577
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2007/Cherezov et al/Cherezov et al. - 2007 - High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2583103%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
      \keyw{Bacteriophage T4,Bacteriophage T4: enzymology,Binding Sites,Cell Membrane,Cell Membrane: chemistry,Cell Membrane: metabolism,Cholesterol,Cholesterol: chemistry,Cholesterol: metabolism,Crystallization,Crystallography,X-Ray,Drug Inverse Agonism,Humans,Ligands,Models,Molecular,Muramidase,Muramidase: chemistry,Muramidase: metabolism,Propanolamines,Propanolamines: chemistry,Propanolamines: metabolism,Protein Conformation,Protein Folding,Protein Structure,Secondary,Receptors,Adrenergic,beta-2,Receptors,Adrenergic,beta-2: chemistry,Receptors,Adrenergic,beta-2: metabolism,Recombinant Fusion Proteins,Recombinant Fusion Proteins: chemistry,Recombinant Fusion Proteins: metabolism,Rhodopsin,Rhodopsin: chemistry,Rhodopsin: metabolism,Static Electricity}
    \endentry
    \entry{Chuang1979}{article}{}
      \name{labelname}{2}{}{%
        {{uniquename=0,hash=7c2747f38341a9bf2a0d88975bc6bbfe}{Chuang}{C\bibinitperiod}{D\bibnamedelima M}{D\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ebd54062a432036c7c751e148f75a4f3}{Costa}{C\bibinitperiod}{E}{E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{uniquename=0,hash=7c2747f38341a9bf2a0d88975bc6bbfe}{Chuang}{C\bibinitperiod}{D\bibnamedelima M}{D\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ebd54062a432036c7c751e148f75a4f3}{Costa}{C\bibinitperiod}{E}{E\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{5e2d13913e1aa0b5ca28a93ca3601e23}
      \strng{fullhash}{7394bbdab3e03bdccb7801760b4df8a6}
      \field{sortinit}{C}
      \field{sortinithash}{dd0e4ddd17488a6ebf12cd6de2f2c237}
      \field{labelyear}{1979}
      \field{datelabelsource}{}
      \field{labeltitle}{{Evidence for internalization of the recognition site of beta-adrenergic receptors during receptor subsensitivity induced by (-)-isoproterenol.}}
      \field{abstract}{In the supernatant (30,000 x g) of frog erythrocyte homogenates, by using gel filtration we detected a protein that could bind [(3)H]dihydroalprenolol ([(3)H]DHA) with high affinity. This binding was greatly enhanced when the erythrocytes were preincubated with (-)-isoproterenol. After various periods of incubation with (-)-isoproterenol, the extent of the increase in the density of [(3)H]DHA binding sites in the cytosol was paralleled by a proportional decrease in the number of [(3)H]DHA binding sites in the corresponding pellet; both events peaked after 2-3 hr of incubation with (-)-isoproterenol. The K(a) of the (-)-isoproterenol-induced increase in [(3)H]DHA binding in cytosol and the decrease in this binding in the membrane ranged between 60 and 90 nM. The changes in the cytosol and particulate [(3)H]DHA binding sites were independent of RNA and protein synthesis. The increase in cytosol binding elicited by (-)-isoproterenol was blocked by exposure of the cells to (-)-alprenolol which per se failed to change the cytosol binding of [(3)H]DHA. Scatchard analysis revealed that the enhanced [(3)H]DHA binding to cytosol material was due to a 4-fold increase in the B(max) with little or no change in K(d) ( approximately 9 nM). Binding displacement data show that these soluble [(3)H]DHA binding sites resemble the surface membrane recognition sites. Moreover, the ability of various beta-adrenergic agents to increase [(3)H]DHA binding to cytosol after they were incubated with frog erythrocytes paralleled their affinity for membrane-bound beta receptors. These findings support the view that the beta-adrenergic receptor desensitization caused by prolonged exposure to (-)-isoproterenol is due, at least in part, to an internalization of the recognition site of beta-adrenergic receptors.}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proc Natl Acad Sci U S A}
      \field{number}{6}
      \field{title}{{Evidence for internalization of the recognition site of beta-adrenergic receptors during receptor subsensitivity induced by (-)-isoproterenol.}}
      \field{volume}{76}
      \field{year}{1979}
      \field{pages}{3024\bibrangedash 3028}
      \verb{doi}
      \verb 10.1073/pnas.76.6.3024
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/1979/Chuang, Costa/Chuang, Costa - 1979 - Evidence for internalization of the recognition site of beta-adrenergic receptors during receptor subsensitivity.pdf:pdf
      \endverb
    \endentry
    \entry{Chung2011}{article}{}
      \name{labelname}{3}{}{%
        {{uniquename=0,hash=717128206aa5937c55a02a8af40fe05a}{Chung}{C\bibinitperiod}{L\bibnamedelima P}{L\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0cb42bc27040f57cfade081c3474f3fb}{Waterer}{W\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f80afc32463fabbf65b510dfbc90b735}{Thompson}{T\bibinitperiod}{P\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{uniquename=0,hash=717128206aa5937c55a02a8af40fe05a}{Chung}{C\bibinitperiod}{L\bibnamedelima P}{L\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0cb42bc27040f57cfade081c3474f3fb}{Waterer}{W\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f80afc32463fabbf65b510dfbc90b735}{Thompson}{T\bibinitperiod}{P\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ddc39fdda68acd710adbeecf4eaa2ce1}
      \strng{fullhash}{bb7b8e12433cb1b9aaedde8801cb0df4}
      \field{sortinit}{C}
      \field{sortinithash}{dd0e4ddd17488a6ebf12cd6de2f2c237}
      \field{labelyear}{2011}
      \field{labelmonth}{03}
      \field{datelabelsource}{}
      \field{labeltitle}{{Pharmacogenetics of $\beta$2 adrenergic receptor gene polymorphisms, long-acting $\beta$-agonists and asthma.}}
      \field{abstract}{Adrenergic $\beta$2 receptor (ADR$\beta$2) agonists are widely used in asthma. Approximately 10{\%} of patients have severe, poorly controlled disease despite extensive use of ADR$\beta$2 agonists. Variations in responses to ADR$\beta$2 agonists can, in part, be attributed to genetic variation, with 49 different polymorphisms having been identified for the ADR$\beta$2 gene. Although clear associations exist between ADR$\beta$2 gene polymorphisms, such as +46G>A, and patient response, the importance of these polymorphisms remains controversial. Patient selection, the number of polymorphisms analysed, differences in the type/dose of ADR$\beta$2 agonist, use of inhaled corticosteroids and population sizes have all varied. Most studies were limited to mild or moderate asthmatics using ADR$\beta$2 agonists sparingly. It is difficult to extrapolate from these studies to individual patients who have severe asthma, use a variety of ADR$\beta$2 agonists and do so frequently. The extent to which ADR$\beta$2 gene polymorphisms are relevant to asthma management needs further review, both clinically and at the molecular level. In vitro studies have helped to define the functional changes induced by specific ADR$\beta$2 gene polymorphisms, including 3'-untranslated region poly-C repeat. The resulting ADR$\beta$2 gene haplotypes (rather than genotypes), the interactions among ADR$\beta$2 gene haplotypes and variations in the chemistry of different agonists deserve more detailed assessment. Responses to ADR$\beta$2 agonists depend on effective downstream signalling following ADR$\beta$2 activation and also on receptor regulation. Studies on other regulators of ADR$\beta$2 receptor signalling and trafficking may be equally important in understanding the functional role of ADR$\beta$2 gene polymorphisms. The role of ADR$\beta$2 gene polymorphisms in the pathogenesis and management of severe asthma cannot be clearly defined until more specific and targeted research studies are performed.}
      \field{issn}{1365-2222}
      \field{journaltitle}{Clin Exp Allergy}
      \field{month}{03}
      \field{number}{3}
      \field{title}{{Pharmacogenetics of $\beta$2 adrenergic receptor gene polymorphisms, long-acting $\beta$-agonists and asthma.}}
      \field{volume}{41}
      \field{year}{2011}
      \field{pages}{312\bibrangedash 26}
      \verb{doi}
      \verb 10.1111/j.1365-2222.2011.03696.x
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/21294785
      \endverb
      \keyw{Adrenergic beta-Agonists,Adrenergic beta-Agonists: therapeutic use,Asthma,Asthma: drug therapy,Delayed-Action Preparations,Drug Resistance,Drug Resistance: genetics,Humans,Pharmacogenetics,Polymorphism,Genetic,Receptors,Adrenergic,beta-2,Receptors,Adrenergic,beta-2: genetics}
    \endentry
    \entry{Comps-agrar2011}{book}{}
      \name{labelname}{6}{}{%
        {{uniquename=0,hash=de70b63fa77dce8cac6ed2caf22698d3}{Comps-agrar}{C\bibinithyphendelim a\bibinitperiod}{La{ë}titia}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=be172cd935205c533b6f658671a141ab}{Maurel}{M\bibinitperiod}{Damien}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7edd3e215e6aff59da58e36b965e2c82}{Rondard}{R\bibinitperiod}{Philippe}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5a4b0a532a1a475298c7646b0a04a0ba}{Pin}{P\bibinitperiod}{Jean-philippe}{J\bibinithyphendelim p\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2256344e7e48a51afd66ddff0072d45b}{Trinquet}{T\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d695a6e475955e242cf20983bdd77264}{Pr{é}zeau}{P\bibinitperiod}{Laurent}{L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{uniquename=0,hash=de70b63fa77dce8cac6ed2caf22698d3}{Comps-agrar}{C\bibinithyphendelim a\bibinitperiod}{La{ë}titia}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=be172cd935205c533b6f658671a141ab}{Maurel}{M\bibinitperiod}{Damien}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7edd3e215e6aff59da58e36b965e2c82}{Rondard}{R\bibinitperiod}{Philippe}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5a4b0a532a1a475298c7646b0a04a0ba}{Pin}{P\bibinitperiod}{Jean-philippe}{J\bibinithyphendelim p\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2256344e7e48a51afd66ddff0072d45b}{Trinquet}{T\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d695a6e475955e242cf20983bdd77264}{Pr{é}zeau}{P\bibinitperiod}{Laurent}{L\bibinitperiod}{}{}{}{}}%
      }
      \name{editor}{2}{}{%
        {{hash=0b5b89b74eae1f2945a8e00f8c6e07a7}{Luttrell}{L\bibinitperiod}{Louis\bibnamedelima M.}{L\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=c1f0041d336c92764a0cbf0acde4e1d3}{Ferguson}{F\bibinitperiod}{Stephen\bibnamedelimb S.\bibnamedelimi G.}{S\bibinitperiod\bibinitdelim S\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {Totowa, NJ}%
      }
      \list{publisher}{1}{%
        {Humana Press}%
      }
      \strng{namehash}{1dbbcf97e2d544f93d1405be9cdf9f57}
      \strng{fullhash}{81302bc6b0422062979643105efa539a}
      \field{sortinit}{C}
      \field{sortinithash}{dd0e4ddd17488a6ebf12cd6de2f2c237}
      \field{labelyear}{2011}
      \field{datelabelsource}{}
      \field{labeltitle}{{Signal Transduction Protocols}}
      \field{booktitle}{Signal Transduct}
      \field{isbn}{978-1-61779-159-8}
      \field{series}{Methods in Molecular Biology}
      \field{title}{{Signal Transduction Protocols}}
      \field{volume}{756}
      \field{year}{2011}
      \verb{doi}
      \verb 10.1007/978-1-61779-160-4
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2011/Comps-agrar et al/Comps-agrar et al. - 2011 - Signal Transduction Protocols.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.springerlink.com/index/10.1007/978-1-61779-160-4
      \endverb
      \keyw{dimerization,fluorescence resonance energy transfer,g protein-coupled receptor,gaba b receptor,snaptag}
    \endentry
    \entry{Cottet2012a}{article}{}
      \name{labelname}{8}{}{%
        {{uniquename=0,hash=6c3b851874e0dcad28edb2db00d78d7f}{Cottet}{C\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=74be6eb179a8e83115c8eaff2e7100b9}{Faklaris}{F\bibinitperiod}{Orestis}{O\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=be172cd935205c533b6f658671a141ab}{Maurel}{M\bibinitperiod}{Damien}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=174ef3f7000922cfbf6d255a37fcf2e7}{Scholler}{S\bibinitperiod}{Pauline}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0b2219fc31c6f1ca04f54dfcbd10b211}{Doumazane}{D\bibinitperiod}{Etienne}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2256344e7e48a51afd66ddff0072d45b}{Trinquet}{T\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b176a802ab7b11c217ab95a7ad84d820}{Durroux}{D\bibinitperiod}{Thierry}{T\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{uniquename=0,hash=6c3b851874e0dcad28edb2db00d78d7f}{Cottet}{C\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=74be6eb179a8e83115c8eaff2e7100b9}{Faklaris}{F\bibinitperiod}{Orestis}{O\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=be172cd935205c533b6f658671a141ab}{Maurel}{M\bibinitperiod}{Damien}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=174ef3f7000922cfbf6d255a37fcf2e7}{Scholler}{S\bibinitperiod}{Pauline}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0b2219fc31c6f1ca04f54dfcbd10b211}{Doumazane}{D\bibinitperiod}{Etienne}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2256344e7e48a51afd66ddff0072d45b}{Trinquet}{T\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b176a802ab7b11c217ab95a7ad84d820}{Durroux}{D\bibinitperiod}{Thierry}{T\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{f021ea1fe3917e657e29f7be165a9317}
      \strng{fullhash}{213f50b8dc106c67979b5ace0f55a3fa}
      \field{sortinit}{C}
      \field{sortinithash}{dd0e4ddd17488a6ebf12cd6de2f2c237}
      \field{labelyear}{2012}
      \field{labelmonth}{01}
      \field{datelabelsource}{}
      \field{labeltitle}{{BRET and Time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues.}}
      \field{abstract}{The concept of oligomerization of G protein-coupled receptor (GPCR) opens new perspectives regarding physiological function regulation. The capacity of one GPCR to modify its binding and coupling properties by interacting with a second one can be at the origin of regulations unsuspected two decades ago. Although the concept is interesting, its validation at a physiological level is challenging and probably explains why receptor oligomerization is still controversial. Demonstrating direct interactions between two proteins is not trivial since few techniques present a spatial resolution allowing this precision. Resonance energy transfer (RET) strategies are actually the most convenient ones. During the last two decades, bioluminescent resonance energy transfer and time-resolved fluorescence resonance energy transfer (TR-FRET) have been widely used since they exhibit high signal-to-noise ratio. Most of the experiments based on GPCR labeling have been performed in cell lines and it has been shown that all GPCRs have the propensity to form homo- or hetero-oligomers. However, whether these data can be extrapolated to GPCRs expressed in native tissues and explain receptor functioning in real life, remains an open question. Native tissues impose different constraints since GPCR sequences cannot be modified. Recently, a fluorescent ligand-based GPCR labeling strategy combined to a TR-FRET approach has been successfully used to prove the existence of GPCR oligomerization in native tissues. Although the RET-based strategies are generally quite simple to implement, precautions have to be taken before concluding to the absence or the existence of specific interactions between receptors. For example, one should exclude the possibility of collision of receptors diffusing throughout the membrane leading to a specific FRET signal. The advantages and the limits of different approaches will be reviewed and the consequent perspectives discussed.}
      \field{issn}{1664-2392}
      \field{journaltitle}{Front Endocrinol (Lausanne)}
      \field{month}{01}
      \field{number}{July}
      \field{title}{{BRET and Time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues.}}
      \field{volume}{3}
      \field{year}{2012}
      \field{pages}{92}
      \verb{doi}
      \verb 10.3389/fendo.2012.00092
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2012/Cottet et al/Cottet et al. - 2012 - BRET and Time-resolved FRET strategy to study GPCR oligomerization from cell lines toward native tissues.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3401989%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
      \keyw{bret,fluorescence,fluorescent ligand,fret,g protein-coupled receptor,oligomer,time-resolved fret}
    \endentry
    \entry{Daniels2005}{article}{}
      \name{labelname}{6}{}{%
        {{uniquename=0,hash=363d912a5db8361b6b0b169a86a36649}{Daniels}{D\bibinitperiod}{David\bibnamedelima J}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=111912eb9d4c74dd04950aea1488c48b}{Lenard}{L\bibinitperiod}{Natalie\bibnamedelima R}{N\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6e3dae61e5c8912f2fc71213cb8298ce}{Etienne}{E\bibinitperiod}{Chris\bibnamedelima L}{C\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2c1d566aff476656db34c0883b9f3a34}{Law}{L\bibinitperiod}{Ping-Yee}{P\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b1628e84ebefe250760dd2378de10c55}{Roerig}{R\bibinitperiod}{Sandra\bibnamedelima C}{S\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1b9ef4f82d1e8668afdb51c73d65e132}{Portoghese}{P\bibinitperiod}{Philip\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{uniquename=0,hash=363d912a5db8361b6b0b169a86a36649}{Daniels}{D\bibinitperiod}{David\bibnamedelima J}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=111912eb9d4c74dd04950aea1488c48b}{Lenard}{L\bibinitperiod}{Natalie\bibnamedelima R}{N\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6e3dae61e5c8912f2fc71213cb8298ce}{Etienne}{E\bibinitperiod}{Chris\bibnamedelima L}{C\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2c1d566aff476656db34c0883b9f3a34}{Law}{L\bibinitperiod}{Ping-Yee}{P\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b1628e84ebefe250760dd2378de10c55}{Roerig}{R\bibinitperiod}{Sandra\bibnamedelima C}{S\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1b9ef4f82d1e8668afdb51c73d65e132}{Portoghese}{P\bibinitperiod}{Philip\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{1acbc0ac29e5d72382d31d77459b1650}
      \strng{fullhash}{49543eb1ae5dff86efef38f4eb3b16e1}
      \field{sortinit}{D}
      \field{sortinithash}{a01c54d1737685bc6dbf0ea0673fa44c}
      \field{labelyear}{2005}
      \field{labelmonth}{12}
      \field{datelabelsource}{}
      \field{labeltitle}{{Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.}}
      \field{abstract}{Given the mounting evidence for involvement of delta opioid receptors in the tolerance and physical dependence of mu opioid receptor agonists, we have investigated the possible physical interaction between mu and delta opioid receptors by using bivalent ligands. Based on reports of suppression of antinociceptive tolerance by the delta antagonist naltrindole (NTI), bivalent ligands [mu-delta agonist-antagonist (MDAN) series] that contain different length spacers, and pharmacophores derived from NTI and the mu agonist oxymorphone, have been synthesized and evaluated by intracerebroventricular (i.c.v.) administration in the tail-flick test in mice. In acute i.c.v. studies, the bivalent ligands functioned as agonists with potencies ranging from 1.6- to 45-fold greater than morphine. In contrast, the monovalent mu agonist analogues were substantially more potent than the MDAN congeners and were essentially equipotent with one another and oxymorphone. Pretreatment with NTI decreased the ED(50) values for MDAN-19 to a greater degree than for MDAN-16 but had no effect on MDAN-21. Chronic i.c.v. studies revealed that MDAN ligands whose spacer was 16 atoms or longer produced less dependence than either morphine or mu monovalent control MA-19. On the other hand, both physical dependence and tolerance were suppressed at MDAN spacer lengths of 19 atoms or greater. These data suggest that physical interaction between the mu and delta opioid receptors modulates mu-mediated tolerance and dependence. Because MDAN-21 was found to be 50-fold more potent than morphine by the i.v. route (i.v.), it offers a previously uncharacterized approach for the development of analgesics devoid of tolerance and dependence.}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proc Natl Acad Sci U S A}
      \field{month}{12}
      \field{number}{52}
      \field{title}{{Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.}}
      \field{volume}{102}
      \field{year}{2005}
      \field{pages}{19208\bibrangedash 13}
      \verb{doi}
      \verb 10.1073/pnas.0506627102
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2005/Daniels et al/Daniels et al. - 2005 - Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalen.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1323165%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
      \keyw{Analgesics,Analgesics: pharmacology,Animals,Chemical,Chemistry,Dose-Response Relationship,Drug,Inbred ICR,Ligands,Male,Mice,Models,Morphine,Morphine: pharmacology,Naltrexone,Naltrexone: analogs {\&} derivatives,Naltrexone: pharmacology,Narcotic Antagonists,Narcotic Antagonists: pharmacology,Narcotics,Narcotics: metabolism,Opioid,Opioid: pharmacology,Pharmaceutical,Pharmaceutical: methods,Receptors,Statistical,Time Factors,delta,delta: chemistry,mu,mu: chemistry}
    \endentry
    \entry{DeJong2005}{article}{}
      \name{labelname}{4}{}{%
        {{uniquename=0,hash=f91f034330941b277876019ed0cae211}{{De\bibnamedelimb Jong}}{D\bibinitperiod}{L.\bibnamedelimi a\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0ca290d187dcf3c5e87e90a22e1cbc8a}{Uges}{U\bibinitperiod}{D.\bibnamedelimi R\bibnamedelima a}{D\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bfaec99d3683b7c200dcc094d7c6d0b1}{Franke}{F\bibinitperiod}{Jan\bibnamedelima Piet}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2f914bbe64bd82c123d0ef61b9e00bac}{Bischoff}{B\bibinitperiod}{Rainer}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{uniquename=0,hash=f91f034330941b277876019ed0cae211}{{De\bibnamedelimb Jong}}{D\bibinitperiod}{L.\bibnamedelimi a\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0ca290d187dcf3c5e87e90a22e1cbc8a}{Uges}{U\bibinitperiod}{D.\bibnamedelimi R\bibnamedelima a}{D\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bfaec99d3683b7c200dcc094d7c6d0b1}{Franke}{F\bibinitperiod}{Jan\bibnamedelima Piet}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2f914bbe64bd82c123d0ef61b9e00bac}{Bischoff}{B\bibinitperiod}{Rainer}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{1176e7bd93711d352a091a196448d01a}
      \strng{fullhash}{7f281294647c9cfd08c58394c807b426}
      \field{sortinit}{D}
      \field{sortinithash}{a01c54d1737685bc6dbf0ea0673fa44c}
      \field{labelyear}{2005}
      \field{datelabelsource}{}
      \field{labeltitle}{{Receptor-ligand binding assays: Technologies and applications}}
      \field{abstract}{Receptor-ligand interactions play a crucial role in biological systems and their measurement forms an important part of modern pharmaceutical development. Numerous assay formats are available that can be used to screen and quantify receptor ligands. In this review, we give an overview over both radioactive and non-radioactive assay technologies with emphasis on the latter. While radioreceptor assays are fast, easy to use and reproducible, their major disadvantage is that they are hazardous to human health, produce radioactive waste, require special laboratory conditions and are thus rather expensive on a large scale. This has led to the development of non-radioactive assays based on optical methods like fluorescence polarization, fluorescence resonance energy transfer or surface plasmon resonance. In light of their application in high-throughput screening environments, there has been an emphasis on so called "mix-and-measure" assays that do not require separation of bound from free ligand. The advent of recombinant production of receptors has contributed to the increased availability of specific assays and some aspects of the expression of recombinant receptors will be reviewed. Applications of receptor-ligand binding assays described in this review will relate to screening and the quantification of pharmaceuticals in biological matrices. ?? 2005 Elsevier B.V. All rights reserved.}
      \field{isbn}{1570-0232}
      \field{issn}{15700232}
      \field{journaltitle}{J Chromatogr B Anal Technol Biomed Life Sci}
      \field{number}{1-2}
      \field{title}{{Receptor-ligand binding assays: Technologies and applications}}
      \field{volume}{829}
      \field{year}{2005}
      \field{pages}{1\bibrangedash 25}
      \verb{doi}
      \verb 10.1016/j.jchromb.2005.10.002
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2005/De Jong et al/De Jong et al. - 2005 - Receptor-ligand binding assays Technologies and applications.pdf:pdf
      \endverb
      \keyw{Assay technologies,High-throughput screening,Quantitative receptor assay,Receptor-ligand binding,Recombinant receptor expression}
    \endentry
    \entry{Dorsch2009}{article}{}
      \name{labelname}{5}{}{%
        {{uniquename=0,hash=8ed927b27a0386e937d4a344325c33c1}{Dorsch}{D\bibinitperiod}{Sandra}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1486253e620677e4d13ef08981045d87}{Klotz}{K\bibinitperiod}{Karl-Norbert}{K\bibinithyphendelim N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=acaea11c14b745fade9d24235dd48bae}{Engelhardt}{E\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f39e29f598b25bb1d3ead141b888bdd0}{B{ü}nemann}{B\bibinitperiod}{Moritz}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{uniquename=0,hash=8ed927b27a0386e937d4a344325c33c1}{Dorsch}{D\bibinitperiod}{Sandra}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1486253e620677e4d13ef08981045d87}{Klotz}{K\bibinitperiod}{Karl-Norbert}{K\bibinithyphendelim N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=acaea11c14b745fade9d24235dd48bae}{Engelhardt}{E\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f39e29f598b25bb1d3ead141b888bdd0}{B{ü}nemann}{B\bibinitperiod}{Moritz}{M\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{3af95e849f8868f142218f9d095647f7}
      \strng{fullhash}{fc82225c62dcac686c832bc07ab41384}
      \field{sortinit}{D}
      \field{sortinithash}{a01c54d1737685bc6dbf0ea0673fa44c}
      \field{labelyear}{2009}
      \field{labelmonth}{03}
      \field{datelabelsource}{}
      \field{labeltitle}{{Analysis of receptor oligomerization by FRAP microscopy.}}
      \field{abstract}{Here we describe an approach to investigate di- or oligomerization of transmembrane receptors in living cells with fluorescence recovery after photobleaching (FRAP). We immobilized a defined fraction of receptors with antibodies and then measured lateral mobility of the nonimmobilized fraction by FRAP. We validated this approach with CD86 and CD28 as monomeric and dimeric reference proteins, respectively. Di- or oligomerization of G protein-coupled receptors is strongly debated. We studied human beta-adrenergic receptors as prototypical G protein-coupled receptors and found that beta(1)-AR shows transient interactions whereas beta(2)-AR can form stable oligomers. We propose that this FRAP method can be widely applied to study di- or oligomerization of cell-surface proteins.}
      \field{issn}{1548-7105}
      \field{journaltitle}{Nat Methods}
      \field{month}{03}
      \field{number}{3}
      \field{title}{{Analysis of receptor oligomerization by FRAP microscopy.}}
      \field{volume}{6}
      \field{year}{2009}
      \field{pages}{225\bibrangedash 30}
      \verb{doi}
      \verb 10.1038/nmeth.1304
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2009/Dorsch et al/Dorsch et al. - 2009 - Analysis of receptor oligomerization by FRAP microscopy.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/nmeth/journal/vaop/ncurrent/full/nmeth.1304.html%20http://www.ncbi.nlm.nih.gov/pubmed/19234451
      \endverb
      \keyw{Activin Receptors,Adrenergic,Animals,Antibodies,Antibodies: immunology,Antigens,Bacterial Proteins,Bacterial Proteins: genetics,Bacterial Proteins: immunology,CD28,CD28: genetics,CD28: metabolism,CD86,CD86: genetics,CD86: metabolism,Cardiac,Cardiac: metabolism,Cell Line,Cell Surface,Cell Surface: genetics,Cell Surface: metabolism,Fluorescence,Fluorescence Recovery After Photobleaching,Fluorescence Recovery After Photobleaching: method,Fluorescence: methods,Green Fluorescent Proteins,Green Fluorescent Proteins: genetics,Humans,Luminescent Proteins,Luminescent Proteins: genetics,Luminescent Proteins: immunology,Mice,Microscopy,Myocytes,Protein Binding,Protein Binding: physiology,Rats,Receptors,Recombinant Fusion Proteins,Recombinant Fusion Proteins: genetics,Recombinant Fusion Proteins: metabolism,Transfection,Type II,Type II: metabolism,beta-1,beta-1: genetics,beta-1: metabolism,beta-2,beta-2: genetics,beta-2: metabolism}
    \endentry
    \entry{Doumazane2011}{article}{}
      \name{labelname}{6}{}{%
        {{uniquename=0,hash=0b2219fc31c6f1ca04f54dfcbd10b211}{Doumazane}{D\bibinitperiod}{Etienne}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=174ef3f7000922cfbf6d255a37fcf2e7}{Scholler}{S\bibinitperiod}{Pauline}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=dc62d90c5d963428e7811c6ee2a4fb6c}{Zwier}{Z\bibinitperiod}{Jurriaan\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=23d43ec3f71fc596e73b92b98d09938b}{Eric}{E\bibinitperiod}{Trinquet}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7edd3e215e6aff59da58e36b965e2c82}{Rondard}{R\bibinitperiod}{Philippe}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{uniquename=0,hash=0b2219fc31c6f1ca04f54dfcbd10b211}{Doumazane}{D\bibinitperiod}{Etienne}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=174ef3f7000922cfbf6d255a37fcf2e7}{Scholler}{S\bibinitperiod}{Pauline}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=dc62d90c5d963428e7811c6ee2a4fb6c}{Zwier}{Z\bibinitperiod}{Jurriaan\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=23d43ec3f71fc596e73b92b98d09938b}{Eric}{E\bibinitperiod}{Trinquet}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7edd3e215e6aff59da58e36b965e2c82}{Rondard}{R\bibinitperiod}{Philippe}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{b8dc421b91edbebd9670dbd13054353b}
      \strng{fullhash}{a9d17d26f82e39ec371d2ed34009394c}
      \field{sortinit}{D}
      \field{sortinithash}{a01c54d1737685bc6dbf0ea0673fa44c}
      \field{labelyear}{2011}
      \field{labelmonth}{01}
      \field{datelabelsource}{}
      \field{labeltitle}{{A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors.}}
      \field{abstract}{G-protein-coupled receptors (GPCRs) can form heteromeric complexes. Herein, we describe a new approach to test the heteromerization of 2 receptors, or 2 receptor subunits, and to study the stoichiometry of the resulting complexes. As a proof-of-concept study, we investigated whether metabotropic glutamate receptors (mGluRs), in addition to being well-known homodimers, can form heteromers. To that aim, we combine the benefits of time-resolved fluorescence resonance energy transfer (trFRET) with the specific, cell-surface labeling of SNAP- and CLIP-tagged rat mGluR subunits, expressed in a mammalian cell line. First, we show that mGlu2 and mGlu4 subunits (but not mGlu2 and mGlu1) can heteromerize. Moreover, our trFRET data are consistent with mGluR subunits forming strict homodimeric receptors on single expression, and a combination of strict heterodimeric and strict homodimeric receptors on coexpression. Second, a comprehensive analysis reveals that from the 21 possible pairs of 2 mGluR subunits out of 7 subtypes (mGlu1 to 8, but not 6), only 11 are able to form heterodimers. These findings were further validated by biochemical and functional complementation studies. In addition to describing a new method to analyze cell-surface receptor complexes, our data reveal a new level of complexity within the mGluR family.}
      \field{issn}{1530-6860}
      \field{journaltitle}{FASEB J}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors.}}
      \field{volume}{25}
      \field{year}{2011}
      \field{pages}{66\bibrangedash 77}
      \verb{doi}
      \verb 10.1096/fj.10-163147
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2011/Doumazane et al/Doumazane et al. - 2011 - A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/20826542
      \endverb
      \keyw{Animals,Blotting,COS Cells,Cercopithecus aethiops,Fluorescence Resonance Energy Transfer,Fluorescence Resonance Energy Transfer: methods,HEK293 Cells,Humans,Membrane Proteins,Membrane Proteins: chemistry,Membrane Proteins: genetics,Membrane Proteins: metabolism,Metabotropic Glutamate,Metabotropic Glutamate: chemistry,Metabotropic Glutamate: genetics,Metabotropic Glutamate: metabolism,Phylogeny,Protein Binding,Protein Multimerization,Protein Subunits,Protein Subunits: chemistry,Protein Subunits: genetics,Protein Subunits: metabolism,Rats,Receptors,Transfection,Western}
    \endentry
    \entry{Emami-Nemini2013}{article}{}
      \name{labelname}{7}{}{%
        {{uniquename=0,hash=1f01452346d39736b8c34ed454bb777b}{Emami-Nemini}{E\bibinithyphendelim N\bibinitperiod}{Alexander}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b8e5d1a171939e8cda64e24c38e6c849}{Roux}{R\bibinitperiod}{Thomas}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=52a6591b25bfd16cb091935f1af4582d}{Leblay}{L\bibinitperiod}{Marion}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6c342792fc270b296facafd4add2ee26}{Bourrier}{B\bibinitperiod}{Emmanuel}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=72fb7cd45e5626359e483f4760c86fb5}{Lamarque}{L\bibinitperiod}{Laurent}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2256344e7e48a51afd66ddff0072d45b}{Trinquet}{T\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{uniquename=0,hash=1f01452346d39736b8c34ed454bb777b}{Emami-Nemini}{E\bibinithyphendelim N\bibinitperiod}{Alexander}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b8e5d1a171939e8cda64e24c38e6c849}{Roux}{R\bibinitperiod}{Thomas}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=52a6591b25bfd16cb091935f1af4582d}{Leblay}{L\bibinitperiod}{Marion}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6c342792fc270b296facafd4add2ee26}{Bourrier}{B\bibinitperiod}{Emmanuel}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=72fb7cd45e5626359e483f4760c86fb5}{Lamarque}{L\bibinitperiod}{Laurent}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2256344e7e48a51afd66ddff0072d45b}{Trinquet}{T\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{360a7a92a3ed64977dca5753584c4c1e}
      \strng{fullhash}{50c38ae9dc493b69dbdca6d8cf3ab733}
      \field{sortinit}{E}
      \field{sortinithash}{655e26c7438ff123e5c69c6c3f702107}
      \field{labelyear}{2013}
      \field{datelabelsource}{}
      \field{labeltitle}{{Time-resolved fluorescence ligand binding for G protein-coupled receptors.}}
      \field{abstract}{G protein-coupled receptors (GPCRs) and their ligands are traditionally characterized by radioligand-binding experiments. These experiments yield excellent quantitative data, but have low temporal and spatial resolution. In addition, the use of radioligands presents safety concerns. Here we provide a general procedure for an alternative approach with high temporal and spatial resolution, based on Tb(+)-labeled fluorescent receptor ligands and time-resolved fluorescence resonance energy transfer (TR-FRET). This protocol and its design are detailed here for the parathyroid hormone receptor, a class B GPCR, and its fluorescently labeled 34-amino acid peptide ligand, but it can be easily modified for other receptors and their appropriately labeled ligands. We discuss three protocol options that use Tb(+)-labeled fluorescent ligands: a time-resolved fluorescence separation option that works on native receptors but requires separation of bound and unbound ligand; a TR-FRET option using SNAP-tag-labeled receptors for high-throughput screening; and a TR-FRET option that uses fluorescently labeled antibodies directed against an epitope engineered into the Flag-labeled receptors' N terminus. These protocol options can be used as standard procedures with very high signal-to-background ratios in order to characterize ligands and their receptors in living cells and in cell membranes via straightforward plate-reader measurements.}
      \field{issn}{1750-2799}
      \field{journaltitle}{Nat Protoc}
      \field{number}{7}
      \field{title}{{Time-resolved fluorescence ligand binding for G protein-coupled receptors.}}
      \field{volume}{8}
      \field{year}{2013}
      \field{pages}{1307\bibrangedash 20}
      \verb{doi}
      \verb 10.1038/nprot.2013.073
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2013/Emami-Nemini et al/Emami-Nemini et al. - 2013 - Time-resolved fluorescence ligand binding for G protein-coupled receptors.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/23764938
      \endverb
      \keyw{Fluorescence Resonance Energy Transfer,Fluorescence Resonance Energy Transfer: methods,Fluorescent Dyes,Fluorescent Dyes: chemistry,G-Protein-Coupled,G-Protein-Coupled: analysis,G-Protein-Coupled: metabolism,Ligands,Peptide Fragments,Peptide Fragments: chemistry,Peptide Fragments: metabolism,Receptors,Terbium,Terbium: chemistry,Teriparatide,Teriparatide: analogs {\&} derivatives,Teriparatide: chemistry,Teriparatide: metabolism,Time Factors}
    \endentry
    \entry{Ferre2014}{article}{}
      \name{labelname}{9}{}{%
        {{uniquename=0,hash=4cf7b2a170b143f30a95815bd1120011}{Ferr{é}}{F\bibinitperiod}{Sergi}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8c52ca5c3745e829bb3b3648bd297648}{Casad{ó}}{C\bibinitperiod}{Vicent}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e087092cccd54f956e674d1e2c3b44a3}{Devi}{D\bibinitperiod}{Lakshmi\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=caa7ad34df0c6628c95c1dbbf147fe90}{Filizola}{F\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9dcc8785b9d21dddb5fbe97848b4e63e}{Jockers}{J\bibinitperiod}{Ralf}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=65ce19b54b395e37b896e60b30df47e9}{Milligan}{M\bibinitperiod}{Graeme}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0ab16eece503b085769f674c2e9f793d}{Guitart}{G\bibinitperiod}{Xavier}{X\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{uniquename=0,hash=4cf7b2a170b143f30a95815bd1120011}{Ferr{é}}{F\bibinitperiod}{Sergi}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8c52ca5c3745e829bb3b3648bd297648}{Casad{ó}}{C\bibinitperiod}{Vicent}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e087092cccd54f956e674d1e2c3b44a3}{Devi}{D\bibinitperiod}{Lakshmi\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=caa7ad34df0c6628c95c1dbbf147fe90}{Filizola}{F\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9dcc8785b9d21dddb5fbe97848b4e63e}{Jockers}{J\bibinitperiod}{Ralf}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=65ce19b54b395e37b896e60b30df47e9}{Milligan}{M\bibinitperiod}{Graeme}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0ab16eece503b085769f674c2e9f793d}{Guitart}{G\bibinitperiod}{Xavier}{X\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a582df33bfe1acd7be0400d5926a23b9}
      \strng{fullhash}{6c3168e841cf8677e0eea7b6cc206a97}
      \field{sortinit}{F}
      \field{sortinithash}{9661cce5f16ac30b6b0c804d4583ed99}
      \field{labelyear}{2014}
      \field{datelabelsource}{}
      \field{labeltitle}{{G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.}}
      \field{abstract}{Most evidence indicates that, as for family C G protein-coupled receptors (GPCRs), family A GPCRs form homo- and heteromers. Homodimers seem to be a predominant species, with potential dynamic formation of higher-order oligomers, particularly tetramers. Although monomeric GPCRs can activate G proteins, the pentameric structure constituted by one GPCR homodimer and one heterotrimeric G protein may provide a main functional unit, and oligomeric entities can be viewed as multiples of dimers. It still needs to be resolved if GPCR heteromers are preferentially heterodimers or if they are mostly constituted by heteromers of homodimers. Allosteric mechanisms determine a multiplicity of possible unique pharmacological properties of GPCR homomers and heteromers. Some general mechanisms seem to apply, particularly at the level of ligand-binding properties. In the frame of the dimer-cooperativity model, the two-state dimer model provides the most practical method to analyze ligand-GPCR interactions when considering receptor homomers. In addition to ligand-binding properties, unique properties for each GPCR oligomer emerge in relation to different intrinsic efficacy of ligands for different signaling pathways (functional selectivity). This gives a rationale for the use of GPCR oligomers, and particularly heteromers, as novel targets for drug development. Herein, we review the functional and pharmacological properties of GPCR oligomers and provide some guidelines for the application of discrete direct screening and high-throughput screening approaches to the discovery of receptor-heteromer selective compounds.}
      \field{isbn}{1521-0081 (Electronic)0031-6997 (Linking)}
      \field{issn}{1521-0081}
      \field{journaltitle}{Pharmacol Rev}
      \field{number}{2}
      \field{title}{{G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.}}
      \field{volume}{66}
      \field{year}{2014}
      \field{pages}{413\bibrangedash 34}
      \verb{doi}
      \verb 10.1124/pr.113.008052
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2014/Ferr{é} et al/Ferr{é} et al. - 2014 - G protein-coupled receptor oligomerization revisited functional and pharmacological perspectives.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3973609%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Floyd2003}{article}{}
      \name{labelname}{6}{}{%
        {{uniquename=0,hash=09619d0bc23499edabc4f01f7e1221d9}{Floyd}{F\bibinitperiod}{Desiree\bibnamedelima H}{D\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=82e327c5daf647d7f712a44400737178}{Geva}{G\bibinitperiod}{Adi}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c67bbb526b5ae9f6e004518b051fa930}{Bruinsma}{B\bibinitperiod}{Stephen\bibnamedelima P}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3cf859a2b3742958369f1a98c93fc386}{Overton}{O\bibinitperiod}{Mark\bibnamedelima C}{M\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2008cedd472f3e742a40ef02fb10cd3f}{Blumer}{B\bibinitperiod}{Kendall\bibnamedelima J}{K\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7eaba38c62b5566d030b955b8847fc8b}{Baranski}{B\bibinitperiod}{Thomas\bibnamedelima J}{T\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{uniquename=0,hash=09619d0bc23499edabc4f01f7e1221d9}{Floyd}{F\bibinitperiod}{Desiree\bibnamedelima H}{D\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=82e327c5daf647d7f712a44400737178}{Geva}{G\bibinitperiod}{Adi}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c67bbb526b5ae9f6e004518b051fa930}{Bruinsma}{B\bibinitperiod}{Stephen\bibnamedelima P}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3cf859a2b3742958369f1a98c93fc386}{Overton}{O\bibinitperiod}{Mark\bibnamedelima C}{M\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2008cedd472f3e742a40ef02fb10cd3f}{Blumer}{B\bibinitperiod}{Kendall\bibnamedelima J}{K\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7eaba38c62b5566d030b955b8847fc8b}{Baranski}{B\bibinitperiod}{Thomas\bibnamedelima J}{T\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{d10b4f563be61c8db735ee31a43ea23a}
      \strng{fullhash}{cea8c49d62cf4c32cd80060cc95591d0}
      \field{sortinit}{F}
      \field{sortinithash}{9661cce5f16ac30b6b0c804d4583ed99}
      \field{labelyear}{2003}
      \field{datelabelsource}{}
      \field{labeltitle}{{C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast.}}
      \field{abstract}{Recent studies demonstrate that members of the superfamily of G protein-coupled receptors (GPCRs) form oligomers both in vitro and in vivo. The mechanisms by which GPCRs oligomerize and the roles of accessory proteins in this process are not well understood. We used disulfide-trapping experiments to show that C5a receptors, expressed in mammalian cells, reside in membranes as oligomers (Klco, J. M., Lassere, T. B., and Baranski, T. J. (2003) J. Biol. Chem. 278, 35345-35353). To begin to address how C5a receptors form oligomers, we now use fluorescence resonance energy transfer experiments on human C5a receptors expressed in the lower eukaryote Saccharomyces cerevisiae. C5a receptors tagged with variants of the green fluorescent protein display energy transfer in intact yeast, demonstrating that mammalian accessory proteins are not required for C5a receptor oligomerization. In both intact yeast cells and membrane preparations, agonist does not affect FRET efficiency, and little energy transfer is observed between the C5a receptor and a co-expressed yeast pheromone receptor (encoded by STE2), indicating that C5a receptor oligomerization is both receptor-specific and constitutive. FRET studies performed on fractionated membranes demonstrate similar levels of energy transfer between tagged C5a receptors in endoplasmic reticulum compared with plasma membrane, and urea washing of membranes has little effect on the extent of energy transfer. The oligomerization of C5a receptors expressed in yeast displays characteristics similar to those observed for other GPCRs studied in mammalian cells. This model system should prove useful for further studies to define mechanisms of oligomerization of mammalian GPCRs.}
      \field{issn}{0021-9258}
      \field{journaltitle}{J Biol Chem}
      \field{number}{37}
      \field{title}{{C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast.}}
      \field{volume}{278}
      \field{year}{2003}
      \field{pages}{35354\bibrangedash 35361}
      \verb{doi}
      \verb 10.1074/jbc.M305607200
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2003/Floyd et al/Floyd et al. - 2003 - C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled rece.pdf:pdf
      \endverb
    \endentry
    \entry{Forster1948}{article}{}
      \name{labelname}{1}{}{%
        {{uniquename=0,hash=f9c30ba769fede083735572055748a93}{F{ö}rster}{F\bibinitperiod}{Th.}{T\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{uniquename=0,hash=f9c30ba769fede083735572055748a93}{F{ö}rster}{F\bibinitperiod}{Th.}{T\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{f9c30ba769fede083735572055748a93}
      \strng{fullhash}{f9c30ba769fede083735572055748a93}
      \field{sortinit}{F}
      \field{sortinithash}{9661cce5f16ac30b6b0c804d4583ed99}
      \field{labelyear}{1948}
      \field{datelabelsource}{}
      \field{labeltitle}{{Zwischenmolekulare Energiewanderung und Fluoreszenz}}
      \field{issn}{00033804}
      \field{journaltitle}{Ann Phys}
      \field{number}{1-2}
      \field{title}{{Zwischenmolekulare Energiewanderung und Fluoreszenz}}
      \field{volume}{437}
      \field{year}{1948}
      \field{pages}{55\bibrangedash 75}
      \verb{doi}
      \verb 10.1002/andp.19484370105
      \endverb
      \verb{url}
      \verb http://doi.wiley.com/10.1002/andp.19484370105
      \endverb
    \endentry
    \entry{Fredriksson2003}{article}{}
      \name{labelname}{4}{}{%
        {{uniquename=0,hash=9b83f491ff3f27404628c94dcecceef7}{Fredriksson}{F\bibinitperiod}{Robert}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7fbb37a2403148a68c980ab0748bdc9b}{Lagerstr{ö}m}{L\bibinitperiod}{Malin\bibnamedelima C}{M\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3b2cdea7b9370d89f1cb0548a9cddf83}{Lundin}{L\bibinitperiod}{Lars-Gustav}{L\bibinithyphendelim G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f3aaa97742c4057fd56f8c2c7a264462}{Schi{ö}th}{S\bibinitperiod}{Helgi\bibnamedelima B}{H\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{uniquename=0,hash=9b83f491ff3f27404628c94dcecceef7}{Fredriksson}{F\bibinitperiod}{Robert}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7fbb37a2403148a68c980ab0748bdc9b}{Lagerstr{ö}m}{L\bibinitperiod}{Malin\bibnamedelima C}{M\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3b2cdea7b9370d89f1cb0548a9cddf83}{Lundin}{L\bibinitperiod}{Lars-Gustav}{L\bibinithyphendelim G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f3aaa97742c4057fd56f8c2c7a264462}{Schi{ö}th}{S\bibinitperiod}{Helgi\bibnamedelima B}{H\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ecf7fafd7fcb1f6cec2d319ef007f695}
      \strng{fullhash}{9705496006498511ae20c92511bf38a1}
      \field{sortinit}{F}
      \field{sortinithash}{9661cce5f16ac30b6b0c804d4583ed99}
      \field{labelyear}{2003}
      \field{datelabelsource}{}
      \field{labeltitle}{{The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.}}
      \field{abstract}{The superfamily of G-protein-coupled receptors (GPCRs) is very diverse in structure and function and its members are among the most pursued targets for drug development. We identified more than 800 human GPCR sequences and simultaneously analyzed 342 unique functional nonolfactory human GPCR sequences with phylogenetic analyses. Our results show, with high bootstrap support, five main families, named glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin, forming the GRAFS classification system. The rhodopsin family is the largest and forms four main groups with 13 sub-branches. Positions of the GPCRs in chromosomal paralogons regions indicate the importance of tetraploidizations or local gene duplication events for their creation. We also searched for "fingerprint" motifs using Hidden Markov Models delineating the putative inter-relationship of the GRAFS families. We show several common structural features indicating that the human GPCRs in the GRAFS families share a common ancestor. This study represents the first overall map of the GPCRs in a single mammalian genome. Our novel approach of analyzing such large and diverse sequence sets may be useful for studies on GPCRs in other genomes and divergent protein families.}
      \field{isbn}{0026-895X}
      \field{issn}{0026-895X}
      \field{journaltitle}{Mol Pharmacol}
      \field{number}{6}
      \field{title}{{The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.}}
      \field{volume}{63}
      \field{year}{2003}
      \field{pages}{1256\bibrangedash 1272}
      \verb{doi}
      \verb 10.1124/mol.63.6.1256
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2003/Fredriksson et al/Fredriksson et al. - 2003 - The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogo.pdf:pdf
      \endverb
    \endentry
    \entry{Fribourg2011a}{article}{}
      \name{labelname}{22}{}{%
        {{uniquename=0,hash=3fdabaf2a6761389cb87972dc3135ceb}{Fribourg}{F\bibinitperiod}{Miguel}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=137fe6d617d41c24ef6c7145f0106670}{Moreno}{M\bibinitperiod}{Jos{é}\bibnamedelima L.}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=fba2de7070bfbb26b4137d7bc62b102c}{Holloway}{H\bibinitperiod}{Terrell}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=34982c1c650e8b504180d99b1fe6c8cf}{Provasi}{P\bibinitperiod}{Davide}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=222bc8e4368da4cd313a4794c668dfac}{Baki}{B\bibinitperiod}{Lia}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3a400eac5907d7bdd36e9cc45749ec4d}{Mahajan}{M\bibinitperiod}{Rahul}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=814479f1bf844da8a36dad4c835c1489}{Park}{P\bibinitperiod}{Gyu}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1ac3699c06d3ce6edb724d08c720099c}{Adney}{A\bibinitperiod}{Scott\bibnamedelima K.}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8b2f75dc61cda5f8e9ff73e1ec9cc5f5}{Hatcher}{H\bibinitperiod}{Candice}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f13a7f0cc22bee2298a6c51527f38bfd}{Eltit}{E\bibinitperiod}{Jos{é}\bibnamedelima M.}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=88631aa9de641a20ea7820cd6f002232}{Ruta}{R\bibinitperiod}{Jeffrey\bibnamedelima D.}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d0c53dc31e957130274b15205768df98}{Albizu}{A\bibinitperiod}{Laura}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=80c88b1c7cc92f9bcb33605a25e00dab}{Li}{L\bibinitperiod}{Zheng}{Z\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=43668724c855ccee3bf70e8169756499}{Umali}{U\bibinitperiod}{Adrienne}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6b7275af22b1a6379172191bfeaeebe0}{Shim}{S\bibinitperiod}{Jihyun}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=da4cc897808b434d7e8154b053008dfe}{Fabiato}{F\bibinitperiod}{Alexandre}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2c566668065920587f28e9543e220b38}{MacKerell}{M\bibinitperiod}{Alexander\bibnamedelima D.}{A\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f3661157a2936f0f103e1d729bca6721}{Brezina}{B\bibinitperiod}{Vladimir}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e1effe9cb7f07efd170d06a1a965c22f}{Sealfon}{S\bibinitperiod}{Stuart\bibnamedelima C.}{S\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=caa7ad34df0c6628c95c1dbbf147fe90}{Filizola}{F\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ec54ad048e6b6f51cc2c9cb075818a2e}{Gonz{á}lez-Maeso}{G\bibinithyphendelim M\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c5f78cdc5eed20f47b1e49861fd5c724}{Logothetis}{L\bibinitperiod}{Diomedes\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{22}{}{%
        {{uniquename=0,hash=3fdabaf2a6761389cb87972dc3135ceb}{Fribourg}{F\bibinitperiod}{Miguel}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=137fe6d617d41c24ef6c7145f0106670}{Moreno}{M\bibinitperiod}{Jos{é}\bibnamedelima L.}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=fba2de7070bfbb26b4137d7bc62b102c}{Holloway}{H\bibinitperiod}{Terrell}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=34982c1c650e8b504180d99b1fe6c8cf}{Provasi}{P\bibinitperiod}{Davide}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=222bc8e4368da4cd313a4794c668dfac}{Baki}{B\bibinitperiod}{Lia}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3a400eac5907d7bdd36e9cc45749ec4d}{Mahajan}{M\bibinitperiod}{Rahul}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=814479f1bf844da8a36dad4c835c1489}{Park}{P\bibinitperiod}{Gyu}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1ac3699c06d3ce6edb724d08c720099c}{Adney}{A\bibinitperiod}{Scott\bibnamedelima K.}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8b2f75dc61cda5f8e9ff73e1ec9cc5f5}{Hatcher}{H\bibinitperiod}{Candice}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f13a7f0cc22bee2298a6c51527f38bfd}{Eltit}{E\bibinitperiod}{Jos{é}\bibnamedelima M.}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=88631aa9de641a20ea7820cd6f002232}{Ruta}{R\bibinitperiod}{Jeffrey\bibnamedelima D.}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d0c53dc31e957130274b15205768df98}{Albizu}{A\bibinitperiod}{Laura}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=80c88b1c7cc92f9bcb33605a25e00dab}{Li}{L\bibinitperiod}{Zheng}{Z\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=43668724c855ccee3bf70e8169756499}{Umali}{U\bibinitperiod}{Adrienne}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6b7275af22b1a6379172191bfeaeebe0}{Shim}{S\bibinitperiod}{Jihyun}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=da4cc897808b434d7e8154b053008dfe}{Fabiato}{F\bibinitperiod}{Alexandre}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2c566668065920587f28e9543e220b38}{MacKerell}{M\bibinitperiod}{Alexander\bibnamedelima D.}{A\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f3661157a2936f0f103e1d729bca6721}{Brezina}{B\bibinitperiod}{Vladimir}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e1effe9cb7f07efd170d06a1a965c22f}{Sealfon}{S\bibinitperiod}{Stuart\bibnamedelima C.}{S\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=caa7ad34df0c6628c95c1dbbf147fe90}{Filizola}{F\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ec54ad048e6b6f51cc2c9cb075818a2e}{Gonz{á}lez-Maeso}{G\bibinithyphendelim M\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c5f78cdc5eed20f47b1e49861fd5c724}{Logothetis}{L\bibinitperiod}{Diomedes\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{04494e7e4823f86f500141d4ee8a1efb}
      \strng{fullhash}{679258c2739f36f0cf6eab3e9b943dae}
      \field{sortinit}{F}
      \field{sortinithash}{9661cce5f16ac30b6b0c804d4583ed99}
      \field{labelyear}{2011}
      \field{labelmonth}{11}
      \field{datelabelsource}{}
      \field{labeltitle}{{Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs}}
      \field{issn}{00928674}
      \field{journaltitle}{Cell}
      \field{month}{11}
      \field{number}{5}
      \field{title}{{Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs}}
      \field{volume}{147}
      \field{year}{2011}
      \field{pages}{1011\bibrangedash 1023}
      \verb{doi}
      \verb 10.1016/j.cell.2011.09.055
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2011/Fribourg et al/Fribourg et al. - 2011 - Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic(2).pdf:pdf;:Users/ska/Documents/thesis/literature/2011/Fribourg et al/Fribourg et al. - 2011 - Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic(3).pdf:pdf
      \endverb
      \verb{url}
      \verb http://linkinghub.elsevier.com/retrieve/pii/S0092867411012724
      \endverb
    \endentry
    \entry{Fung2009}{article}{}
      \name{labelname}{8}{}{%
        {{uniquename=0,hash=d09bdcff5079c37920614cdb726cb1a4}{Fung}{F\bibinitperiod}{Juan\bibnamedelima Jos{é}}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a128c61e0bfd8a3756411d1233dcd583}{Deupi}{D\bibinitperiod}{Xavier}{X\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=def1cdb974af3ecdde6ccd24e44e5ca5}{Pardo}{P\bibinitperiod}{Leonardo}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=63c57315703db012bfd2be6f7938e4be}{Yao}{Y\bibinitperiod}{Xiao\bibnamedelima Jie}{X\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8b59cd87e14d0106c576d48f41202480}{Velez-Ruiz}{V\bibinithyphendelim R\bibinitperiod}{Gisselle\bibnamedelima a}{G\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7f526e75c6eaf88652c0835bb83b96df}{Devree}{D\bibinitperiod}{Brian\bibnamedelima T}{B\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f7e147d808035020d8efae131779b1ce}{Sunahara}{S\bibinitperiod}{Roger\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=decc5062cdeca8b403aad00dc8d4ce14}{Kobilka}{K\bibinitperiod}{Brian\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{uniquename=0,hash=d09bdcff5079c37920614cdb726cb1a4}{Fung}{F\bibinitperiod}{Juan\bibnamedelima Jos{é}}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a128c61e0bfd8a3756411d1233dcd583}{Deupi}{D\bibinitperiod}{Xavier}{X\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=def1cdb974af3ecdde6ccd24e44e5ca5}{Pardo}{P\bibinitperiod}{Leonardo}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=63c57315703db012bfd2be6f7938e4be}{Yao}{Y\bibinitperiod}{Xiao\bibnamedelima Jie}{X\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8b59cd87e14d0106c576d48f41202480}{Velez-Ruiz}{V\bibinithyphendelim R\bibinitperiod}{Gisselle\bibnamedelima a}{G\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7f526e75c6eaf88652c0835bb83b96df}{Devree}{D\bibinitperiod}{Brian\bibnamedelima T}{B\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f7e147d808035020d8efae131779b1ce}{Sunahara}{S\bibinitperiod}{Roger\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=decc5062cdeca8b403aad00dc8d4ce14}{Kobilka}{K\bibinitperiod}{Brian\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{61930d3df148b06e047b8cb6b52807f1}
      \strng{fullhash}{0c55618eaa7076c5e33f20f75f0ce121}
      \field{sortinit}{F}
      \field{sortinithash}{9661cce5f16ac30b6b0c804d4583ed99}
      \field{labelyear}{2009}
      \field{labelmonth}{11}
      \field{datelabelsource}{}
      \field{labeltitle}{{Ligand-regulated oligomerization of beta(2)-adrenoceptors in a model lipid bilayer.}}
      \field{abstract}{The beta(2)-adrenoceptor (beta(2)AR) was one of the first Family A G protein-coupled receptors (GPCRs) shown to form oligomers in cellular membranes, yet we still know little about the number and arrangement of protomers in oligomers, the influence of ligands on the organization or stability of oligomers, or the requirement for other proteins to promote oligomerization. We used fluorescence resonance energy transfer (FRET) to characterize the oligomerization of purified beta(2)AR site-specifically labelled at three different positions with fluorophores and reconstituted into a model lipid bilayer. Our results suggest that the beta(2)AR is predominantly tetrameric following reconstitution into phospholipid vesicles. Agonists and antagonists have little effect on the relative orientation of protomers in oligomeric complexes. In contrast, binding of inverse agonists leads to significant increases in FRET efficiencies for most labelling pairs, suggesting that this class of ligand promotes tighter packing of protomers and/or the formation of more complex oligomers by reducing conformational fluctuations in individual protomers. The results provide new structural insights into beta(2)AR oligomerization and suggest a possible mechanism for the functional effects of inverse agonists.}
      \field{issn}{1460-2075}
      \field{journaltitle}{EMBO J}
      \field{month}{11}
      \field{number}{21}
      \field{title}{{Ligand-regulated oligomerization of beta(2)-adrenoceptors in a model lipid bilayer.}}
      \field{volume}{28}
      \field{year}{2009}
      \field{pages}{3315\bibrangedash 28}
      \verb{doi}
      \verb 10.1038/emboj.2009.267
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2009/Fung et al/Fung et al. - 2009 - Ligand-regulated oligomerization of beta(2)-adrenoceptors in a model lipid bilayer.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2748299%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
      \keyw{Cysteine,Cysteine: genetics,Fluorescence Resonance Energy Transfer,GTP-Binding Proteins,GTP-Binding Proteins: metabolism,Humans,Ligands,Lipid Bilayers,Lipid Bilayers: metabolism,Liposomes,Liposomes: metabolism,Models,Molecular,Point Mutation,Protein Binding,Protein Multimerization,Receptors,Adrenergic,beta-2,Receptors,Adrenergic,beta-2: analysis,Receptors,Adrenergic,beta-2: genetics,Receptors,Adrenergic,beta-2: metabolism}
    \endentry
    \entry{Fuxe2003}{article}{}
      \name{labelname}{17}{uniquelist=2}{%
        {{uniquename=0,hash=c4b48e7715b5e6a77fb44f8c0dabaf97}{Fuxe}{F\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d41ece86096a17e5934a03c4e954d5b8}{Agnati}{A\bibinitperiod}{L\bibnamedelima F}{L\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=38e270b2cbdfa30c6f410ff6cc097407}{Jacobsen}{J\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=411b6f7d8cb655e4861cccb6d4835349}{Hillion}{H\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=dd4df552704941c5b200713b4f48e15b}{Canals}{C\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f7d3820424d71f3beda336a23e1e9ef4}{Torvinen}{T\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e17bff139adfa86abff6ab7e95926008}{Tinner-Staines}{T\bibinithyphendelim S\bibinitperiod}{B}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b10f6f4b93180cf6b177360b1c51af09}{Staines}{S\bibinitperiod}{W}{W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0a4daadb412d5c834e697ad8a31ff78f}{Rosin}{R\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=31f2735939927dff5c402a9d623410ed}{Terasmaa}{T\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=be5b461b9159055cebeb75730b44c39b}{Popoli}{P\bibinitperiod}{P}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1c27f92397e46340eed672848f3824d8}{Leo}{L\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ea4e82fa2d79871c79571f40229d6c57}{Vergoni}{V\bibinitperiod}{V}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b06cb33c196c7e78c5f5831e435dbaed}{Lluis}{L\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a3ced928768305b68c0ed171a7adc975}{Ciruela}{C\bibinitperiod}{F}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=db704d82e661984cef0d9b49bdd55bc4}{Franco}{F\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3f744a63ca07411116ce3244dbbb696a}{Ferr{é}}{F\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{17}{uniquelist=2}{%
        {{uniquename=0,hash=c4b48e7715b5e6a77fb44f8c0dabaf97}{Fuxe}{F\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d41ece86096a17e5934a03c4e954d5b8}{Agnati}{A\bibinitperiod}{L\bibnamedelima F}{L\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=38e270b2cbdfa30c6f410ff6cc097407}{Jacobsen}{J\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=411b6f7d8cb655e4861cccb6d4835349}{Hillion}{H\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=dd4df552704941c5b200713b4f48e15b}{Canals}{C\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f7d3820424d71f3beda336a23e1e9ef4}{Torvinen}{T\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e17bff139adfa86abff6ab7e95926008}{Tinner-Staines}{T\bibinithyphendelim S\bibinitperiod}{B}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b10f6f4b93180cf6b177360b1c51af09}{Staines}{S\bibinitperiod}{W}{W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0a4daadb412d5c834e697ad8a31ff78f}{Rosin}{R\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=31f2735939927dff5c402a9d623410ed}{Terasmaa}{T\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=be5b461b9159055cebeb75730b44c39b}{Popoli}{P\bibinitperiod}{P}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1c27f92397e46340eed672848f3824d8}{Leo}{L\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ea4e82fa2d79871c79571f40229d6c57}{Vergoni}{V\bibinitperiod}{V}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b06cb33c196c7e78c5f5831e435dbaed}{Lluis}{L\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a3ced928768305b68c0ed171a7adc975}{Ciruela}{C\bibinitperiod}{F}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=db704d82e661984cef0d9b49bdd55bc4}{Franco}{F\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3f744a63ca07411116ce3244dbbb696a}{Ferr{é}}{F\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{bdc7547cee519e8c71a89f46066828d7}
      \strng{fullhash}{d45f661dbe90c61ead055088e652d5a1}
      \field{sortinit}{F}
      \field{sortinithash}{9661cce5f16ac30b6b0c804d4583ed99}
      \field{labelyear}{2003}
      \field{labelmonth}{12}
      \field{datelabelsource}{}
      \field{labeltitle}{{Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.}}
      \field{abstract}{Recently evidence has been presented that adenosine A2A and dopamine D2 receptors form functional heteromeric receptor complexes as demonstrated in human neuroblastoma cells and mouse fibroblast Ltk- cells. These A2A/D2 heteromeric receptor complexes undergo coaggregation, cointernalization, and codesensitization on D2 or A2A receptor agonist treatments and especially after combined agonist treatment. It is hypothesized that the A2A/D2 receptor heteromer represents the molecular basis for the antagonistic A2A/D2 receptor interactions demonstrated at the biochemical and behavioral levels. Functional heteromeric complexes between A2A and metabotropic glutamate 5 receptors (mGluR5) have also recently been demonstrated in HEK-293 cells and rat striatal membrane preparations. The A2A/mGluR5 receptor heteromer may account for the synergism found after combined agonist treatments demonstrated in different in vitro and in vivo models. D2, A2A, and mGluR5 receptors are found together in the dendritic spines of the striatopallidal GABA neurons. Therefore, possible D2/A2A/mGluR5 multimeric receptor complexes and the receptor interactions within them may have a major role in controlling the dorsal and ventral striatopallidal GABA neurons involved in Parkinson's disease and in schizophrenia and drug addiction, respectively.}
      \field{issn}{1526-632X}
      \field{journaltitle}{Neurology}
      \field{month}{12}
      \field{number}{11 Suppl 6}
      \field{title}{{Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.}}
      \field{volume}{61}
      \field{year}{2003}
      \field{pages}{S19\bibrangedash 23}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/14663004
      \endverb
      \keyw{Animals,Cell Line,Corpus Striatum,Corpus Striatum: metabolism,Dimerization,Humans,Macromolecular Substances,Mice,Parkinson Disease,Parkinson Disease: metabolism,Parkinson Disease: therapy,Receptor,Adenosine A2A,Receptor,Adenosine A2A: metabolism,Receptor,Metabotropic Glutamate 5,Receptors,Dopamine D2,Receptors,Dopamine D2: metabolism,Receptors,Metabotropic Glutamate,Receptors,Metabotropic Glutamate: metabolism,Signal Transduction,Signal Transduction: physiology,gamma-Aminobutyric Acid,gamma-Aminobutyric Acid: metabolism}
    \endentry
    \entry{Fuxe2005}{article}{}
      \name{labelname}{13}{uniquelist=2}{%
        {{uniquename=0,hash=6043dcc976ab16e0954f1c2f851bccde}{Fuxe}{F\bibinitperiod}{Kjell}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4cf7b2a170b143f30a95815bd1120011}{Ferr{é}}{F\bibinitperiod}{Sergi}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1d5d31e7190d53a48db76e82381f1954}{Canals}{C\bibinitperiod}{Meritxell}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e500d37ea5d8b0f6a6962f97dac6e428}{Torvinen}{T\bibinitperiod}{Maria}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e83d933519ddc80a8e87ba74882ebde1}{Terasmaa}{T\bibinitperiod}{Anton}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=96f7019559f60d4e2fc45b0b03a30083}{Marcellino}{M\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c69ec78696ca4f4df67ff0c9fd5d1216}{Goldberg}{G\bibinitperiod}{Steven\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=706f6ad4674b6b049c6606a751a49336}{Staines}{S\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=09685e56c6cfd8616d5e0e312654453c}{Jacobsen}{J\bibinitperiod}{Kirsten\bibnamedelima X}{K\bibinitperiod\bibinitdelim X\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=409f99192e48b6dfc41badb5f1600a18}{Lluis}{L\bibinitperiod}{Carmen}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9b943194ddb7d28d51ab68f9b140a2dc}{Woods}{W\bibinitperiod}{Amina\bibnamedelima S}{A\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=014bfe300b84cb2a84fc336ea005aeed}{Agnati}{A\bibinitperiod}{Luigi\bibnamedelima F}{L\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f319c58242417e6551e0dc6058fdd4f3}{Franco}{F\bibinitperiod}{Rafael}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{13}{uniquelist=2}{%
        {{uniquename=0,hash=6043dcc976ab16e0954f1c2f851bccde}{Fuxe}{F\bibinitperiod}{Kjell}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4cf7b2a170b143f30a95815bd1120011}{Ferr{é}}{F\bibinitperiod}{Sergi}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1d5d31e7190d53a48db76e82381f1954}{Canals}{C\bibinitperiod}{Meritxell}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e500d37ea5d8b0f6a6962f97dac6e428}{Torvinen}{T\bibinitperiod}{Maria}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e83d933519ddc80a8e87ba74882ebde1}{Terasmaa}{T\bibinitperiod}{Anton}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=96f7019559f60d4e2fc45b0b03a30083}{Marcellino}{M\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c69ec78696ca4f4df67ff0c9fd5d1216}{Goldberg}{G\bibinitperiod}{Steven\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=706f6ad4674b6b049c6606a751a49336}{Staines}{S\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=09685e56c6cfd8616d5e0e312654453c}{Jacobsen}{J\bibinitperiod}{Kirsten\bibnamedelima X}{K\bibinitperiod\bibinitdelim X\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=409f99192e48b6dfc41badb5f1600a18}{Lluis}{L\bibinitperiod}{Carmen}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9b943194ddb7d28d51ab68f9b140a2dc}{Woods}{W\bibinitperiod}{Amina\bibnamedelima S}{A\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=014bfe300b84cb2a84fc336ea005aeed}{Agnati}{A\bibinitperiod}{Luigi\bibnamedelima F}{L\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f319c58242417e6551e0dc6058fdd4f3}{Franco}{F\bibinitperiod}{Rafael}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{70163fd997b01c5afc4feb7245847fe5}
      \strng{fullhash}{e4480166494fcf09c69349105bb2d582}
      \field{sortinit}{F}
      \field{sortinithash}{9661cce5f16ac30b6b0c804d4583ed99}
      \field{labelyear}{2005}
      \field{labelmonth}{01}
      \field{datelabelsource}{}
      \field{labeltitle}{{Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.}}
      \field{abstract}{The existence of A2A-D2 heteromeric complexes is based on coimmunoprecipitation studies and on fluorescence resonance energy transfer and bioluminescence resonance energy transfer analyses. It has now become possible to show that A2A and D2 receptors also coimmunoprecipitate in striatal tissue, giving evidence for the existence of A2A-D2 heteromeric receptor complexes also in rat striatal tissue. The analysis gives evidence that these heteromers are constitutive, as they are observed in the absence of A2A and D2 agonists. The A2A-D2 heteromers could either be A2A-D2 heterodimers and/or higher-order A2A -D2 hetero-oligomers. In striatal neurons there are probably A2A-D2 heteromeric complexes, together with A2A-D2 homomeric complexes in the neuronal surface membrane. Their stoichiometry in various microdomains will have a major role in determining A2A and D2 signaling in the striatopallidal GABA neurons. Through the use of D2/D1 chimeras, evidence has been obtained that the fifth transmembrane (TM) domain and/or the I3 of the D2 receptor are part of the A2A-D2 receptor interface, where electrostatic epitope-epitope interactions involving the N-terminal part of I3 of the D2 receptor (arginine-rich epitope) play a major role, interacting with the carboxyl terminus of the A2A receptor. Computerized modeling of A2A-D2 heteromers are in line with these findings. It seems likely that A2A receptor-induced reduction of D2 receptor recognition, G protein coupling, and signaling, as well as the existence of A2A-D2 co-trafficking, are the consequence of the existence of an A2A-D2 receptor heteromer. The relevance of A2A-D2 heteromeric receptor complexes for Parkinson's disease and schizophrenia is emphasized as well as for the treatment of these diseases. Finally, recent evidence for the existence of antagonistic A2A-D3 heteromeric receptor complexes in cotransfected cell lines has been summarized.}
      \field{issn}{0895-8696}
      \field{journaltitle}{J Mol Neurosci}
      \field{month}{01}
      \field{number}{2-3}
      \field{title}{{Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.}}
      \field{volume}{26}
      \field{year}{2005}
      \field{pages}{209\bibrangedash 20}
      \verb{doi}
      \verb 10.1385/JMN:26:2-3:209
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/16012194
      \endverb
      \keyw{Animals,Antipsychotic Agents,Antipsychotic Agents: pharmacology,Antipsychotic Agents: therapeutic use,Brain,Brain: physiopathology,Fluorescence Resonance Energy Transfer,Humans,Macromolecular Substances,Macromolecular Substances: chemistry,Macromolecular Substances: metabolism,Receptor,Adenosine A2A,Receptor,Adenosine A2A: chemistry,Receptor,Adenosine A2A: physiology,Receptors,Dopamine D2,Receptors,Dopamine D2: chemistry,Receptors,Dopamine D2: physiology,Recombinant Proteins,Recombinant Proteins: chemistry,Recombinant Proteins: metabolism,Schizophrenia,Schizophrenia: drug therapy,Schizophrenia: physiopathology}
    \endentry
    \entry{Gagne2002}{article}{}
      \name{labelname}{3}{}{%
        {{uniquename=0,hash=2ee6114122dbd93524cd619a3daa717a}{Gagne}{G\bibinitperiod}{a}{a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9ad3d4a1ae94fc848c02ad4a24928487}{Banks}{B\bibinitperiod}{P}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=161bb52ea5cbc2ca11ba41080ef82e2d}{Hurt}{H\bibinitperiod}{S\bibnamedelima D}{S\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{uniquename=0,hash=2ee6114122dbd93524cd619a3daa717a}{Gagne}{G\bibinitperiod}{a}{a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9ad3d4a1ae94fc848c02ad4a24928487}{Banks}{B\bibinitperiod}{P}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=161bb52ea5cbc2ca11ba41080ef82e2d}{Hurt}{H\bibinitperiod}{S\bibnamedelima D}{S\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{7b951bdedbdbd5c8720b368d2653d835}
      \strng{fullhash}{1a9d643b0e33dcc0a2a1da2bd527d600}
      \field{sortinit}{G}
      \field{sortinithash}{480ee01f9ffd559b3258d822f54a8ac2}
      \field{labelyear}{2002}
      \field{datelabelsource}{}
      \field{labeltitle}{{Use of fluorescence polarization detection for the measurement of fluopeptidetm binding to G protein-coupled receptors.}}
      \field{abstract}{G protein-coupled receptors (GPCRs) represent the single largest molecular target of therapeutic drugs currently on the market, and are also the most common target in high throughput screening assays designed to identify potential new drug candidates. A large percentage of these assays are now formatted as radioligand binding assays. Fluorescence polarization ligand binding assays can offer a non-rad alternative to radioligand binding assays. In addition, fluorescence polarization assays are a homogenous format that is easy to automate for high throughput screening. We have developed a series of peptide ligands labeled with the fluorescent dye BODIPY TMR whose binding to GPCRs can be detected using fluorescence polarization methodology. BODIPY TMR has advantages over the more commonly used fluorescein dye in high throughput screening (HTS) assays due to the fact that its excitation and emission spectra are red-shifted approximately 50 nm relative to fluorescein. Assays based on BODIPY TMR ligands are therefore less susceptible to interference from tissue auto-fluorescence in the assay matrix, or the effects of colored or fluorescent compounds in the screening libraries. A series of BODIPY TMR labeled peptides have been prepared that bind to a range of GPCRs including melanin concentrating hormone, bradykinin, and melanocortin receptors. Conditions have been optimized in order to utilize a comparable amount of receptor membrane preparation as is used in a radioligand binding assay. The assays are formatted in 384-well microplates with a standard volume of 40 microL. We have compared the assays across the different fluorescence polarization (FP) readers available to determine the parameters for each instrument necessary to achieve the required precision.}
      \field{issn}{10799893}
      \field{journaltitle}{J Recept Signal Transduct Res}
      \field{number}{1-4}
      \field{title}{{Use of fluorescence polarization detection for the measurement of fluopeptidetm binding to G protein-coupled receptors.}}
      \field{volume}{22}
      \field{year}{2002}
      \field{pages}{333\bibrangedash 343}
      \verb{doi}
      \verb 10.1081/RRS-120014605
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2002/Gagne, Banks, Hurt/Gagne, Banks, Hurt - 2002 - Use of fluorescence polarization detection for the measurement of fluopeptidetm binding to G protein-coupled.pdf:pdf
      \endverb
    \endentry
    \entry{Gautier2008}{article}{}
      \name{labelname}{7}{}{%
        {{uniquename=0,hash=3996ebdbf561cabd95e300be227c239f}{Gautier}{G\bibinitperiod}{Arnaud}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e9c47c4b727032b6b7b3d499445f42b0}{Juillerat}{J\bibinitperiod}{Alexandre}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=17d8535e58377e118cc26c2956c98c61}{Heinis}{H\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1c20bbbca7c8322841e1316513f5c381}{Corr{ê}a}{C\bibinitperiod}{Ivan\bibnamedelima Reis}{I\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e84a89ef1d4087b5452d257cde3e4f4}{Kindermann}{K\bibinitperiod}{Maik}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b8aa38c28225adaee89d3da1110c5099}{Beaufils}{B\bibinitperiod}{Florent}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4baba1a7076efa3570b3ef15b073806e}{Johnsson}{J\bibinitperiod}{Kai}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{uniquename=0,hash=3996ebdbf561cabd95e300be227c239f}{Gautier}{G\bibinitperiod}{Arnaud}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e9c47c4b727032b6b7b3d499445f42b0}{Juillerat}{J\bibinitperiod}{Alexandre}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=17d8535e58377e118cc26c2956c98c61}{Heinis}{H\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1c20bbbca7c8322841e1316513f5c381}{Corr{ê}a}{C\bibinitperiod}{Ivan\bibnamedelima Reis}{I\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e84a89ef1d4087b5452d257cde3e4f4}{Kindermann}{K\bibinitperiod}{Maik}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b8aa38c28225adaee89d3da1110c5099}{Beaufils}{B\bibinitperiod}{Florent}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4baba1a7076efa3570b3ef15b073806e}{Johnsson}{J\bibinitperiod}{Kai}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8b8655b452b702b866d61e2c187dc946}
      \strng{fullhash}{1250fa3f6ea196f9ac9fe9b374d2df3c}
      \field{sortinit}{G}
      \field{sortinithash}{480ee01f9ffd559b3258d822f54a8ac2}
      \field{labelyear}{2008}
      \field{labelmonth}{02}
      \field{datelabelsource}{}
      \field{labeltitle}{{An engineered protein tag for multiprotein labeling in living cells.}}
      \field{abstract}{The visualization of complex cellular processes involving multiple proteins requires the use of spectroscopically distinguishable fluorescent reporters. We have previously introduced the SNAP-tag as a general tool for the specific labeling of SNAP-tag fusion proteins in living cells. The SNAP-tag is derived from the human DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT) and can be covalently labeled in living cells using O6-benzylguanine derivatives bearing a chemical probe. Here we report the generation of an AGT-based tag, named CLIP-tag, which reacts specifically with O2-benzylcytosine derivatives. Because SNAP-tag and CLIP-tag possess orthogonal substrate specificities, SNAP and CLIP fusion proteins can be labeled simultaneously and specifically with different molecular probes in living cells. We furthermore show simultaneous pulse-chase experiments to visualize different generations of two different proteins in one sample.}
      \field{issn}{1074-5521}
      \field{journaltitle}{Chem Biol}
      \field{month}{02}
      \field{number}{2}
      \field{title}{{An engineered protein tag for multiprotein labeling in living cells.}}
      \field{volume}{15}
      \field{year}{2008}
      \field{pages}{128\bibrangedash 36}
      \verb{doi}
      \verb 10.1016/j.chembiol.2008.01.007
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2008/Gautier et al/Gautier et al. - 2008 - An engineered protein tag for multiprotein labeling in living cells.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/18291317
      \endverb
      \keyw{Animals,Binding Sites,CHO Cells,Cell Survival,Cricetinae,Cricetulus,Cytosine,Cytosine: analogs {\&} derivatives,Cytosine: metabolism,Fluorescent Dyes,Fluorescent Dyes: chemical synthesis,Fluorescent Dyes: chemistry,Fluorescent Dyes: metabolism,Models,Molecular,Mutation,O(6)-Methylguanine-DNA Methyltransferase,O(6)-Methylguanine-DNA Methyltransferase: genetics,O(6)-Methylguanine-DNA Methyltransferase: metaboli,Protein Conformation,Proteins,Proteins: metabolism,Staining and Labeling,Staining and Labeling: methods,Substrate Specificity}
    \endentry
    \entry{George2002}{article}{}
      \name{labelname}{3}{}{%
        {{uniquename=0,hash=4f82f18c8d9bd65242153d4ce726b4c6}{George}{G\bibinitperiod}{Susan\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e57f4894466a9d847d1e45b5c7db77a4}{O'Dowd}{O\bibinitperiod}{Brian\bibnamedelima F}{B\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bd75c83d9e526afc21a34c88ea7706da}{Lee}{L\bibinitperiod}{Samuel\bibnamedelima P}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{uniquename=0,hash=4f82f18c8d9bd65242153d4ce726b4c6}{George}{G\bibinitperiod}{Susan\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e57f4894466a9d847d1e45b5c7db77a4}{O'Dowd}{O\bibinitperiod}{Brian\bibnamedelima F}{B\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bd75c83d9e526afc21a34c88ea7706da}{Lee}{L\bibinitperiod}{Samuel\bibnamedelima P}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{495b35f2f8d19df5f3af0e0e9428d799}
      \strng{fullhash}{1097317c74f96f49d67e33d4139cb540}
      \field{sortinit}{G}
      \field{sortinithash}{480ee01f9ffd559b3258d822f54a8ac2}
      \field{labelyear}{2002}
      \field{labelmonth}{10}
      \field{datelabelsource}{}
      \field{labeltitle}{{G-Protein-coupled receptor oligomerization and its potential for drug discovery}}
      \field{abstract}{G-protein-coupled receptors (GPCRs) represent by far the largest class of targets for modern drugs. Virtually all therapeutics that are directed towards GPCRs have been designed using assays that presume that these receptors are monomeric. The recent realization that these receptors form homo-oligomeric and hetero-oligomeric complexes has added a new dimension to rational drug design. However, this important aspect of GPCR biology remains largely unincorporated into schemes to search for new therapeutics. This review provides a synopsis of the current thinking surrounding GPCR homo-oligomerization and hetero-oligomerization and shows how new models point towards unexplored avenues in the development of new therapies.}
      \field{isbn}{1474-1776}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nat Rev Drug Discov}
      \field{month}{10}
      \field{number}{10}
      \field{title}{{G-Protein-coupled receptor oligomerization and its potential for drug discovery}}
      \field{volume}{1}
      \field{year}{2002}
      \field{pages}{808\bibrangedash 820}
      \verb{doi}
      \verb 10.1038/nrd913
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2002/George, O'Dowd, Lee/George, O'Dowd, Lee - 2002 - G-Protein-coupled receptor oligomerization and its potential for drug discovery.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/doifinder/10.1038/nrd913
      \endverb
    \endentry
    \entry{Gomes2004}{article}{}
      \name{labelname}{6}{}{%
        {{uniquename=0,hash=56e29dfc4145ad88e4c296bb1fc6566f}{Gomes}{G\bibinitperiod}{Ivone}{I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ec9eb2d9c55d53a54bc4e3d1f632c32f}{Gupta}{G\bibinitperiod}{Achla}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=53fbb93e62fba73817fc3b951fd394fe}{Filipovska}{F\bibinitperiod}{Julija}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c25e06b0fc8fd121549437cfd9782dd7}{Szeto}{S\bibinitperiod}{Hazel\bibnamedelima H}{H\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0250deeb284b26b02d400e8f455fe05c}{Pintar}{P\bibinitperiod}{John\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e087092cccd54f956e674d1e2c3b44a3}{Devi}{D\bibinitperiod}{Lakshmi\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{uniquename=0,hash=56e29dfc4145ad88e4c296bb1fc6566f}{Gomes}{G\bibinitperiod}{Ivone}{I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ec9eb2d9c55d53a54bc4e3d1f632c32f}{Gupta}{G\bibinitperiod}{Achla}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=53fbb93e62fba73817fc3b951fd394fe}{Filipovska}{F\bibinitperiod}{Julija}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c25e06b0fc8fd121549437cfd9782dd7}{Szeto}{S\bibinitperiod}{Hazel\bibnamedelima H}{H\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0250deeb284b26b02d400e8f455fe05c}{Pintar}{P\bibinitperiod}{John\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e087092cccd54f956e674d1e2c3b44a3}{Devi}{D\bibinitperiod}{Lakshmi\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{e8b799668f064cf660e8cd70ecdadcf3}
      \strng{fullhash}{f48b7d9b3670cc52d7cf8abd8200f9c0}
      \field{sortinit}{G}
      \field{sortinithash}{480ee01f9ffd559b3258d822f54a8ac2}
      \field{labelyear}{2004}
      \field{datelabelsource}{}
      \field{labeltitle}{{A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia.}}
      \field{abstract}{Opiates such as morphine are the choice analgesic in the treatment of chronic pain. However their long-term use is limited because of the development of tolerance and dependence. Due to its importance in therapy, different strategies have been considered for making opiates such as morphine more effective, while curbing its liability to be abused. One such strategy has been to use a combination of drugs to improve the effectiveness of morphine. In particular, delta opioid receptor ligands have been useful in enhancing morphine's potency. The underlying molecular basis for these observations is not understood. We propose the modulation of receptor function by physical association between mu and delta opioid receptors as a potential mechanism. In support of this hypothesis, we show that mu-delta interacting complexes exist in live cells and native membranes and that the occupancy of delta receptors (by antagonists) is sufficient to enhance mu opioid receptor binding and signaling activity. Furthermore, delta receptor antagonists enhance morphine-mediated intrathecal analgesia. Thus, heterodimeric associations between mu-delta opioid receptors can be used as a model for the development of novel combination therapies for the treatment of chronic pain and other pathologies.}
      \field{isbn}{0027-8424 (Print) 0027-8424 (Linking)}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proc Natl Acad Sci U S A}
      \field{number}{14}
      \field{title}{{A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia.}}
      \field{volume}{101}
      \field{year}{2004}
      \field{pages}{5135\bibrangedash 5139}
      \verb{doi}
      \verb 10.1073/pnas.0307601101
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2004/Gomes et al/Gomes et al. - 2004 - A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia.pdf:pdf
      \endverb
    \endentry
    \entry{Green1994}{article}{}
      \name{labelname}{4}{}{%
        {{uniquename=0,hash=95c97e8d887a3e8247c54b4df2977f1c}{Green}{G\bibinitperiod}{S\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=58df66f16ccdc3f04fcc0233834561a0}{Turki}{T\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bed6ae5d5b879109e52ecfca99fa9b7a}{Innis}{I\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=335cdc65554fce0d30d68c34c3e6f775}{Liggett}{L\bibinitperiod}{S\bibnamedelima B}{S\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{uniquename=0,hash=95c97e8d887a3e8247c54b4df2977f1c}{Green}{G\bibinitperiod}{S\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=58df66f16ccdc3f04fcc0233834561a0}{Turki}{T\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bed6ae5d5b879109e52ecfca99fa9b7a}{Innis}{I\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=335cdc65554fce0d30d68c34c3e6f775}{Liggett}{L\bibinitperiod}{S\bibnamedelima B}{S\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8e2ffd156a70dbcafaa4e9ffe9964692}
      \strng{fullhash}{b9adc8e471f4f0cd38a5d131d6fb0d34}
      \field{sortinit}{G}
      \field{sortinithash}{480ee01f9ffd559b3258d822f54a8ac2}
      \field{labelyear}{1994}
      \field{labelmonth}{08}
      \field{datelabelsource}{}
      \field{labeltitle}{{Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.}}
      \field{abstract}{We have recently delineated three naturally occurring polymorphisms of the human beta 2-adrenergic receptor caused by missense mutations encoding for amino acids 16 and 27 of the extracellular N-terminus of the receptor. We have studied the functional consequences of these polymorphisms by site-directed mutagenesis and the recombinant expression of these receptors in Chinese hamster fibroblasts. The polymorphisms consist of substitutions of Gly for Arg at amino acid 16 (Arg16-->Gly), Glu for Gln at amino acid 27 (Gln27-->Glu), and a combination of both substitutions. All three mutated receptors displayed normal agonist binding and functional coupling to Gs, resulting in the stimulation of adenylyl cyclase activity. However, these mutations markedly altered the degree of agonist-promoted downregulation of receptor expression. After 24-h exposure to 10 microM isoproterenol, wild-type beta 2AR underwent a 26 +/- 3{\%} reduction in receptor density. In contrast, Arg16-->Gly underwent a 41 +/- 3{\%} reduction. Gln27-->Glu, on the other hand, was found to be completely resistant to downregulation. Arg16-->Gly+Gln27-->Glu also underwent an increased downregulation compared to wild-type beta 2AR (39 +/- 4{\%}). The rates of new receptor synthesis after irreversible alkylation were not different between these receptors, nor were the rates of agonist-promoted receptor internalization to the intracellular pool. Gln27-->Glu cellular mRNA minimally increased during agonist exposure, and wild-type beta 2AR and the other mutated receptor mRNAs did not change, which infer that the aberrant downregulation patterns of these polymorphisms may be due to the altered degradation of receptor protein.(ABSTRACT TRUNCATED AT 250 WORDS)}
      \field{issn}{0006-2960}
      \field{journaltitle}{Biochemistry}
      \field{month}{08}
      \field{number}{32}
      \field{title}{{Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.}}
      \field{volume}{33}
      \field{year}{1994}
      \field{pages}{9414\bibrangedash 9}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/7915137
      \endverb
      \keyw{Adenylate Cyclase,Adenylate Cyclase: analysis,Adrenergic beta-Agonists,Adrenergic beta-Agonists: metabolism,Amino Acid Sequence,Animals,CHO Cells,Cell Compartmentation,Cricetinae,Down-Regulation,Humans,Molecular Sequence Data,Mutagenesis,Site-Directed,Polymorphism,Genetic,Protein Conformation,Radioligand Assay,Receptors,Adrenergic,beta-2,Receptors,Adrenergic,beta-2: genetics,Receptors,Adrenergic,beta-2: metabolism,Recombinant Proteins,Recombinant Proteins: metabolism,Signal Transduction,Structure-Activity Relationship}
    \endentry
    \entry{Gronemeyer2006}{article}{}
      \name{labelname}{5}{}{%
        {{uniquename=0,hash=ea849cec379edeec252ccf8c15e38a11}{Gronemeyer}{G\bibinitperiod}{Thomas}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e26a6088950423d91da3a6b628624b62}{Chidley}{C\bibinitperiod}{Christopher}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e9c47c4b727032b6b7b3d499445f42b0}{Juillerat}{J\bibinitperiod}{Alexandre}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=17d8535e58377e118cc26c2956c98c61}{Heinis}{H\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4baba1a7076efa3570b3ef15b073806e}{Johnsson}{J\bibinitperiod}{Kai}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{uniquename=0,hash=ea849cec379edeec252ccf8c15e38a11}{Gronemeyer}{G\bibinitperiod}{Thomas}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e26a6088950423d91da3a6b628624b62}{Chidley}{C\bibinitperiod}{Christopher}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e9c47c4b727032b6b7b3d499445f42b0}{Juillerat}{J\bibinitperiod}{Alexandre}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=17d8535e58377e118cc26c2956c98c61}{Heinis}{H\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4baba1a7076efa3570b3ef15b073806e}{Johnsson}{J\bibinitperiod}{Kai}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{457c07e221c24f415d978e3967734065}
      \strng{fullhash}{36dfc9a50b2461103a5c748a07ef9a0b}
      \field{sortinit}{G}
      \field{sortinithash}{480ee01f9ffd559b3258d822f54a8ac2}
      \field{labelyear}{2006}
      \field{datelabelsource}{}
      \field{labeltitle}{{Directed evolution of O6-alkylguanine-DNA alkyltransferase for applications in protein labeling}}
      \field{abstract}{The specific reaction of O6-alkylguanine-DNA alkyltransferase (AGT) with O6-benzylguanine (BG) derivatives allows for a specific labeling of AGT fusion proteins with chemically diverse compounds in living cells and in vitro. The efficiency of the labeling depends on a number of factors, most importantly on the reactivity, selectivity and stability of AGT. Here, we report the use of directed evolution and two different selection systems to further increase the activity of AGT towards BG derivatives by a factor of 17 and demonstrate the advantages of this mutant for the specific labeling of AGT fusion proteins displayed on the surface of mammalian cells. The results furthermore identify two regions of the protein outside the active site that influence the activity of the protein towards BG derivatives.}
      \field{isbn}{1741-0126 (Print)$\backslash$r1741-0126 (Linking)}
      \field{issn}{17410126}
      \field{journaltitle}{Protein Eng Des Sel}
      \field{number}{7}
      \field{title}{{Directed evolution of O6-alkylguanine-DNA alkyltransferase for applications in protein labeling}}
      \field{volume}{19}
      \field{year}{2006}
      \field{pages}{309\bibrangedash 316}
      \verb{doi}
      \verb 10.1093/protein/gzl014
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2006/Gronemeyer et al/Gronemeyer et al. - 2006 - Directed evolution of O6-alkylguanine-DNA alkyltransferase for applications in protein labeling.pdf:pdf
      \endverb
      \keyw{Directed evolution,O6-alkylguanine-DNA alkyltransferases,Phage display,Protein labeling}
    \endentry
    \entry{Hawkins2006}{article}{}
      \name{labelname}{10}{}{%
        {{uniquename=0,hash=35fdf44d02f837b742eb59bb70fe992f}{Hawkins}{H\bibinitperiod}{Gregory\bibnamedelima A.}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d634c93d35fcd626d9d470ae6ff8f4e1}{Tantisira}{T\bibinitperiod}{Kelan}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=653247ad4af0a5b9f29af56c7cf7533a}{Meyers}{M\bibinitperiod}{Deborah\bibnamedelima A.}{D\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=749b23654f66976640c67f4372ec9756}{Ampleford}{A\bibinitperiod}{Elizabeth\bibnamedelima J.}{E\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=08a75ca66343e52da2a89cf20f942477}{Moore}{M\bibinitperiod}{Wendy\bibnamedelima C.}{W\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c258005fd96a6cce918a4fb7e2641980}{Klanderman}{K\bibinitperiod}{Barbara}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a890fd6581a1638f957649d76c3828ad}{Liggett}{L\bibinitperiod}{Stephen\bibnamedelima B.}{S\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8dcfdca3dc2134e15bab37c648418ad5}{Peters}{P\bibinitperiod}{Stephen\bibnamedelima P.}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=86cf1afaba24a052fbfcbe6185fd3585}{Weiss}{W\bibinitperiod}{Scott\bibnamedelima T.}{S\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=572e0cd8fd641050201f116ef47c6c1a}{Bleecker}{B\bibinitperiod}{Eugene\bibnamedelima R.}{E\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{uniquename=0,hash=35fdf44d02f837b742eb59bb70fe992f}{Hawkins}{H\bibinitperiod}{Gregory\bibnamedelima A.}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d634c93d35fcd626d9d470ae6ff8f4e1}{Tantisira}{T\bibinitperiod}{Kelan}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=653247ad4af0a5b9f29af56c7cf7533a}{Meyers}{M\bibinitperiod}{Deborah\bibnamedelima A.}{D\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=749b23654f66976640c67f4372ec9756}{Ampleford}{A\bibinitperiod}{Elizabeth\bibnamedelima J.}{E\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=08a75ca66343e52da2a89cf20f942477}{Moore}{M\bibinitperiod}{Wendy\bibnamedelima C.}{W\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c258005fd96a6cce918a4fb7e2641980}{Klanderman}{K\bibinitperiod}{Barbara}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a890fd6581a1638f957649d76c3828ad}{Liggett}{L\bibinitperiod}{Stephen\bibnamedelima B.}{S\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8dcfdca3dc2134e15bab37c648418ad5}{Peters}{P\bibinitperiod}{Stephen\bibnamedelima P.}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=86cf1afaba24a052fbfcbe6185fd3585}{Weiss}{W\bibinitperiod}{Scott\bibnamedelima T.}{S\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=572e0cd8fd641050201f116ef47c6c1a}{Bleecker}{B\bibinitperiod}{Eugene\bibnamedelima R.}{E\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{7891ca0f52748862d75cf69c524e59a3}
      \strng{fullhash}{a84b3ebaa2641476d762389e1dfc5fa3}
      \field{sortinit}{H}
      \field{sortinithash}{95b2cb08933fe649b7e9f8beee2132b4}
      \field{labelyear}{2006}
      \field{labelmonth}{11}
      \field{datelabelsource}{}
      \field{labeltitle}{{Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study.}}
      \field{abstract}{RATIONALE The comprehensive evaluation of gene variation, haplotype structure, and linkage disequilibrium is important in understanding the function of beta2-adrenergic receptor gene (ADRbeta2) on disease susceptibility, pulmonary function, and therapeutic responses in different ethnic groups with asthma. OBJECTIVES To identify ADRbeta2 polymorphisms and haplotype structure in white and African American subjects and to test for genotype and haplotype association with asthma phenotypes. METHODS A 5.3-kb region of ADRbeta2 was resequenced in 669 individuals from 429 whites and 240 African Americans. A total of 12 polymorphisms, representing an optimal haplotype tagging set, were genotyped in whites (338 patients and 326 control subjects) and African Americans (222 patients and 299 control subjects). RESULTS A total of 49 polymorphisms were identified, 21 of which are novel; 31 polymorphisms (frequency > 0.03) were used to identify 24 haplotypes (frequency > 0.01) and assess linkage disequilibrium. Association with ratio (FEV1/FVC)2 for single-nucleotide polymorphism +79 (p < 0.05) was observed in African Americans. Significant haplotype association for (FEV1/FVC)2 was also observed in African Americans. CONCLUSIONS There are additional genetic variants besides +46 (Gly16Arg) that are important in determining asthma phenotypes. These data suggest that the length of a poly-C repeat (+1269) in the 3' untranslated region of ADRbeta2 may influence lung function, and may be important in delineating variation in beta-agonist responses, especially in African Americans.}
      \field{isbn}{2005091405}
      \field{issn}{1073-449X}
      \field{journaltitle}{Am J Respir Crit Care Med}
      \field{month}{11}
      \field{number}{10}
      \field{title}{{Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study.}}
      \field{volume}{174}
      \field{year}{2006}
      \field{pages}{1101\bibrangedash 9}
      \verb{doi}
      \verb 10.1164/rccm.200509-1405OC
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2006/Hawkins et al/Hawkins et al. - 2006 - Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/16931635%20http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2648111
      \endverb
      \keyw{Asthma,Dna polymorphisms,Pharmacogenomics,$\beta$-agonist therapy,$\beta$2-adrenergic receptor}
    \endentry
    \entry{He2011}{article}{}
      \name{labelname}{14}{}{%
        {{uniquename=0,hash=a608e12dc298d63624d0c663a79e7db3}{He}{H\bibinitperiod}{Shao-Qiu}{S\bibinithyphendelim Q\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e55378304e87b6b912248fd3482595d}{Zhang}{Z\bibinitperiod}{Zhen-Ning}{Z\bibinithyphendelim N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8ad511582e6d0d7e50cc2f1eafc28890}{Guan}{G\bibinitperiod}{Ji-Song}{J\bibinithyphendelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6ba7d3a97af7aa75a8dd33318f597948}{Liu}{L\bibinitperiod}{Hong-Rui}{H\bibinithyphendelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bc23eb566ce30e1c86e358a959a9d6e7}{Zhao}{Z\bibinitperiod}{Bo}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c21ae731bd01aa4d12be121449ba7638}{Wang}{W\bibinitperiod}{Hai-Bo}{H\bibinithyphendelim B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9885f16be76c4e68e9c2aaf363a53600}{Li}{L\bibinitperiod}{Qian}{Q\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b03eba7abbf5e0cc250656aea12c8a79}{Yang}{Y\bibinitperiod}{Hong}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=13535c907b998556836ce5420388500a}{Luo}{L\bibinitperiod}{Jie}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d8f3e3a30c45421b2f28ceabb4840cc6}{Li}{L\bibinitperiod}{Zi-Yan}{Z\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=872656fa8a8667dc61b0d28d4ac1db1d}{Wang}{W\bibinitperiod}{Qiong}{Q\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a5c932f0bfff0ee45a1fc906ecbaf7af}{Lu}{L\bibinitperiod}{Ying-Jin}{Y\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=30d872af74fd050743aa59c03fa0d025}{Bao}{B\bibinitperiod}{Lan}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1e623f79370754172ef56c2cf87e1cf5}{Zhang}{Z\bibinitperiod}{Xu}{X\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{14}{}{%
        {{uniquename=0,hash=a608e12dc298d63624d0c663a79e7db3}{He}{H\bibinitperiod}{Shao-Qiu}{S\bibinithyphendelim Q\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e55378304e87b6b912248fd3482595d}{Zhang}{Z\bibinitperiod}{Zhen-Ning}{Z\bibinithyphendelim N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8ad511582e6d0d7e50cc2f1eafc28890}{Guan}{G\bibinitperiod}{Ji-Song}{J\bibinithyphendelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6ba7d3a97af7aa75a8dd33318f597948}{Liu}{L\bibinitperiod}{Hong-Rui}{H\bibinithyphendelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bc23eb566ce30e1c86e358a959a9d6e7}{Zhao}{Z\bibinitperiod}{Bo}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c21ae731bd01aa4d12be121449ba7638}{Wang}{W\bibinitperiod}{Hai-Bo}{H\bibinithyphendelim B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9885f16be76c4e68e9c2aaf363a53600}{Li}{L\bibinitperiod}{Qian}{Q\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b03eba7abbf5e0cc250656aea12c8a79}{Yang}{Y\bibinitperiod}{Hong}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=13535c907b998556836ce5420388500a}{Luo}{L\bibinitperiod}{Jie}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d8f3e3a30c45421b2f28ceabb4840cc6}{Li}{L\bibinitperiod}{Zi-Yan}{Z\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=872656fa8a8667dc61b0d28d4ac1db1d}{Wang}{W\bibinitperiod}{Qiong}{Q\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a5c932f0bfff0ee45a1fc906ecbaf7af}{Lu}{L\bibinitperiod}{Ying-Jin}{Y\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=30d872af74fd050743aa59c03fa0d025}{Bao}{B\bibinitperiod}{Lan}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1e623f79370754172ef56c2cf87e1cf5}{Zhang}{Z\bibinitperiod}{Xu}{X\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{64f6b1095f7dc9f65b2551c090032ff3}
      \strng{fullhash}{73af72977a302608ffc76ae6bd72a61c}
      \field{sortinit}{H}
      \field{sortinithash}{95b2cb08933fe649b7e9f8beee2132b4}
      \field{labelyear}{2011}
      \field{labelmonth}{01}
      \field{datelabelsource}{}
      \field{labeltitle}{{Facilitation of $\mu$-opioid receptor activity by preventing $\delta$-opioid receptor-mediated codegradation.}}
      \field{abstract}{$\delta$-opioid receptors (DORs) form heteromers with $\mu$-opioid receptors (MORs) and negatively regulate MOR-mediated spinal analgesia. However, the underlying mechanism remains largely unclear. The present study shows that the activity of MORs can be enhanced by preventing MORs from DOR-mediated codegradation. Treatment with DOR-specific agonists led to endocytosis of both DORs and MORs. These receptors were further processed for ubiquitination and lysosomal degradation, resulting in a reduction of surface MORs. Such effects were attenuated by treatment with an interfering peptide containing the first transmembrane domain of MOR (MOR(TM1)), which interacted with DORs and disrupted the MOR/DOR interaction. Furthermore, the systemically applied fusion protein consisting of MOR(TM1) and TAT at the C terminus could disrupt the MOR/DOR interaction in the mouse spinal cord, enhance the morphine analgesia, and reduce the antinociceptive tolerance to morphine. Thus, dissociation of MORs from DORs in the cell membrane is a potential strategy to improve opioid analgesic therapies.}
      \field{issn}{1097-4199}
      \field{journaltitle}{Neuron}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Facilitation of $\mu$-opioid receptor activity by preventing $\delta$-opioid receptor-mediated codegradation.}}
      \field{volume}{69}
      \field{year}{2011}
      \field{pages}{120\bibrangedash 31}
      \verb{doi}
      \verb 10.1016/j.neuron.2010.12.001
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/21220103
      \endverb
      \keyw{Analgesia,Analgesia: methods,Analgesics,Opioid,Analgesics,Opioid: administration {\&} dosage,Analgesics,Opioid: pharmacology,Animals,Disease Models,Animal,Endocytosis,HEK293 Cells,Humans,Immunoblotting,In Situ Hybridization,Lysosomes,Lysosomes: metabolism,Male,Mice,Mice,Inbred Strains,Microscopy,Electron,Morphine,Morphine: administration {\&} dosage,Morphine: pharmacology,Pain,Pain Measurement,Pain Measurement: methods,Pain: drug therapy,Peptides,Peptides: pharmacology,Plasmids,Receptors,Opioid,delta,Receptors,Opioid,delta: metabolism,Receptors,Opioid,mu,Receptors,Opioid,mu: metabolism,Signal Transduction,Signal Transduction: drug effects,Spinal Cord,Spinal Cord: drug effects,Spinal Cord: metabolism,Transfection,Ubiquitination}
    \endentry
    \entry{Hebert1996}{article}{}
      \name{labelname}{7}{}{%
        {{uniquename=0,hash=8593f55286db92ac9c5da02adea38109}{Hebert}{H\bibinitperiod}{T\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3825b70da5f502f0700f3adfae3c6206}{Moffett}{M\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=20ae609bdfe85b9ab3074b850fde42f0}{Morello}{M\bibinitperiod}{J\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5aca03239a9eb908ce378c86f55f358e}{Loisel}{L\bibinitperiod}{T\bibnamedelima P}{T\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3414b1b8ba5855f8e18b1d6897f52c6a}{Bichet}{B\bibinitperiod}{D\bibnamedelima G}{D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=37e2bfa43348e30c03bb3aa8d03963bf}{Barret}{B\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c65aaf3405b44a897e3073f4c531aed7}{Bouvier}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{uniquename=0,hash=8593f55286db92ac9c5da02adea38109}{Hebert}{H\bibinitperiod}{T\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3825b70da5f502f0700f3adfae3c6206}{Moffett}{M\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=20ae609bdfe85b9ab3074b850fde42f0}{Morello}{M\bibinitperiod}{J\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5aca03239a9eb908ce378c86f55f358e}{Loisel}{L\bibinitperiod}{T\bibnamedelima P}{T\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3414b1b8ba5855f8e18b1d6897f52c6a}{Bichet}{B\bibinitperiod}{D\bibnamedelima G}{D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=37e2bfa43348e30c03bb3aa8d03963bf}{Barret}{B\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c65aaf3405b44a897e3073f4c531aed7}{Bouvier}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{101600691c56d5774a3d906691da5042}
      \strng{fullhash}{db7bcb6a124c6651fa308da12076a3a3}
      \field{sortinit}{H}
      \field{sortinithash}{95b2cb08933fe649b7e9f8beee2132b4}
      \field{labelyear}{1996}
      \field{labelmonth}{07}
      \field{datelabelsource}{}
      \field{labeltitle}{{A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation.}}
      \field{abstract}{One of the assumptions of the mobile receptor hypothesis as it relates to G protein-coupled receptors is that the stoichiometry of receptor, G protein, and effector is 1:1:1 (Bourne, H. R., Sanders, D. A., and McCormick, F.(1990) Nature 348, 125-132). Many studies on the cooperativity of agonist binding are incompatible with this notion and have suggested that both G proteins and their associated receptors can be oligomeric. However, a clear physical demonstration that G protein-coupled receptors can indeed interact as dimers and that such interactions may have functional consequences was lacking. Here, using differential epitope tagging we demonstrate that beta2-adrenergic receptors do form SDS-resistant homodimers and that transmembrane domain VI of the receptor may represent part of an interface for receptor dimerization. The functional importance of dimerization is supported by the observation that a peptide derived from this domain that inhibits dimerization also inhibits beta-adrenergic agonist-promoted stimulation of adenylyl cyclase activity. Moreover, agonist stimulation was found to stabilize the dimeric state of the receptor, while inverse agonists favored the monomeric species, which suggests that interconversion between monomeric and dimeric forms may be important for biological activity.}
      \field{issn}{0021-9258}
      \field{journaltitle}{J Biol Chem}
      \field{month}{07}
      \field{number}{27}
      \field{title}{{A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation.}}
      \field{volume}{271}
      \field{year}{1996}
      \field{pages}{16384\bibrangedash 92}
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/1996/Hebert et al/Hebert et al. - 1996 - A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and a.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/8663163
      \endverb
      \keyw{Adenylate Cyclase,Adenylate Cyclase: metabolism,Amino Acid Sequence,Animals,Baculoviridae,Cell Line,Cercopithecus aethiops,Chromatography,Affinity,Cricetinae,Cricetulus,Humans,Isoproterenol,Isoproterenol: pharmacology,Macromolecular Substances,Molecular Sequence Data,Peptide Fragments,Peptide Fragments: pharmacology,Proto-Oncogene Proteins c-myc,Proto-Oncogene Proteins c-myc: biosynthesis,Receptor,Muscarinic M2,Receptors,Adrenergic,beta-2,Receptors,Adrenergic,beta-2: chemistry,Receptors,Adrenergic,beta-2: isolation {\&} purific,Receptors,Adrenergic,beta-2: physiology,Receptors,Dopamine D2,Receptors,Dopamine D2: chemistry,Receptors,Dopamine D2: physiology,Receptors,Muscarinic,Receptors,Muscarinic: biosynthesis,Receptors,Vasopressin,Receptors,Vasopressin: biosynthesis,Receptors,Vasopressin: chemistry,Recombinant Fusion Proteins,Recombinant Fusion Proteins: biosynthesis,Recombinant Proteins,Recombinant Proteins: biosynthesis,Recombinant Proteins: chemistry,Recombinant Proteins: isolation {\&} purification,Sequence Tagged Sites,Spodoptera,Transfection}
    \endentry
    \entry{Heldin1995}{article}{}
      \name{labelname}{1}{}{%
        {{uniquename=0,hash=0b6e98e1e5ec320a9d04783df7c3ccbd}{Heldin}{H\bibinitperiod}{C\bibnamedelima H}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{uniquename=0,hash=0b6e98e1e5ec320a9d04783df7c3ccbd}{Heldin}{H\bibinitperiod}{C\bibnamedelima H}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0b6e98e1e5ec320a9d04783df7c3ccbd}
      \strng{fullhash}{0b6e98e1e5ec320a9d04783df7c3ccbd}
      \field{sortinit}{H}
      \field{sortinithash}{95b2cb08933fe649b7e9f8beee2132b4}
      \field{labelyear}{1995}
      \field{labelmonth}{01}
      \field{datelabelsource}{}
      \field{labeltitle}{{Dimerization of cell surface receptors in signal transduction.}}
      \field{issn}{0092-8674}
      \field{journaltitle}{Cell}
      \field{month}{01}
      \field{number}{2}
      \field{title}{{Dimerization of cell surface receptors in signal transduction.}}
      \field{volume}{80}
      \field{year}{1995}
      \field{pages}{213\bibrangedash 23}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/7834741
      \endverb
      \keyw{Animals,Humans,Macromolecular Substances,Phosphorylation,Protein-Serine-Threonine Kinases,Protein-Serine-Threonine Kinases: metabolism,Protein-Tyrosine Kinases,Protein-Tyrosine Kinases: metabolism,Receptor Protein-Tyrosine Kinases,Receptor Protein-Tyrosine Kinases: metabolism,Receptors,Antigen,Receptors,Antigen: metabolism,Receptors,Cell Surface,Receptors,Cell Surface: chemistry,Receptors,Cell Surface: metabolism,Receptors,Cytokine,Receptors,Cytokine: metabolism,Receptors,Tumor Necrosis Factor,Receptors,Tumor Necrosis Factor: metabolism,Signal Transduction}
    \endentry
    \entry{Herrick-Davis2013}{article}{}
      \name{labelname}{4}{}{%
        {{uniquename=0,hash=0a91fb5c6f53c67bbb86f7f5a37fb96a}{Herrick-Davis}{H\bibinithyphendelim D\bibinitperiod}{Katharine}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ad0c75517afe44aa6ce27efa97f6d86e}{Grinde}{G\bibinitperiod}{Ellinor}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9d0a16f4e00ca77c78569c50a53a754a}{Cowan}{C\bibinitperiod}{Ann}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f5d274ea09dcabf53058361d8f39baf4}{Mazurkiewicz}{M\bibinitperiod}{Joseph\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{uniquename=0,hash=0a91fb5c6f53c67bbb86f7f5a37fb96a}{Herrick-Davis}{H\bibinithyphendelim D\bibinitperiod}{Katharine}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ad0c75517afe44aa6ce27efa97f6d86e}{Grinde}{G\bibinitperiod}{Ellinor}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9d0a16f4e00ca77c78569c50a53a754a}{Cowan}{C\bibinitperiod}{Ann}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f5d274ea09dcabf53058361d8f39baf4}{Mazurkiewicz}{M\bibinitperiod}{Joseph\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ca6e68ccfa87902091271828862045ff}
      \strng{fullhash}{13a3b532857f3a046ea74f76f13c880a}
      \field{sortinit}{H}
      \field{sortinithash}{95b2cb08933fe649b7e9f8beee2132b4}
      \field{labelyear}{2013}
      \field{labelmonth}{10}
      \field{datelabelsource}{}
      \field{labeltitle}{{Fluorescence Correlation Spectroscopy Analysis of Serotonin, Adrenergic, Muscarinic, and Dopamine Receptor Dimerization: The Oligomer Number Puzzle}}
      \field{abstract}{The issue of G protein-coupled receptor (GPCR) oligomer status has not been resolved. Although many studies have provided evidence in favor of receptor-receptor interactions, there is no consensus as to the exact oligomer size of class A GPCRs. Previous studies have reported monomers, dimers, tetramers, and higher-order oligomers. In the present study, this issue was examined using fluorescence correlation spectroscopy (FCS) with photon counting histogram (PCH) analysis, a sensitive method for monitoring diffusion and oligomer size of plasma membrane proteins. Six different class A GPCRs were selected from the serotonin (5-HT2A), adrenergic ($\alpha$1b-AR and $\beta$2-AR), muscarinic (M1 and M2), and dopamine (D1) receptor families. Each GPCR was C-terminally labeled with green fluorescent protein (GFP) or yellow fluorescent protein (YFP) and expressed in human embryonic kidney 293 cells. FCS provided plasma membrane diffusion coefficients on the order of 7.5 × 10(-9) cm(2)/s. PCH molecular brightness analysis was used to determine the GPCR oligomer size. Known monomeric (CD-86) and dimeric (CD-28) receptors with GFP and YFP tags were used as controls to determine the molecular brightness of monomers and dimers. PCH analysis of fluorescence-tagged GPCRs revealed molecular brightness values that were twice the monomeric controls and similar to the dimeric controls. Reduced $\chi$(2) analyses of the PCH data best fit a model for a homogeneous population of homodimers, without tetramers or higher-order oligomers. The homodimer configuration was unaltered by agonist treatment and was stable over a 10-fold range of receptor expression level. The results of this study demonstrate that biogenic amine receptors freely diffusing within the plasma membrane are predominantly homodimers.}
      \field{annotation}{incorporate!}
      \field{issn}{1521-0111}
      \field{journaltitle}{Mol Pharmacol}
      \field{month}{10}
      \field{number}{4}
      \field{title}{{Fluorescence Correlation Spectroscopy Analysis of Serotonin, Adrenergic, Muscarinic, and Dopamine Receptor Dimerization: The Oligomer Number Puzzle}}
      \field{volume}{84}
      \field{year}{2013}
      \field{pages}{630\bibrangedash 642}
      \verb{doi}
      \verb 10.1124/mol.113.087072
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2013/Herrick-Davis et al/Herrick-Davis et al. - 2013 - Fluorescence Correlation Spectroscopy Analysis of Serotonin, Adrenergic, Muscarinic, and Dopamine Receptor.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/23907214%20http://molpharm.aspetjournals.org/cgi/doi/10.1124/mol.113.087072
      \endverb
      \keyw{Adrenergic,Adrenergic: chemistry,Adrenergic: metabolism,Dopamine,Dopamine: chemistry,Dopamine: metabolism,Fluorescence,Fluorescence: methods,HEK293 Cells,Humans,Muscarinic,Muscarinic: chemistry,Muscarinic: metabolism,Protein Multimerization,Protein Multimerization: physiology,Receptors,Adrenergic,Receptors,Adrenergic: chemistry,Receptors,Adrenergic: metabolism,Receptors,Dopamine,Receptors,Dopamine: chemistry,Receptors,Dopamine: metabolism,Receptors,Muscarinic,Receptors,Muscarinic: chemistry,Receptors,Muscarinic: metabolism,Receptors,Serotonin,Receptors,Serotonin: chemistry,Receptors,Serotonin: metabolism,Serotonin,Serotonin: chemistry,Serotonin: metabolism,Spectrometry,Fluorescence,Spectrometry,Fluorescence: methods}
    \endentry
    \entry{Hiller2013}{article}{}
      \name{labelname}{3}{}{%
        {{uniquename=0,hash=04d52487dc485e01373cb28c16778883}{Hiller}{H\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5fc546ff37722133742d9ea1a4b42827}{K{ü}hhorn}{K\bibinitperiod}{Julia}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=82ff0839aea9373651903358e94c549d}{Gmeiner}{G\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{uniquename=0,hash=04d52487dc485e01373cb28c16778883}{Hiller}{H\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5fc546ff37722133742d9ea1a4b42827}{K{ü}hhorn}{K\bibinitperiod}{Julia}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=82ff0839aea9373651903358e94c549d}{Gmeiner}{G\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{df01714e71b354735a633ad17feb5550}
      \strng{fullhash}{c566ea09d92478043c5017476be19923}
      \field{sortinit}{H}
      \field{sortinithash}{95b2cb08933fe649b7e9f8beee2132b4}
      \field{labelyear}{2013}
      \field{datelabelsource}{}
      \field{labeltitle}{{Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands}}
      \field{abstract}{G-protein-coupled receptors (GPCRs) represent the largest family of membrane proteins involved in cellular signal transduction and are activated by various different ligand types including photons, peptides, proteins, but also small molecules like biogenic amines. Therefore, GPCRs are involved in diverse physiological processes and provide valuable drug targets for numerous diseases. Emerging body of evidence suggests that GPCRs exist as monomers or cross-react forming dimers and higher-ordered oligomers. In this Perspective we will review current biochemical and biophysical techniques to visualize GPCR dimerization, functional consequences of homo- and heterodimers, and approaches of medicinal chemists to target these receptor complexes with homo- and heterobivalent ligands.}
      \field{isbn}{00222623}
      \field{issn}{00222623}
      \field{journaltitle}{J Med Chem}
      \field{number}{17}
      \field{title}{{Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands}}
      \field{volume}{56}
      \field{year}{2013}
      \field{pages}{6542\bibrangedash 6559}
      \verb{doi}
      \verb 10.1021/jm4004335
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2013/Hiller, K{ü}hhorn, Gmeiner/Hiller, K{ü}hhorn, Gmeiner - 2013 - Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands.pdf:pdf
      \endverb
    \endentry
    \entry{Hillion2002}{article}{}
      \name{labelname}{18}{}{%
        {{uniquename=0,hash=81bf224fd8770d8f7e2c71ceec3e70dc}{Hillion}{H\bibinitperiod}{Jo{ë}lle}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1d5d31e7190d53a48db76e82381f1954}{Canals}{C\bibinitperiod}{Meritxell}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e500d37ea5d8b0f6a6962f97dac6e428}{Torvinen}{T\bibinitperiod}{Maria}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8c52ca5c3745e829bb3b3648bd297648}{Casad{ó}}{C\bibinitperiod}{Vicent}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ac997537ee13db13c18ed99d99145e83}{Scott}{S\bibinitperiod}{Rizaldy}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e83d933519ddc80a8e87ba74882ebde1}{Terasmaa}{T\bibinitperiod}{Anton}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=41b75ea2c31d4274c41bc37473d57784}{Hansson}{H\bibinitperiod}{Anita}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d94226ddda3b7631c695a59f7eed84ca}{Watson}{W\bibinitperiod}{Stanley}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1d19769813a18c5108dd032e9fb6f6e2}{Olah}{O\bibinitperiod}{Mark\bibnamedelima E.}{M\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0ecd0062fb904a083fda7e5fcf00070f}{Mallol}{M\bibinitperiod}{Josefa}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1e1eb96b815231fc369f0805a8715fda}{Canela}{C\bibinitperiod}{Enric\bibnamedelima I.}{E\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=dbdb49c5b24ba27b9570be22404a4409}{Zoli}{Z\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=cd3a86e3210921be5b05fd90ab593906}{Agnati}{A\bibinitperiod}{Luigi\bibnamedelima F.}{L\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=06f0d71069ac00bb54b0cb69848d738c}{Ib{á}{ñ}ez}{I\bibinitperiod}{Carlos\bibnamedelima F.}{C\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ad2b9ec304a8b6e1c80f0b87b6f7e702}{Lluis}{L\bibinitperiod}{Carme}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f319c58242417e6551e0dc6058fdd4f3}{Franco}{F\bibinitperiod}{Rafael}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4cf7b2a170b143f30a95815bd1120011}{Ferr{é}}{F\bibinitperiod}{Sergi}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6043dcc976ab16e0954f1c2f851bccde}{Fuxe}{F\bibinitperiod}{Kjell}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{18}{}{%
        {{uniquename=0,hash=81bf224fd8770d8f7e2c71ceec3e70dc}{Hillion}{H\bibinitperiod}{Jo{ë}lle}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1d5d31e7190d53a48db76e82381f1954}{Canals}{C\bibinitperiod}{Meritxell}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e500d37ea5d8b0f6a6962f97dac6e428}{Torvinen}{T\bibinitperiod}{Maria}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8c52ca5c3745e829bb3b3648bd297648}{Casad{ó}}{C\bibinitperiod}{Vicent}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ac997537ee13db13c18ed99d99145e83}{Scott}{S\bibinitperiod}{Rizaldy}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e83d933519ddc80a8e87ba74882ebde1}{Terasmaa}{T\bibinitperiod}{Anton}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=41b75ea2c31d4274c41bc37473d57784}{Hansson}{H\bibinitperiod}{Anita}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d94226ddda3b7631c695a59f7eed84ca}{Watson}{W\bibinitperiod}{Stanley}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1d19769813a18c5108dd032e9fb6f6e2}{Olah}{O\bibinitperiod}{Mark\bibnamedelima E.}{M\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0ecd0062fb904a083fda7e5fcf00070f}{Mallol}{M\bibinitperiod}{Josefa}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1e1eb96b815231fc369f0805a8715fda}{Canela}{C\bibinitperiod}{Enric\bibnamedelima I.}{E\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=dbdb49c5b24ba27b9570be22404a4409}{Zoli}{Z\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=cd3a86e3210921be5b05fd90ab593906}{Agnati}{A\bibinitperiod}{Luigi\bibnamedelima F.}{L\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=06f0d71069ac00bb54b0cb69848d738c}{Ib{á}{ñ}ez}{I\bibinitperiod}{Carlos\bibnamedelima F.}{C\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ad2b9ec304a8b6e1c80f0b87b6f7e702}{Lluis}{L\bibinitperiod}{Carme}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f319c58242417e6551e0dc6058fdd4f3}{Franco}{F\bibinitperiod}{Rafael}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4cf7b2a170b143f30a95815bd1120011}{Ferr{é}}{F\bibinitperiod}{Sergi}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6043dcc976ab16e0954f1c2f851bccde}{Fuxe}{F\bibinitperiod}{Kjell}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{cc9e09e5ee06692c146f5c5f1406ea1a}
      \strng{fullhash}{0277ed2e70782a316bd3b71caea81def}
      \field{sortinit}{H}
      \field{sortinithash}{95b2cb08933fe649b7e9f8beee2132b4}
      \field{labelyear}{2002}
      \field{datelabelsource}{}
      \field{labeltitle}{{Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors}}
      \field{abstract}{Antagonistic and reciprocal interactions are known to exist between adenosine and dopamine receptors in the striatum. In the present study, double immunofluorescence experiments with confocal laser microscopy showed a high degree of colocalization of adenosine A(2A) receptors (A(2A)R) and dopamine D(2) receptors (D(2)R) in cell membranes of SH-SY5Y human neuroblastoma cells stably transfected with human D(2)R and in cultured striatal cells. A(2A)R/D(2)R heteromeric complexes were demonstrated in coimmunoprecipitation experiments in membrane preparations from D(2)R-transfected SH-SY5Y cells and from mouse fibroblast Ltk(-) cells stably transfected with human D(2)R (long form) and transiently cotransfected with the A(2A)R double-tagged with hemagglutinin. Long term exposure to A(2A)R and D(2)R agonists in D(2)R-cotransfected SH-SY5Y cells resulted in coaggregation, cointernalization and codesensitization of A(2A)R and D(2)R. These results give a molecular basis for adenosine-dopamine antagonism at the membrane level and have implications for treatment of Parkinson's disease and schizophrenia, in which D(2)R are involved.}
      \field{isbn}{0021-9258 (Print)}
      \field{issn}{00219258}
      \field{journaltitle}{J Biol Chem}
      \field{number}{20}
      \field{title}{{Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors}}
      \field{volume}{277}
      \field{year}{2002}
      \field{pages}{18091\bibrangedash 18097}
      \verb{doi}
      \verb 10.1074/jbc.M107731200
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2002/Hillion et al/Hillion et al. - 2002 - Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors.pdf:pdf
      \endverb
    \endentry
    \entry{Hoffman1982}{article}{}
      \name{labelname}{2}{}{%
        {{uniquename=0,hash=d22dc10ec14eefc866adb12824acb835}{Hoffman}{H\bibinitperiod}{B\bibnamedelima B}{B\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5a82c57b9578526b9979bd4f3f6194d5}{Lefkowitz}{L\bibinitperiod}{R\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{uniquename=0,hash=d22dc10ec14eefc866adb12824acb835}{Hoffman}{H\bibinitperiod}{B\bibnamedelima B}{B\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5a82c57b9578526b9979bd4f3f6194d5}{Lefkowitz}{L\bibinitperiod}{R\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{4a7495f7f2ed75562acbbf1253fae8f1}
      \strng{fullhash}{6e0f5bb6f580c33501cbeda3427b42ae}
      \field{sortinit}{H}
      \field{sortinithash}{95b2cb08933fe649b7e9f8beee2132b4}
      \field{labelyear}{1982}
      \field{labelmonth}{10}
      \field{datelabelsource}{}
      \field{labeltitle}{{Adrenergic receptors in the heart.}}
      \field{issn}{0066-4278}
      \field{journaltitle}{Annu Rev Physiol}
      \field{month}{10}
      \field{number}{1}
      \field{title}{{Adrenergic receptors in the heart.}}
      \field{volume}{44}
      \field{year}{1982}
      \field{pages}{475\bibrangedash 484}
      \verb{doi}
      \verb 10.1146/annurev.ph.44.030182.002355
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/1982/Hoffman, Lefkowitz/Hoffman, Lefkowitz - 1982 - Adrenergic receptors in the heart.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.annualreviews.org/doi/abs/10.1146/annurev.ph.44.030182.002355
      \endverb
    \endentry
    \entry{Issafras2002}{article}{}
      \name{labelname}{8}{}{%
        {{uniquename=0,hash=a9d98db133b0e2b223648ce30fe5a106}{Issafras}{I\bibinitperiod}{Hassan}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9d32033589c02cfef3725bc02c4165d5}{Angers}{A\bibinitperiod}{St{é}phane}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=974e091bdd314bb024fc2858fc6544a4}{Bulenger}{B\bibinitperiod}{S{é}bastien}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=83a84f2ccfa69bd8ffaa0170e32c3e4f}{Blanpain}{B\bibinitperiod}{C{é}dric}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=30e885bad4cfa3a6da5ab1d66d31a1e8}{Parmentier}{P\bibinitperiod}{Marc}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=820a5f4b93645e7dd2503b2cea1fdb44}{Labb{é}-Julli{é}}{L\bibinithyphendelim J\bibinitperiod}{Catherine}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7ea48095889361f5fa9410c51a3acfa2}{Bouvier}{B\bibinitperiod}{Michel}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bc5ddd1bd419c9c57f7e3dd80489a3a3}{Marullo}{M\bibinitperiod}{Stefano}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{uniquename=0,hash=a9d98db133b0e2b223648ce30fe5a106}{Issafras}{I\bibinitperiod}{Hassan}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9d32033589c02cfef3725bc02c4165d5}{Angers}{A\bibinitperiod}{St{é}phane}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=974e091bdd314bb024fc2858fc6544a4}{Bulenger}{B\bibinitperiod}{S{é}bastien}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=83a84f2ccfa69bd8ffaa0170e32c3e4f}{Blanpain}{B\bibinitperiod}{C{é}dric}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=30e885bad4cfa3a6da5ab1d66d31a1e8}{Parmentier}{P\bibinitperiod}{Marc}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=820a5f4b93645e7dd2503b2cea1fdb44}{Labb{é}-Julli{é}}{L\bibinithyphendelim J\bibinitperiod}{Catherine}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7ea48095889361f5fa9410c51a3acfa2}{Bouvier}{B\bibinitperiod}{Michel}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bc5ddd1bd419c9c57f7e3dd80489a3a3}{Marullo}{M\bibinitperiod}{Stefano}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{aced76a7d229ed112956d9076f7c92e5}
      \strng{fullhash}{8769fbb2cf91b664834b2f2df6bc39b8}
      \field{sortinit}{I}
      \field{sortinithash}{b2e302e575c74beffcc96ef7059003aa}
      \field{labelyear}{2002}
      \field{datelabelsource}{}
      \field{labeltitle}{{Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors}}
      \field{abstract}{Although homo-oligomerization has been reported for several G protein-coupled receptors, this phenomenon was not studied at low concentrations of receptors. Furthermore, it is not clear whether homo-oligomerization corresponds to an intrinsic property of nascent receptors or if it is a consequence of receptor activation. Here CCR5 receptor oligomerization was studied by bioluminescence resonance energy transfer (BRET) in cells expressing physiological levels of receptors. A strong energy transfer could be observed, in the absence of ligands, in whole cells and in both endoplasmic reticulum and plasma membrane subfractions, supporting the hypothesis of a constitutive oligomerization that occurs early after biosynthesis. No change in BRET was observed upon agonist binding, indicating that the extent of oligomerization is unrelated to the activation state of the receptor. In contrast, a robust increase of BRET, induced by a monoclonal antibody known to promote receptor clustering, suggests that microaggregation of preformed receptor homo-oligomers can occur. Taken together, our data indicate that constitutive receptor homo-oligomerization has a biologically relevant significance and might be involved in the process of receptor biosynthesis.}
      \field{isbn}{0021-9258 (Print)}
      \field{issn}{00219258}
      \field{journaltitle}{J Biol Chem}
      \field{number}{38}
      \field{title}{{Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors}}
      \field{volume}{277}
      \field{year}{2002}
      \field{pages}{34666\bibrangedash 34673}
      \verb{doi}
      \verb 10.1074/jbc.M202386200
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2002/Issafras et al/Issafras et al. - 2002 - Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiologic.pdf:pdf
      \endverb
    \endentry
    \entry{Jordan1999}{article}{}
      \name{labelname}{2}{}{%
        {{uniquename=0,hash=84e95f315a496edaf6c9d06e86064d47}{Jordan}{J\bibinitperiod}{Bryen\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2074fe608f2cb2dcac53060e8a724b70}{Devi}{D\bibinitperiod}{Lakshmi\bibnamedelima A}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{uniquename=0,hash=84e95f315a496edaf6c9d06e86064d47}{Jordan}{J\bibinitperiod}{Bryen\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2074fe608f2cb2dcac53060e8a724b70}{Devi}{D\bibinitperiod}{Lakshmi\bibnamedelima A}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{569c7f6f141f25f1109792b482498ec8}
      \strng{fullhash}{6bffb81decf0e45366d3446a227836bb}
      \field{sortinit}{J}
      \field{sortinithash}{f75b22df8c340a961dce37019e29107f}
      \field{labelyear}{1999}
      \field{labelmonth}{06}
      \field{datelabelsource}{}
      \field{labeltitle}{{G-protein-coupled receptor heterodimerization modulates receptor function }}
      \field{annotation}{10.1038/21441}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{06}
      \field{number}{6737}
      \field{title}{{G-protein-coupled receptor heterodimerization modulates receptor function }}
      \field{volume}{399}
      \field{year}{1999}
      \field{pages}{697\bibrangedash 700}
      \verb{url}
      \verb http://dx.doi.org/10.1038/21441
      \endverb
    \endentry
    \entry{Keppler2004}{article}{}
      \name{labelname}{5}{}{%
        {{uniquename=0,hash=195bc1e5409d1c6f1a34b1e1e929cc26}{Keppler}{K\bibinitperiod}{Antje}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=22a6c1359b784d10d1682cc09183c6fa}{Pick}{P\bibinitperiod}{Horst}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d4430af6e02f37b2313049a0f2570f4c}{Arrivoli}{A\bibinitperiod}{Claudio}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3e03ba5604e981fd33254810cf11ad35}{Vogel}{V\bibinitperiod}{Horst}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4baba1a7076efa3570b3ef15b073806e}{Johnsson}{J\bibinitperiod}{Kai}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{uniquename=0,hash=195bc1e5409d1c6f1a34b1e1e929cc26}{Keppler}{K\bibinitperiod}{Antje}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=22a6c1359b784d10d1682cc09183c6fa}{Pick}{P\bibinitperiod}{Horst}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d4430af6e02f37b2313049a0f2570f4c}{Arrivoli}{A\bibinitperiod}{Claudio}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3e03ba5604e981fd33254810cf11ad35}{Vogel}{V\bibinitperiod}{Horst}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4baba1a7076efa3570b3ef15b073806e}{Johnsson}{J\bibinitperiod}{Kai}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{fa57d51fd55e769fe986eb6240371103}
      \strng{fullhash}{e854bab39312c3f83d22e2697791fad9}
      \field{sortinit}{K}
      \field{sortinithash}{33bf4c961fa093ee6a297ccbd88eacc0}
      \field{labelyear}{2004}
      \field{datelabelsource}{}
      \field{labeltitle}{{Labeling of fusion proteins with synthetic fluorophores in live cells.}}
      \field{abstract}{A general approach for the sequential labeling of fusion proteins of O(6)-alkylguanine-DNA alkyltransferase (AGT) with different fluorophores in mammalian cells is presented. AGT fusion proteins with different localizations in the cell can be labeled specifically with different fluorophores, and the fluorescence labeling can be used for applications such as multicolor analysis of dynamic processes and fluorescence resonance energy transfer measurements. The facile access to a variety of different AGT substrates as well as the specificity of the labeling reaction should make the approach an important tool to study protein function in live cells.}
      \field{isbn}{0027-8424 1091-6490}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proc Natl Acad Sci U S A}
      \field{number}{27}
      \field{title}{{Labeling of fusion proteins with synthetic fluorophores in live cells.}}
      \field{volume}{101}
      \field{year}{2004}
      \field{pages}{9955\bibrangedash 9959}
      \verb{doi}
      \verb 10.1073/pnas.0401923101
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2004/Keppler et al/Keppler et al. - 2004 - Labeling of fusion proteins with synthetic fluorophores in live cells.pdf:pdf
      \endverb
    \endentry
    \entry{Khelashvili2010}{article}{}
      \name{labelname}{19}{}{%
        {{uniquename=0,hash=20215724a2d47f4b12c7c36d1f9d6f44}{Khelashvili}{K\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f7c37146e2d494625797b800b9317d4d}{Dorff}{D\bibinitperiod}{Kevin}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=514c64e052d318ca9284c990dab47590}{Shan}{S\bibinitperiod}{Jufang}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=005793faf358c249b5c91b1d4db62cad}{Camacho-Artacho}{C\bibinithyphendelim A\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d17f458288ebec03eada081a0990f3a3}{Skrabanek}{S\bibinitperiod}{Lucy}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0effd8ec65672a71f9a7dfcb04a3b1b8}{Vroling}{V\bibinitperiod}{Bas}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7ea48095889361f5fa9410c51a3acfa2}{Bouvier}{B\bibinitperiod}{Michel}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e087092cccd54f956e674d1e2c3b44a3}{Devi}{D\bibinitperiod}{Lakshmi\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4f82f18c8d9bd65242153d4ce726b4c6}{George}{G\bibinitperiod}{Susan\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e8062702653a27fc60dc0eb0ffc3c4e}{Javitch}{J\bibinitperiod}{Jonathan\bibnamedelima a}{J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=65ce19b54b395e37b896e60b30df47e9}{Milligan}{M\bibinitperiod}{Graeme}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2fa41bbe54ea5f71cc1599fc2f00b826}{Neubig}{N\bibinitperiod}{Richard\bibnamedelima R}{R\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=673b0f5d52008ad1441686dd78512e9a}{Palczewski}{P\bibinitperiod}{Krzysztof}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=30e885bad4cfa3a6da5ab1d66d31a1e8}{Parmentier}{P\bibinitperiod}{Marc}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=55f22e3d2ba18b80a85e509d3d3ea173}{Vriend}{V\bibinitperiod}{Gerrit}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b0fb4ba78e3921c205e02e07e10a0a99}{Campagne}{C\bibinitperiod}{Fabien}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=caa7ad34df0c6628c95c1dbbf147fe90}{Filizola}{F\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{19}{}{%
        {{uniquename=0,hash=20215724a2d47f4b12c7c36d1f9d6f44}{Khelashvili}{K\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f7c37146e2d494625797b800b9317d4d}{Dorff}{D\bibinitperiod}{Kevin}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=514c64e052d318ca9284c990dab47590}{Shan}{S\bibinitperiod}{Jufang}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=005793faf358c249b5c91b1d4db62cad}{Camacho-Artacho}{C\bibinithyphendelim A\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d17f458288ebec03eada081a0990f3a3}{Skrabanek}{S\bibinitperiod}{Lucy}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0effd8ec65672a71f9a7dfcb04a3b1b8}{Vroling}{V\bibinitperiod}{Bas}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7ea48095889361f5fa9410c51a3acfa2}{Bouvier}{B\bibinitperiod}{Michel}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e087092cccd54f956e674d1e2c3b44a3}{Devi}{D\bibinitperiod}{Lakshmi\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4f82f18c8d9bd65242153d4ce726b4c6}{George}{G\bibinitperiod}{Susan\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e8062702653a27fc60dc0eb0ffc3c4e}{Javitch}{J\bibinitperiod}{Jonathan\bibnamedelima a}{J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=65ce19b54b395e37b896e60b30df47e9}{Milligan}{M\bibinitperiod}{Graeme}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2fa41bbe54ea5f71cc1599fc2f00b826}{Neubig}{N\bibinitperiod}{Richard\bibnamedelima R}{R\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=673b0f5d52008ad1441686dd78512e9a}{Palczewski}{P\bibinitperiod}{Krzysztof}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=30e885bad4cfa3a6da5ab1d66d31a1e8}{Parmentier}{P\bibinitperiod}{Marc}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=55f22e3d2ba18b80a85e509d3d3ea173}{Vriend}{V\bibinitperiod}{Gerrit}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b0fb4ba78e3921c205e02e07e10a0a99}{Campagne}{C\bibinitperiod}{Fabien}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=caa7ad34df0c6628c95c1dbbf147fe90}{Filizola}{F\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{b4da880aeb95ede68422785f9357b7c4}
      \strng{fullhash}{500dd97a1abed668b10ae5b904274972}
      \field{sortinit}{K}
      \field{sortinithash}{33bf4c961fa093ee6a297ccbd88eacc0}
      \field{labelyear}{2010}
      \field{labelmonth}{07}
      \field{datelabelsource}{}
      \field{labeltitle}{{GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base.}}
      \field{abstract}{SUMMARY: Rapid expansion of available data about G Protein Coupled Receptor (GPCR) dimers/oligomers over the past few years requires an effective system to organize this information electronically. Based on an ontology derived from a community dialog involving colleagues using experimental and computational methodologies, we developed the GPCR-Oligomerization Knowledge Base (GPCR-OKB). GPCR-OKB is a system that supports browsing and searching for GPCR oligomer data. Such data were manually derived from the literature. While focused on GPCR oligomers, GPCR-OKB is seamlessly connected to GPCRDB, facilitating the correlation of information about GPCR protomers and oligomers. Availability and Implementation: The GPCR-OKB web application is freely available at http://www.gpcr-okb.org}
      \field{issn}{1367-4811}
      \field{journaltitle}{Bioinformatics}
      \field{month}{07}
      \field{number}{14}
      \field{title}{{GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base.}}
      \field{volume}{26}
      \field{year}{2010}
      \field{pages}{1804\bibrangedash 5}
      \verb{doi}
      \verb 10.1093/bioinformatics/btq264
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2010/Khelashvili et al/Khelashvili et al. - 2010 - GPCR-OKB the G Protein Coupled Receptor Oligomer Knowledge Base.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2894509%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
      \keyw{Databases,Factual,Internet,Knowledge Bases,Receptors,G-Protein-Coupled,Receptors,G-Protein-Coupled: chemistry,Software}
    \endentry
    \entry{Koo2012}{article}{}
      \name{labelname}{11}{}{%
        {{uniquename=0,hash=07b4c3f1b9e66a01c71e45a580343299}{Koo}{K\bibinitperiod}{Bon-Kyoung}{B\bibinithyphendelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bfaad10b07c3a70955d99079a4c36fd1}{Spit}{S\bibinitperiod}{Maureen}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=38a8b7b3dc4b81d2ee5d00dc926f17da}{Jordens}{J\bibinitperiod}{Ingrid}{I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ba6ddf578f955ff2a0464e11996df01a}{Low}{L\bibinitperiod}{Teck\bibnamedelima Y.}{T\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7373b768690fbb02b1ae6a23384de275}{Stange}{S\bibinitperiod}{Daniel\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=fa77136f81eb644e2236064f7f9cca53}{Wetering}{W\bibinitperiod}{Marc}{M\bibinitperiod}{van\bibnamedelima de}{v\bibinitperiod\bibinitdelim d\bibinitperiod}{}{}}%
        {{uniquename=0,hash=709b67039a112ee5547c7914b2b4fddf}{Es}{E\bibinitperiod}{Johan\bibnamedelima H.}{J\bibinitperiod\bibinitdelim H\bibinitperiod}{van}{v\bibinitperiod}{}{}}%
        {{uniquename=0,hash=faca32073973641228e4e0d06ecfb592}{Mohammed}{M\bibinitperiod}{Shabaz}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=78d9d8335874e16c3b880735002d59a5}{Heck}{H\bibinitperiod}{Albert\bibnamedelimb J.\bibnamedelimi R.}{A\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4fe51bf4b4ae1872a229477a8206add2}{Maurice}{M\bibinitperiod}{Madelon\bibnamedelima M.}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=33c24f144adf9910fa9b0cf732e641a0}{Clevers}{C\bibinitperiod}{Hans}{H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{uniquename=0,hash=07b4c3f1b9e66a01c71e45a580343299}{Koo}{K\bibinitperiod}{Bon-Kyoung}{B\bibinithyphendelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bfaad10b07c3a70955d99079a4c36fd1}{Spit}{S\bibinitperiod}{Maureen}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=38a8b7b3dc4b81d2ee5d00dc926f17da}{Jordens}{J\bibinitperiod}{Ingrid}{I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ba6ddf578f955ff2a0464e11996df01a}{Low}{L\bibinitperiod}{Teck\bibnamedelima Y.}{T\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7373b768690fbb02b1ae6a23384de275}{Stange}{S\bibinitperiod}{Daniel\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=fa77136f81eb644e2236064f7f9cca53}{Wetering}{W\bibinitperiod}{Marc}{M\bibinitperiod}{van\bibnamedelima de}{v\bibinitperiod\bibinitdelim d\bibinitperiod}{}{}}%
        {{uniquename=0,hash=709b67039a112ee5547c7914b2b4fddf}{Es}{E\bibinitperiod}{Johan\bibnamedelima H.}{J\bibinitperiod\bibinitdelim H\bibinitperiod}{van}{v\bibinitperiod}{}{}}%
        {{uniquename=0,hash=faca32073973641228e4e0d06ecfb592}{Mohammed}{M\bibinitperiod}{Shabaz}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=78d9d8335874e16c3b880735002d59a5}{Heck}{H\bibinitperiod}{Albert\bibnamedelimb J.\bibnamedelimi R.}{A\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4fe51bf4b4ae1872a229477a8206add2}{Maurice}{M\bibinitperiod}{Madelon\bibnamedelima M.}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=33c24f144adf9910fa9b0cf732e641a0}{Clevers}{C\bibinitperiod}{Hans}{H\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{86e830e86473314ab3a89da0d8d0f8ee}
      \strng{fullhash}{672efbb901e3120f30ebf0062bc4d41d}
      \field{sortinit}{K}
      \field{sortinithash}{33bf4c961fa093ee6a297ccbd88eacc0}
      \field{labelyear}{2012}
      \field{datelabelsource}{}
      \field{labeltitle}{{Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors}}
      \field{abstract}{LGR5+ stem cells reside at crypt bottoms, intermingled with Paneth cells that provide Wnt, Notch and epidermal growth factor signals. Here we find that the related RNF43 and ZNRF3 transmembrane E3 ubiquitin ligases are uniquely expressed in LGR5+ stem cells. Simultaneous deletion of the two genes encoding these proteins in the intestinal epithelium of mice induces rapidly growing adenomas containing high numbers of Paneth and LGR5+ stem cells. In vitro, growth of organoids derived from these adenomas is arrested when Wnt secretion is inhibited, indicating a dependence of the adenoma stem cells on Wnt produced by adenoma Paneth cells. In the HEK293T human cancer cell line, expression of RNF43 blocks Wnt responses and targets surface-expressed frizzled receptors to lysosomes. In the RNF43-mutant colorectal cancer cell line HCT116, reconstitution of RNF43 expression removes its response to exogenous Wnt. We conclude that RNF43 and ZNRF3 reduce Wnt signals by selectively ubiquitinating frizzled receptors, thereby targeting these Wnt receptors for degradation.}
      \field{isbn}{1476-4687 (Electronic)$\backslash$r0028-0836 (Linking)}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{number}{7413}
      \field{title}{{Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors}}
      \field{volume}{488}
      \field{year}{2012}
      \field{pages}{665\bibrangedash 669}
      \verb{doi}
      \verb 10.1038/nature11308
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2012/Koo et al/Koo et al. - 2012 - Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature11308
      \endverb
    \endentry
    \entry{Lan2011}{article}{}
      \name{labelname}{3}{}{%
        {{uniquename=0,hash=72ab99e5880ec325649e8d73ca3104a1}{Lan}{L\bibinitperiod}{Tien-Hung}{T\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3d3a297edf5f8f410f9f1cac1e14e3c2}{Kuravi}{K\bibinitperiod}{Sudhakiranmayi}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=24c4b3ad3f66b2b18d5a355acbee4670}{Lambert}{L\bibinitperiod}{Nevin\bibnamedelima a}{N\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{uniquename=0,hash=72ab99e5880ec325649e8d73ca3104a1}{Lan}{L\bibinitperiod}{Tien-Hung}{T\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3d3a297edf5f8f410f9f1cac1e14e3c2}{Kuravi}{K\bibinitperiod}{Sudhakiranmayi}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=24c4b3ad3f66b2b18d5a355acbee4670}{Lambert}{L\bibinitperiod}{Nevin\bibnamedelima a}{N\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{48919b6f002b48ec5af8cfa7d9b6d0ec}
      \strng{fullhash}{9d8638027518ca4c9fcc6021d9d91e85}
      \field{sortinit}{L}
      \field{sortinithash}{c41a2b5886eeae464e75d1a9df4cd13e}
      \field{labelyear}{2011}
      \field{labelmonth}{01}
      \field{datelabelsource}{}
      \field{labeltitle}{{Internalization dissociates $\beta$2-adrenergic receptors.}}
      \field{abstract}{G protein-coupled receptors (GPCRs) self-associate as dimers or higher-order oligomers in living cells. The stability of associated GPCRs has not been extensively studied, but it is generally thought that these receptors move between the plasma membrane and intracellular compartments as intact dimers or oligomers. Here we show that $\beta$(2)-adrenergic receptors ($\beta$(2)ARs) that self-associate at the plasma membrane can dissociate during agonist-induced internalization. We use bioluminescence-resonance energy transfer (BRET) to monitor movement of $\beta$(2)ARs between subcellular compartments. BRET between $\beta$(2)ARs and plasma membrane markers decreases in response to agonist activation, while at the same time BRET between $\beta$(2)ARs and endosome markers increases. Energy transfer between $\beta$(2)ARs is decreased in a similar manner if either the donor- or acceptor-labeled receptor is mutated to impair agonist binding and internalization. These changes take place over the course of 30 minutes, persist after agonist is removed, and are sensitive to several inhibitors of arrestin- and clathrin-mediated endocytosis. The magnitude of the decrease in BRET between donor- and acceptor-labeled $\beta$(2)ARs suggests that at least half of the receptors that contribute to the BRET signal are physically segregated by internalization. These results are consistent with the possibility that $\beta$(2)ARs associate transiently with each other in the plasma membrane, or that $\beta$(2)AR dimers or oligomers are actively disrupted during internalization.}
      \field{issn}{1932-6203}
      \field{journaltitle}{PLoS One}
      \field{month}{01}
      \field{number}{2}
      \field{title}{{Internalization dissociates $\beta$2-adrenergic receptors.}}
      \field{volume}{6}
      \field{year}{2011}
      \field{pages}{e17361}
      \verb{doi}
      \verb 10.1371/journal.pone.0017361
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2011/Lan, Kuravi, Lambert/Lan, Kuravi, Lambert - 2011 - Internalization dissociates $\beta$2-adrenergic receptors.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3043075%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
      \keyw{Adrenergic,Animals,Biological,Cells,Cultured,Endocytosis,Endocytosis: genetics,Endocytosis: physiology,Energy Transfer,Energy Transfer: genetics,Energy Transfer: physiology,Humans,Models,Protein Binding,Protein Binding: genetics,Protein Binding: physiology,Protein Multimerization,Protein Multimerization: genetics,Protein Multimerization: physiology,Protein Transport,Protein Transport: genetics,Protein Transport: physiology,Receptors,Transfection,beta-2,beta-2: genetics,beta-2: metabolism}
    \endentry
    \entry{Latif2002}{article}{}
      \name{labelname}{3}{}{%
        {{uniquename=0,hash=a1b0bb28ca7c9eda62e44b344577019b}{Latif}{L\bibinitperiod}{Rauf}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d7a20169736db373f1e445bb79868588}{Graves}{G\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=56371f54a055a1c48399e0d6ea749796}{Davies}{D\bibinitperiod}{Terry\bibnamedelima F.}{T\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{uniquename=0,hash=a1b0bb28ca7c9eda62e44b344577019b}{Latif}{L\bibinitperiod}{Rauf}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d7a20169736db373f1e445bb79868588}{Graves}{G\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=56371f54a055a1c48399e0d6ea749796}{Davies}{D\bibinitperiod}{Terry\bibnamedelima F.}{T\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{020c6eff102be652e7f543067d97adc1}
      \strng{fullhash}{5c4725a1c643b29608160dfc81ae266e}
      \field{sortinit}{L}
      \field{sortinithash}{c41a2b5886eeae464e75d1a9df4cd13e}
      \field{labelyear}{2002}
      \field{datelabelsource}{}
      \field{labeltitle}{{Ligand-dependent inhibition of oligomerization at the human thyrotropin receptor}}
      \field{abstract}{Recently, several studies have reported oligomerization of G protein-coupled receptors, although the functional implications of this phenomenon are still unclear. Using fluorescence resonance energy transfer (FRET) and coimmunoprecipitation (COIP), we previously reported that the human thyrotropin (TSH) receptor tagged with green fluorescent protein (TSHR(GFP)) and expressed in a heterologous system was present as oligomeric complexes on the cell surface. Here, we have extended this biophysical and biochemical approach to study the regulation of such oligomeric complexes. Co-expression of TSHR(GFP) and TSHR(Myc) constructs in Chinese hamster ovary cells resulted in FRET-positive cells. The specificity of the FRET signal was verified by the absence of energy transfer in individually transfected TSHR(GFP) and TSHR(Myc):Cy3 cells cultured together and also by acceptor photobleaching. Occupation of the receptor molecule by the ligand (TSH) resulted in a dose-dependent decrease in the FRET index from 20{\%} in the absence of TSH to <1{\%} with 10(3) microunits/ml of TSH. Such reduction in oligomeric forms was also confirmed by coimmunoprecipitation. Exposure of TSHR(GFP/Myc) cells to forskolin or cytochalasin D caused no change in the FRET index, confirming that the decrease in the oligomeric complexes was a receptor-dependent phenomenon and free of energy or microtuble requirements. The TSH-induced decrease in TSHR oligomers was found to be secondary to dissociation of the TSHR complexes as evidenced by an increase in fluorescent intensity of photobleached spots of GFP fluorescence with 10(3) microunits/ml of TSH. These data indicated that the less active conformation of the TSHR was comprised of receptor complexes and that such complexes were dissociated on the binding of ligand. Such observations support the concept of a constitutively active TSHR dimer or monomer that is naturally inhibited by the formation of higher order complexes. Inhibition of these oligomeric forms by ligand binding returns the TSHR to an activated state.}
      \field{isbn}{0021-9258 (Print)$\backslash$n0021-9258 (Linking)}
      \field{issn}{00219258}
      \field{journaltitle}{J Biol Chem}
      \field{number}{47}
      \field{title}{{Ligand-dependent inhibition of oligomerization at the human thyrotropin receptor}}
      \field{volume}{277}
      \field{year}{2002}
      \field{pages}{45059\bibrangedash 45067}
      \verb{doi}
      \verb 10.1074/jbc.M206693200
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2002/Latif, Graves, Davies/Latif, Graves, Davies - 2002 - Ligand-dependent inhibition of oligomerization at the human thyrotropin receptor.pdf:pdf
      \endverb
    \endentry
    \entry{Lee2000}{article}{}
      \name{labelname}{8}{}{%
        {{uniquename=0,hash=7271427713b5ff92ad9a3552432c05a9}{Lee}{L\bibinitperiod}{S\bibnamedelima P}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c07b21febaac34e0b881b997341d0ccf}{O'Dowd}{O\bibinitperiod}{B\bibnamedelima F}{B\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d3d2968138c00c1d9aff2007d906fd76}{Ng}{N\bibinitperiod}{G\bibnamedelima Y}{G\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=841e1cb00f4bbe60eef298f4ff64f57d}{Varghese}{V\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3d4ee99f46a9f2af003e91ba710ecf37}{Akil}{A\bibinitperiod}{H}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=15874deedb3506144a899866ec3d9478}{Mansour}{M\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b09b9fab0bc3ed13d1127f4ee47fa373}{Nguyen}{N\bibinitperiod}{T}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b3f01755c516c0a4ff8b8cf634fbaa4a}{George}{G\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{uniquename=0,hash=7271427713b5ff92ad9a3552432c05a9}{Lee}{L\bibinitperiod}{S\bibnamedelima P}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c07b21febaac34e0b881b997341d0ccf}{O'Dowd}{O\bibinitperiod}{B\bibnamedelima F}{B\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d3d2968138c00c1d9aff2007d906fd76}{Ng}{N\bibinitperiod}{G\bibnamedelima Y}{G\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=841e1cb00f4bbe60eef298f4ff64f57d}{Varghese}{V\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3d4ee99f46a9f2af003e91ba710ecf37}{Akil}{A\bibinitperiod}{H}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=15874deedb3506144a899866ec3d9478}{Mansour}{M\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b09b9fab0bc3ed13d1127f4ee47fa373}{Nguyen}{N\bibinitperiod}{T}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b3f01755c516c0a4ff8b8cf634fbaa4a}{George}{G\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \list{language}{1}{%
        {eng}%
      }
      \strng{namehash}{9f2d80f9be32f69ab419250a43809b9e}
      \strng{fullhash}{0027f678e58a0b86416bb07ca0dae64c}
      \field{sortinit}{L}
      \field{sortinithash}{c41a2b5886eeae464e75d1a9df4cd13e}
      \field{labelyear}{2000}
      \field{labelmonth}{07}
      \field{datelabelsource}{}
      \field{labeltitle}{{Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell.}}
      \field{abstract}{Numerous mutant G protein-coupled receptors with diminished or no function have been described that are naturally occurring or that are the product of gene manipulation. It has largely been assumed that receptor mutants do not affect the function of the wild-type receptor; however, the occurrence of G protein-coupled receptor dimerization suggests the possibility that an intermolecular interaction between mutant and wild-type receptors can occur. We have shown previously that the D2 dopamine receptor (D2DR) exists as dimers in cell lines and brain tissue. In this study, we demonstrated that mutant D2DR can modulate the function of the wild-type D2DR. While attempting to elucidate the structure of the D2DR dimer, we demonstrated that nonfunctional D2DR substitution and truncation mutants antagonized wild-type D2DR function. Furthermore, from analyses of this interaction between the receptor mutants and the D2DR, using photoaffinity labeling, we provide evidence that the D2DR is oligomeric in the cell.}
      \field{issn}{0026-895X (Print)}
      \field{journaltitle}{Mol Pharmacol}
      \field{month}{07}
      \field{number}{1}
      \field{title}{{Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell.}}
      \field{volume}{58}
      \field{year}{2000}
      \field{pages}{120\bibrangedash 128}
      \keyw{Amino Acid Substitution,Animals,Biopolymers,CHO Cells,COS Cells,Cercopithecus aethiops,Cricetinae,Dimerization,Gene Deletion,Membrane Proteins,Point Mutation,Receptors,Cell Surface,Receptors,Dopamine D2,Transfection,biosynthesis,chemistry,genetics,metabolism}
    \endentry
    \entry{Lenard2007}{article}{}
      \name{labelname}{4}{}{%
        {{uniquename=0,hash=111912eb9d4c74dd04950aea1488c48b}{Lenard}{L\bibinitperiod}{Natalie\bibnamedelima R}{N\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=363d912a5db8361b6b0b169a86a36649}{Daniels}{D\bibinitperiod}{David\bibnamedelima J}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1b9ef4f82d1e8668afdb51c73d65e132}{Portoghese}{P\bibinitperiod}{Philip\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b1628e84ebefe250760dd2378de10c55}{Roerig}{R\bibinitperiod}{Sandra\bibnamedelima C}{S\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{uniquename=0,hash=111912eb9d4c74dd04950aea1488c48b}{Lenard}{L\bibinitperiod}{Natalie\bibnamedelima R}{N\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=363d912a5db8361b6b0b169a86a36649}{Daniels}{D\bibinitperiod}{David\bibnamedelima J}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1b9ef4f82d1e8668afdb51c73d65e132}{Portoghese}{P\bibinitperiod}{Philip\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b1628e84ebefe250760dd2378de10c55}{Roerig}{R\bibinitperiod}{Sandra\bibnamedelima C}{S\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{bd4d22464c541b22c59dc264e042dc95}
      \strng{fullhash}{9b6d24249e1c43f62a0fc356df4d9d26}
      \field{sortinit}{L}
      \field{sortinithash}{c41a2b5886eeae464e75d1a9df4cd13e}
      \field{labelyear}{2007}
      \field{labelmonth}{07}
      \field{datelabelsource}{}
      \field{labeltitle}{{Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.}}
      \field{abstract}{Treatment of pain with opioids is limited by their potential abuse liability. In an effort to develop analgesics without this side effect, a series of bivalent ligands containing a mu-opioid receptor agonist pharmacophore connected to a delta-opioid receptor antagonist pharmacophore through variable-length spacers (16-21 atoms) was synthesized. Members of this series [mu-opioid receptor (M)-delta-opioid receptor (D)-agonist (A)-antagonists (N): MDANs] are antinociceptive in the tail flick assay, but antinociceptive tolerance and physical dependence do not develop to ligands having spacers with 19-21 atoms. The current studies compared the rewarding properties of three bivalent ligands (MDAN-16, -19 and -21) and a mu-opioid receptor agonist (MA-19) to those of morphine in the conditioned place preference assay in mice after i.v. administration. Place preference developed to morphine and to MA-19, but not to the MDANs. The responses to MDAN-16 were highly variable, although place preference of borderline significance appeared to develop. Reinstatement was also evaluated after extinguishing morphine conditioned place preference; morphine and MA-19, but not the MDANs, reinstated morphine conditioned place preference. Taken together, these results suggest that the bivalents are less rewarding compared to morphine in opioid-na{ï}ve mice and do not induce reinstatement in previously morphine-preferring mice. The lack of a conditioned place preference response for MDAN-19 and -21, compared to the equivocal results with MDAN-16, suggests a minimum distance requirement between mu-opioid receptor and delta-opioid receptor recognition sites. This requirement may reflect the binding of MDAN-19 and -21 to mu-opioid receptor-delta-opioid receptor heterodimeric receptors that block reward but not antinociception.}
      \field{issn}{0014-2999}
      \field{journaltitle}{Eur J Pharmacol}
      \field{month}{07}
      \field{number}{1-3}
      \field{title}{{Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.}}
      \field{volume}{566}
      \field{year}{2007}
      \field{pages}{75\bibrangedash 82}
      \verb{doi}
      \verb 10.1016/j.ejphar.2007.02.040
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/17383633
      \endverb
      \keyw{Analgesics,Opioid,Analgesics,Opioid: pharmacology,Animals,Behavior,Animal,Behavior,Animal: drug effects,Conditioning (Psychology),Conditioning (Psychology): physiology,Ligands,Male,Mice,Mice,Inbred ICR,Morphine,Morphine: pharmacology,Naltrexone,Naltrexone: analogs {\&} derivatives,Naltrexone: pharmacology,Narcotic Antagonists,Narcotic Antagonists: pharmacology,Oxymorphone,Oxymorphone: analogs {\&} derivatives,Oxymorphone: pharmacology,Pain,Pain: drug therapy,Pain: physiopathology,Receptors,Opioid,delta,Receptors,Opioid,delta: antagonists {\&} inhibitors,Receptors,Opioid,mu,Receptors,Opioid,mu: agonists}
    \endentry
    \entry{Manglik2012}{article}{}
      \name{labelname}{10}{}{%
        {{uniquename=0,hash=a08008fb2ae15184ce36e5d8a821214a}{Manglik}{M\bibinitperiod}{Aashish}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=01367d974c82e4e2e9b3c38b9231e012}{Kruse}{K\bibinitperiod}{Andrew\bibnamedelima C}{A\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2bcba851193b37d5c2cddd70bf1f8763}{Kobilka}{K\bibinitperiod}{Tong\bibnamedelima Sun}{T\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a17351cabe32fd8450fc95c8c3f42f30}{Thian}{T\bibinitperiod}{Foon\bibnamedelima Sun}{F\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b37edaad5298bfb288410466760f46d6}{Mathiesen}{M\bibinitperiod}{Jesper\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f7e147d808035020d8efae131779b1ce}{Sunahara}{S\bibinitperiod}{Roger\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=def1cdb974af3ecdde6ccd24e44e5ca5}{Pardo}{P\bibinitperiod}{Leonardo}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ba52c7efafd2c12a9a0fd5ab9ad79bbd}{Weis}{W\bibinitperiod}{William\bibnamedelima I}{W\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=decc5062cdeca8b403aad00dc8d4ce14}{Kobilka}{K\bibinitperiod}{Brian\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bcad16c778bc5c1c88e0f1aab618840d}{Granier}{G\bibinitperiod}{Sebastien}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{uniquename=0,hash=a08008fb2ae15184ce36e5d8a821214a}{Manglik}{M\bibinitperiod}{Aashish}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=01367d974c82e4e2e9b3c38b9231e012}{Kruse}{K\bibinitperiod}{Andrew\bibnamedelima C}{A\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2bcba851193b37d5c2cddd70bf1f8763}{Kobilka}{K\bibinitperiod}{Tong\bibnamedelima Sun}{T\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a17351cabe32fd8450fc95c8c3f42f30}{Thian}{T\bibinitperiod}{Foon\bibnamedelima Sun}{F\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b37edaad5298bfb288410466760f46d6}{Mathiesen}{M\bibinitperiod}{Jesper\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f7e147d808035020d8efae131779b1ce}{Sunahara}{S\bibinitperiod}{Roger\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=def1cdb974af3ecdde6ccd24e44e5ca5}{Pardo}{P\bibinitperiod}{Leonardo}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ba52c7efafd2c12a9a0fd5ab9ad79bbd}{Weis}{W\bibinitperiod}{William\bibnamedelima I}{W\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=decc5062cdeca8b403aad00dc8d4ce14}{Kobilka}{K\bibinitperiod}{Brian\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bcad16c778bc5c1c88e0f1aab618840d}{Granier}{G\bibinitperiod}{Sebastien}{S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{90e59736cc0e26d564a6bce72ec025c3}
      \strng{fullhash}{e99bdabc808d456c20a1c7ee08370d5b}
      \field{sortinit}{M}
      \field{sortinithash}{4203d16473bc940d4ac780773cb7c5dd}
      \field{labelyear}{2012}
      \field{labelmonth}{05}
      \field{datelabelsource}{}
      \field{labeltitle}{{Crystal structure of the [micro]-opioid receptor bound to a morphinan antagonist}}
      \field{annotation}{10.1038/nature10954}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{05}
      \field{number}{7398}
      \field{title}{{Crystal structure of the [micro]-opioid receptor bound to a morphinan antagonist}}
      \field{volume}{485}
      \field{year}{2012}
      \field{pages}{321\bibrangedash 326}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature10954%20http://www.nature.com/nature/journal/v485/n7398/abs/nature10954.html%7B%5C#%7Dsupplementary-information
      \endverb
    \endentry
    \entry{Maurel2008}{article}{}
      \name{labelname}{12}{}{%
        {{uniquename=0,hash=be172cd935205c533b6f658671a141ab}{Maurel}{M\bibinitperiod}{Damien}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6af7927e996619691d51df4eab030f50}{Comps-Agrar}{C\bibinithyphendelim A\bibinitperiod}{La{ë}titia}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=18d268e6ae75c280a47df2db95046c64}{Brock}{B\bibinitperiod}{Carsten}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a66f38c88cd97a14944cb68a112f397a}{Rives}{R\bibinitperiod}{Marie-laure}{M\bibinithyphendelim l\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6c342792fc270b296facafd4add2ee26}{Bourrier}{B\bibinitperiod}{Emmanuel}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4c82a8dbb934deea9c1e7f835ef671e9}{Ayoub}{A\bibinitperiod}{Mohammed\bibnamedelima Akli}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9501218f1053c238e5c2da3a94f50383}{Bazin}{B\bibinitperiod}{Herv{é}}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=df8f63f06f4e82215e0283d1a49a3aaf}{Tinel}{T\bibinitperiod}{Norbert}{N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b176a802ab7b11c217ab95a7ad84d820}{Durroux}{D\bibinitperiod}{Thierry}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d695a6e475955e242cf20983bdd77264}{Pr{é}zeau}{P\bibinitperiod}{Laurent}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2256344e7e48a51afd66ddff0072d45b}{Trinquet}{T\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{12}{}{%
        {{uniquename=0,hash=be172cd935205c533b6f658671a141ab}{Maurel}{M\bibinitperiod}{Damien}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6af7927e996619691d51df4eab030f50}{Comps-Agrar}{C\bibinithyphendelim A\bibinitperiod}{La{ë}titia}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=18d268e6ae75c280a47df2db95046c64}{Brock}{B\bibinitperiod}{Carsten}{C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a66f38c88cd97a14944cb68a112f397a}{Rives}{R\bibinitperiod}{Marie-laure}{M\bibinithyphendelim l\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6c342792fc270b296facafd4add2ee26}{Bourrier}{B\bibinitperiod}{Emmanuel}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4c82a8dbb934deea9c1e7f835ef671e9}{Ayoub}{A\bibinitperiod}{Mohammed\bibnamedelima Akli}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9501218f1053c238e5c2da3a94f50383}{Bazin}{B\bibinitperiod}{Herv{é}}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=df8f63f06f4e82215e0283d1a49a3aaf}{Tinel}{T\bibinitperiod}{Norbert}{N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b176a802ab7b11c217ab95a7ad84d820}{Durroux}{D\bibinitperiod}{Thierry}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d695a6e475955e242cf20983bdd77264}{Pr{é}zeau}{P\bibinitperiod}{Laurent}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2256344e7e48a51afd66ddff0072d45b}{Trinquet}{T\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{fb7c516e707f6f8bcee41400f675e08d}
      \strng{fullhash}{1bdf57b5f3758f472e8b65fac5c1c9bd}
      \field{sortinit}{M}
      \field{sortinithash}{4203d16473bc940d4ac780773cb7c5dd}
      \field{labelyear}{2008}
      \field{labelmonth}{06}
      \field{datelabelsource}{}
      \field{labeltitle}{{Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization.}}
      \field{abstract}{Cell-surface proteins are important in cell-cell communication. They assemble into heterocomplexes that include different receptors and effectors. Elucidation and manipulation of such protein complexes offers new therapeutic possibilities. We describe a methodology combining time-resolved fluorescence resonance energy transfer (FRET) with snap-tag technology to quantitatively analyze protein-protein interactions at the surface of living cells, in a high throughput-compatible format. Using this approach, we examined whether G protein-coupled receptors (GPCRs) are monomers or assemble into dimers or larger oligomers--a matter of intense debate. We obtained evidence for the oligomeric state of both class A and class C GPCRs. We also observed different quaternary structure of GPCRs for the neurotransmitters glutamate and gamma-aminobutyric acid (GABA): whereas metabotropic glutamate receptors assembled into strict dimers, the GABA(B) receptors spontaneously formed dimers of heterodimers, offering a way to modulate G-protein coupling efficacy. This approach will be useful in systematic analysis of cell-surface protein interaction in living cells.}
      \field{issn}{1548-7105}
      \field{journaltitle}{Nat Methods}
      \field{month}{06}
      \field{number}{6}
      \field{title}{{Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization.}}
      \field{volume}{5}
      \field{year}{2008}
      \field{pages}{561\bibrangedash 7}
      \verb{doi}
      \verb 10.1038/nmeth.1213
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2008/Maurel et al/Maurel et al. - 2008 - Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies application t.pdf:pdf;:Users/ska/Documents/thesis/literature/2008/Maurel et al/Maurel et al. - 2008 - Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies applicatio(2).pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2642604%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
      \keyw{Animals,Biological,Biophysics,Biophysics: methods,COS Cells,Cell Membrane,Cell Membrane: metabolism,Cercopithecus aethiops,Dimerization,Fluorescence Resonance Energy Transfer,Fluorescence Resonance Energy Transfer: methods,G-Protein-Coupled,G-Protein-Coupled: metabolism,GABA-B,GABA-B: chemistry,Humans,Models,Protein Interaction Mapping,Protein Interaction Mapping: methods,Protein Structure,Quaternary,Receptors,Surface Properties,gamma-Aminobutyric Acid}
    \endentry
    \entry{Mauriege1988}{article}{}
      \name{labelname}{4}{}{%
        {{uniquename=0,hash=2a271aa46b7b44cb0b30d58d7de8520a}{Mauri{è}ge}{M\bibinitperiod}{P}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=49cead20d535d0a9eb0d01ed5a39f5ed}{{De\bibnamedelimb Pergola}}{D\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3557ef91c1dc90c963b704a291870885}{Berlan}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4dc216a7a3da99bfc6f4cecb61e15b74}{Lafontan}{L\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{uniquename=0,hash=2a271aa46b7b44cb0b30d58d7de8520a}{Mauri{è}ge}{M\bibinitperiod}{P}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=49cead20d535d0a9eb0d01ed5a39f5ed}{{De\bibnamedelimb Pergola}}{D\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3557ef91c1dc90c963b704a291870885}{Berlan}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4dc216a7a3da99bfc6f4cecb61e15b74}{Lafontan}{L\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{489e80d1f48cc755e840ca5b19f11adf}
      \strng{fullhash}{366eddd95d95aa26e8b23c1ab3c9126a}
      \field{sortinit}{M}
      \field{sortinithash}{4203d16473bc940d4ac780773cb7c5dd}
      \field{labelyear}{1988}
      \field{datelabelsource}{}
      \field{labeltitle}{{Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta 1-antagonists.}}
      \field{abstract}{Beta-adrenergic receptors were characterized in human fat cell membranes using 125I-labeled cyanopindolol (125I-labeled CYP) and highly selective beta 1-antagonists. The iodinated radioligand bound saturably and specifically to a single class of high affinity binding sites. The number of binding sites determined with 125I-labeled CYP closely agreed with that determined with two other tritiated radioligands: [3H]dihydroalprenolol and [3H]CGP-12,177. Since 125I-labeled CYP does not discriminate between beta 1- and beta 2-adrenoceptors, the densities of the two receptor subtypes were determined from the competition curves of 125I-labeled CYP by highly selective beta 1-antagonists (bisoprolol, ICI-89,406, CGP-20,712A, and LK-204,545). Moreover, in order to enable correlation with binding data, the regulation of adenylate cyclase activity and of lipolysis was tested with various beta-agonist and antagonist compounds. The results obtained on fat cell membranes from abdominal subcutaneous adipose tissue demonstrated the following. 1) 125I-labeled CYP represents a valuable tool for the quantification and the delineation of beta-receptor subtypes. 2) The presence of sodium ions in binding buffers causes a modification of the affinity of beta-sites for some beta-antagonists. 3) The human fat cell beta adrenergic receptor population defined by nonselective radioligands is composed of two subtypes that can be interpreted in terms of classic beta 1- and beta 2-adrenergic receptor subtypes as assessed by competition studies with highly selective antagonists; beta 2-sites are predominant (60-70{\%} of 125I-labeled CYP sites) in the adipocytes of slightly overweight women. 4) Results support the idea that beta 1- as well as beta 2-adrenergic receptors are coupled with adenylate cyclase and involved in the induction of lipolysis. 5) The results focus on the interest in some beta 2-agonist drugs (zinterol, clenbuterol) as partial inductors of lipolysis, with the lipolytic efficacies of these compounds being well correlated with their efficacies at 125I-labeled CYP sites.}
      \field{isbn}{0022-2275 (Print)$\backslash$r0022-2275 (Linking)}
      \field{issn}{0022-2275}
      \field{journaltitle}{J Lipid Res}
      \field{number}{5}
      \field{title}{{Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta 1-antagonists.}}
      \field{volume}{29}
      \field{year}{1988}
      \field{pages}{587\bibrangedash 601}
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/1988/Mauri{è}ge et al/Mauri{è}ge et al. - 1988 - Human fat cell beta-adrenergic receptors beta-agonist-dependent lipolytic responses and characterization of be.pdf:pdf
      \endverb
    \endentry
    \entry{McGraw2006}{article}{}
      \name{labelname}{7}{}{%
        {{uniquename=0,hash=728444e71a18d9e5056be5309eadfcfa}{McGraw}{M\bibinitperiod}{Dennis\bibnamedelima W}{D\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2d027ef62219adbbb87192029a2304a0}{Mihlbachler}{M\bibinitperiod}{Kathryn\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4c180775b3b3f925241b50ba17b0c5bc}{Schwarb}{S\bibinitperiod}{Mary\bibnamedelima Rose}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=178ab69acdb608164b8c7974016bcdb7}{Rahman}{R\bibinitperiod}{Fahema\bibnamedelima F}{F\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7051d35ed56388e89859b4b782e4b5ac}{Small}{S\bibinitperiod}{Kersten\bibnamedelima M}{K\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9301ab8ea5069b973949b847de716744}{Almoosa}{A\bibinitperiod}{Khalid\bibnamedelima F}{K\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f8cebb322d86ba0c3f50ac2aaf99810b}{Liggett}{L\bibinitperiod}{Stephen\bibnamedelima B}{S\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{uniquename=0,hash=728444e71a18d9e5056be5309eadfcfa}{McGraw}{M\bibinitperiod}{Dennis\bibnamedelima W}{D\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2d027ef62219adbbb87192029a2304a0}{Mihlbachler}{M\bibinitperiod}{Kathryn\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4c180775b3b3f925241b50ba17b0c5bc}{Schwarb}{S\bibinitperiod}{Mary\bibnamedelima Rose}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=178ab69acdb608164b8c7974016bcdb7}{Rahman}{R\bibinitperiod}{Fahema\bibnamedelima F}{F\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7051d35ed56388e89859b4b782e4b5ac}{Small}{S\bibinitperiod}{Kersten\bibnamedelima M}{K\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9301ab8ea5069b973949b847de716744}{Almoosa}{A\bibinitperiod}{Khalid\bibnamedelima F}{K\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f8cebb322d86ba0c3f50ac2aaf99810b}{Liggett}{L\bibinitperiod}{Stephen\bibnamedelima B}{S\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{4a2f7fe6f9c946ee73435c956be95668}
      \strng{fullhash}{76b18332108785bddaab9303d674abaa}
      \field{sortinit}{M}
      \field{sortinithash}{4203d16473bc940d4ac780773cb7c5dd}
      \field{labelyear}{2006}
      \field{labelmonth}{05}
      \field{datelabelsource}{}
      \field{labeltitle}{{Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex.}}
      \field{abstract}{Multiple and paradoxical effects of airway smooth muscle (ASM) 7-transmembrane-spanning receptors activated during asthma, or by treatment with bronchodilators such as beta(2)-adrenergic receptor (beta(2)AR) agonists, indicate extensive receptor crosstalk. We examined the signaling of the prostanoid-EP(1) receptor, since its endogenous agonist prostaglandin E(2) is abundant in the airway, but its functional implications are poorly defined. Activation of EP(1) failed to elicit ASM contraction in mouse trachea via this G(alphaq)-coupled receptor. However, EP(1) activation markedly reduced the bronchodilatory function of beta(2)AR agonist, but not forskolin, indicating an early pathway interaction. Activation of EP(1) reduced beta(2)AR-stimulated cAMP in ASM but did not promote or augment beta(2)AR phosphorylation or alter beta(2)AR trafficking. Bioluminescence resonant energy transfer showed EP(1) and beta(2)AR formed heterodimers, which were further modified by EP(1) agonist. In cell membrane [(35)S]GTPgammaS binding studies, the presence of the EP(1) component of the dimer uncoupled beta(2)AR from G(alphas), an effect accentuated by EP(1) agonist activation. Thus alone, EP(1) does not appear to have a significant direct effect on airway tone but acts as a modulator of the beta(2)AR, altering G(alphas) coupling via steric interactions imposed by the EP(1):beta(2)AR heterodimeric signaling complex and ultimately affecting beta(2)AR-mediated bronchial relaxation. This mechanism may contribute to beta-agonist resistance found in asthma.}
      \field{issn}{0021-9738}
      \field{journaltitle}{J Clin Invest}
      \field{month}{05}
      \field{number}{5}
      \field{title}{{Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex.}}
      \field{volume}{116}
      \field{year}{2006}
      \field{pages}{1400\bibrangedash 9}
      \verb{doi}
      \verb 10.1172/JCI25840
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2006/McGraw et al/McGraw et al. - 2006 - Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique het.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1451203%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
      \keyw{Adrenergic,Animals,COS Cells,Cell Line,Cercopithecus aethiops,Dimerization,EP1 Subtype,Forskolin,Forskolin: metabolism,Guanosine 5'-O-(3-Thiotriphosphate),Guanosine 5'-O-(3-Thiotriphosphate): metabolism,Humans,Mice,Muscle,Prostaglandin E,Prostaglandin E: physiology,Receptors,Signal Transduction,Smooth,Smooth: metabolism,Trachea,Trachea: cytology,beta-2,beta-2: metabolism,beta-2: physiology}
    \endentry
    \entry{Milligan2010}{article}{}
      \name{labelname}{1}{}{%
        {{uniquename=0,hash=65ce19b54b395e37b896e60b30df47e9}{Milligan}{M\bibinitperiod}{Graeme}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{uniquename=0,hash=65ce19b54b395e37b896e60b30df47e9}{Milligan}{M\bibinitperiod}{Graeme}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{65ce19b54b395e37b896e60b30df47e9}
      \strng{fullhash}{65ce19b54b395e37b896e60b30df47e9}
      \field{sortinit}{M}
      \field{sortinithash}{4203d16473bc940d4ac780773cb7c5dd}
      \field{labelyear}{2010}
      \field{labelmonth}{02}
      \field{datelabelsource}{}
      \field{labeltitle}{{The role of dimerisation in the cellular trafficking of G-protein-coupled receptors}}
      \field{abstract}{The concept that G-protein-coupled receptors can exist as homomeric and/or heteromeric complexes is now well established. Despite this, how dynamic such interactions are and if this may be modulated during receptor trafficking remain topics of debate. Use of endoplasmic reticulum trapping strategies and the generation of asymmetric homomers have started to provide information on the contribution of protein-protein interactions to receptor maturation, cell surface delivery and ligand-mediated endocytosis. Although dimer/oligomer formation appears to be essential for cell surface delivery of class A and class C GPCRs, this may not be the case for class B receptors. ?? 2009 Elsevier Ltd. All rights reserved.}
      \field{isbn}{1471-4973 (Electronic)$\backslash$n1471-4892 (Linking)}
      \field{issn}{14714892}
      \field{journaltitle}{Curr Opin Pharmacol}
      \field{month}{02}
      \field{number}{1}
      \field{title}{{The role of dimerisation in the cellular trafficking of G-protein-coupled receptors}}
      \field{volume}{10}
      \field{year}{2010}
      \field{pages}{23\bibrangedash 29}
      \verb{doi}
      \verb 10.1016/j.coph.2009.09.010
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2010/Milligan/Milligan - 2010 - The role of dimerisation in the cellular trafficking of G-protein-coupled receptors.pdf:pdf
      \endverb
      \verb{url}
      \verb http://linkinghub.elsevier.com/retrieve/pii/S1471489209001581
      \endverb
    \endentry
    \entry{Ortega2007}{article}{}
      \name{labelname}{4}{}{%
        {{uniquename=0,hash=ee182188e42280298cf4077fe9fac68c}{Ortega}{O\bibinitperiod}{Victor\bibnamedelima E}{V\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2a842b898cd2b761c6387c9a132e82c4}{Hawkins}{H\bibinitperiod}{Gregory\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=04dd2c2a0619ef173ed26aaf1d391437}{Peters}{P\bibinitperiod}{Stephen\bibnamedelima P}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=39063dd898a4e849ce5e8965bc77fbe9}{Bleecker}{B\bibinitperiod}{Eugene\bibnamedelima R}{E\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{uniquename=0,hash=ee182188e42280298cf4077fe9fac68c}{Ortega}{O\bibinitperiod}{Victor\bibnamedelima E}{V\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2a842b898cd2b761c6387c9a132e82c4}{Hawkins}{H\bibinitperiod}{Gregory\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=04dd2c2a0619ef173ed26aaf1d391437}{Peters}{P\bibinitperiod}{Stephen\bibnamedelima P}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=39063dd898a4e849ce5e8965bc77fbe9}{Bleecker}{B\bibinitperiod}{Eugene\bibnamedelima R}{E\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{76a53ce2c1d8660be4b7aea56f4b7744}
      \strng{fullhash}{2540bbb015ca40b226845815d973f080}
      \field{sortinit}{O}
      \field{sortinithash}{59512cfd31be1dcef4def024230bdc1d}
      \field{labelyear}{2007}
      \field{labelmonth}{11}
      \field{datelabelsource}{}
      \field{labeltitle}{{Pharmacogenetics of the beta 2-adrenergic receptor gene.}}
      \field{abstract}{Asthma is a complex genetic disease with multiple genetic and environmental determinants contributing to the observed variability in response to common antiasthma therapies. One focus of asthma pharmacogenetic research has been the beta2-adrenergic receptor gene (ADR beta 2) and its effect on individual responses to beta agonist therapy. Knowledge about the effects of ADR beta 2 variation on therapeutic responses is evolving and should not alter current Asthma Guideline approaches, which consist of the use of short-acting beta agonists (SABAs) for as-needed symptom-based therapy and the use of a regular long-acting beta agonist (LABA) in combination with inhaled corticosteroid therapy for those asthmatics whose symptoms are not controlled by inhaled corticosteroid alone. These approaches are based upon studies showing a consistent pharmacogenetic response to regular use of SABAs and less consistent findings in studies evaluating LABAs. The emerging pharmacogenetic studies are provocative and should lead to functional studies. Meanwhile, the conflicting data concerning LABAs may be caused by such factors as small sample sizes of study populations and differences in experimental design.}
      \field{issn}{0889-8561}
      \field{journaltitle}{Immunol Allergy Clin North Am}
      \field{month}{11}
      \field{number}{4}
      \field{title}{{Pharmacogenetics of the beta 2-adrenergic receptor gene.}}
      \field{volume}{27}
      \field{year}{2007}
      \field{pages}{665\bibrangedash 84\bibrangessep vii}
      \verb{doi}
      \verb 10.1016/j.iac.2007.09.007
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2007/Ortega et al/Ortega et al. - 2007 - Pharmacogenetics of the beta 2-adrenergic receptor gene.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0889856107000847
      \endverb
      \keyw{Adrenergic beta-Agonists,Adrenergic beta-Agonists: therapeutic use,Animals,Asthma,Asthma: drug therapy,Asthma: genetics,Forced Expiratory Volume,Humans,Peak Expiratory Flow Rate,Pharmacogenetics,Polymorphism,Single Nucleotide,Receptors,Adrenergic,beta-2,Receptors,Adrenergic,beta-2: genetics}
    \endentry
    \entry{Park2004}{article}{}
      \name{labelname}{2}{}{%
        {{uniquename=0,hash=bb8c175f7d6e0941069ddfa869f70da6}{Park}{P\bibinitperiod}{Paul\bibnamedelima S-H}{P\bibinitperiod\bibinitdelim S\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=52572b3004de573b7031e7069f63e59b}{Wells}{W\bibinitperiod}{James\bibnamedelima W}{J\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{uniquename=0,hash=bb8c175f7d6e0941069ddfa869f70da6}{Park}{P\bibinitperiod}{Paul\bibnamedelima S-H}{P\bibinitperiod\bibinitdelim S\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=52572b3004de573b7031e7069f63e59b}{Wells}{W\bibinitperiod}{James\bibnamedelima W}{J\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{04088f05d06c685564aa109480a5e367}
      \strng{fullhash}{66bc5f0c3f0bfa6a49047512888c48c6}
      \field{sortinit}{P}
      \field{sortinithash}{b8af9282ac256b81613dc9012a0ac921}
      \field{labelyear}{2004}
      \field{datelabelsource}{}
      \field{labeltitle}{{Oligomeric potential of the M2 muscarinic cholinergic receptor.}}
      \field{abstract}{G protein-coupled receptors are known to exist as oligomers. Although such aggregates often are referred to as dimers, there is little direct evidence regarding their oligomeric size. In the present investigation, c-Myc-, FLAG-, and influenza hemagglutinin (HA)-tagged forms of the M2 muscarinic receptor have been coexpressed in Sf9 cells to probe for aggregates larger than a dimer. Immunochromatography, immunoprecipitation, and immunoblotting were carried out with various combinations of antibodies directed against the different epitopes to demonstrate that all three tagged forms of the receptor can be immunopurified within a single complex. Extracts of the M2 muscarinic receptor from Sf9 cells therefore contain aggregates that are at least trimeric, and the levels detected point to the existence of larger complexes. The data also suggest that the oligomers coexist with a sizeable population of monomers.}
      \field{issn}{0022-3042}
      \field{journaltitle}{J Neurochem}
      \field{number}{3}
      \field{title}{{Oligomeric potential of the M2 muscarinic cholinergic receptor.}}
      \field{volume}{90}
      \field{year}{2004}
      \field{pages}{537\bibrangedash 548}
      \verb{doi}
      \verb 10.1111/j.1471-4159.2004.02536.x
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2004/Park, Wells/Park, Wells - 2004 - Oligomeric potential of the M2 muscarinic cholinergic receptor.pdf:pdf
      \endverb
      \keyw{2004,537,548,90,cooperativity,g protein-coupled receptor,immu-,j,neurochem,noprecipitation,protein purification,receptor oligomerization,signal transduction}
    \endentry
    \entry{Pei2010}{article}{}
      \name{labelname}{8}{}{%
        {{uniquename=0,hash=9c83af9b365e733feb96abe49926a146}{Pei}{P\bibinitperiod}{Lin}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=11b6687d295f718892ff6dfe0fdb6109}{Li}{L\bibinitperiod}{Shupeng}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=96fb575ca3e501d621aacb8925f7030e}{Wang}{W\bibinitperiod}{Min}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=17d007869b4309da6bddacc0052f159a}{Diwan}{D\bibinitperiod}{Mustansir}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=76bfeec4a9d2d5e66e319f8700b99ec1}{Anisman}{A\bibinitperiod}{Hymie}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=38079b8a717d69b6b996159401ab6e88}{Fletcher}{F\bibinitperiod}{Paul\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0b67f6186d444e28f73548d2c1a517b9}{Nobrega}{N\bibinitperiod}{Jos{é}\bibnamedelima N}{J\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f366ed4d779dfffcffc0a514cf788132}{Liu}{L\bibinitperiod}{Fang}{F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{uniquename=0,hash=9c83af9b365e733feb96abe49926a146}{Pei}{P\bibinitperiod}{Lin}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=11b6687d295f718892ff6dfe0fdb6109}{Li}{L\bibinitperiod}{Shupeng}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=96fb575ca3e501d621aacb8925f7030e}{Wang}{W\bibinitperiod}{Min}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=17d007869b4309da6bddacc0052f159a}{Diwan}{D\bibinitperiod}{Mustansir}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=76bfeec4a9d2d5e66e319f8700b99ec1}{Anisman}{A\bibinitperiod}{Hymie}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=38079b8a717d69b6b996159401ab6e88}{Fletcher}{F\bibinitperiod}{Paul\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0b67f6186d444e28f73548d2c1a517b9}{Nobrega}{N\bibinitperiod}{Jos{é}\bibnamedelima N}{J\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f366ed4d779dfffcffc0a514cf788132}{Liu}{L\bibinitperiod}{Fang}{F\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ec8dcb6b140794ddd537f7d7a945bed1}
      \strng{fullhash}{555c8134b158022af531ae1470c644b1}
      \field{sortinit}{P}
      \field{sortinithash}{b8af9282ac256b81613dc9012a0ac921}
      \field{labelyear}{2010}
      \field{labelmonth}{12}
      \field{datelabelsource}{}
      \field{labeltitle}{{Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects.}}
      \field{abstract}{We report that coupling between dopamine D1 and D2 receptors was markedly increased in postmortem brain of subjects suffering from major depression. Biochemical analyses revealed that D1 and D2 receptors form heterodimers via a direct protein-protein interaction. Administration of an interfering peptide that disrupts the D1-D2 receptor complex substantially reduced immobility in the forced swim test (FST) without affecting locomotor activity, and decreased escape failures in learned helplessness tests in rats.}
      \field{issn}{1546-170X}
      \field{journaltitle}{Nat Med}
      \field{month}{12}
      \field{number}{12}
      \field{title}{{Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects.}}
      \field{volume}{16}
      \field{year}{2010}
      \field{pages}{1393\bibrangedash 5}
      \verb{doi}
      \verb 10.1038/nm.2263
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/21113156
      \endverb
      \keyw{Analysis of Variance,Animals,Blotting,Western,Cell Line,Depression,Depression: drug therapy,Depression: metabolism,Depression: physiopathology,Dimerization,Escape Reaction,Escape Reaction: drug effects,Helplessness,Learned,Humans,Immunoprecipitation,Locomotion,Locomotion: drug effects,Multiprotein Complexes,Multiprotein Complexes: metabolism,Organic Anion Transporters,Organic Anion Transporters: metabolism,Prefrontal Cortex,Prefrontal Cortex: metabolism,Protein Binding,Protein Binding: drug effects,Rats,Receptors,Dopamine D1,Receptors,Dopamine D1: metabolism,Receptors,Dopamine D2,Receptors,Dopamine D2: metabolism,Recombinant Fusion Proteins,Recombinant Fusion Proteins: metabolism,Recombinant Fusion Proteins: pharmacology,Recombinant Fusion Proteins: therapeutic use,tat Gene Products,Human Immunodeficiency Virus,tat Gene Products,Human Immunodeficiency Virus: g}
    \endentry
    \entry{Pfleger2006}{article}{}
      \name{labelname}{2}{}{%
        {{uniquename=0,hash=60bc43ba8f965889f7372ddc8489bd5e}{Pfleger}{P\bibinitperiod}{Kevin\bibnamedelimb D\bibnamedelima G}{K\bibinitperiod\bibinitdelim D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2f6310074086e5591e7e2d07955d5536}{Eidne}{E\bibinitperiod}{Karin\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{uniquename=0,hash=60bc43ba8f965889f7372ddc8489bd5e}{Pfleger}{P\bibinitperiod}{Kevin\bibnamedelimb D\bibnamedelima G}{K\bibinitperiod\bibinitdelim D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2f6310074086e5591e7e2d07955d5536}{Eidne}{E\bibinitperiod}{Karin\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{26dd0e49c03c79c09715bb27c26f728c}
      \strng{fullhash}{7b00984c31190017b842739b34e715a9}
      \field{sortinit}{P}
      \field{sortinithash}{b8af9282ac256b81613dc9012a0ac921}
      \field{labelyear}{2006}
      \field{labelmonth}{03}
      \field{datelabelsource}{}
      \field{labeltitle}{Nat Meth}
      \field{abstract}{Bioluminescence resonance energy transfer (BRET) is a straightforward biophysical technique for studying protein-protein interactions. It requires: (1) that proteins of interest and suitable controls be labeled with either a donor or acceptor molecule, (2) placement of these labeled proteins in the desired environment for assessing their potential interaction, and (3) use of suitable detection instrumentation to monitor resultant energy transfer. There are now several possible applications, combinations of donor and acceptor molecules, potential assay environments and detection system perturbations. Therefore, this review aims to demystify and clarify the important aspects of the BRET methodology that should be considered when using this technique.}
      \field{issn}{1548-7091}
      \field{journaltitle}{Nat Methods}
      \field{month}{03}
      \field{number}{3}
      \field{shorttitle}{Nat Meth}
      \field{title}{{Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET).}}
      \field{volume}{3}
      \field{year}{2006}
      \field{pages}{165\bibrangedash 74}
      \verb{doi}
      \verb 10.1038/nmeth841
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/nmeth841
      \endverb
      \keyw{Fluorescence Resonance Energy Transfer,Fluorescence Resonance Energy Transfer: instrument,Fluorescence Resonance Energy Transfer: methods,Green Fluorescent Proteins,Green Fluorescent Proteins: chemistry,Luminescent Measurements,Luminescent Measurements: methods,Protein Binding,Proteins,Proteins: chemistry,Recombinant Fusion Proteins,Recombinant Fusion Proteins: chemistry}
    \endentry
    \entry{Pierce2002}{article}{}
      \name{labelname}{3}{}{%
        {{uniquename=0,hash=b5cb25d1cb0ac0ccf2e7d10471a8d275}{Pierce}{P\bibinitperiod}{Kristen\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a0b29ed3da644651168e3480633e748e}{Premont}{P\bibinitperiod}{Richard\bibnamedelima T}{R\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ddf2117fdee0f3dfe5dda552f8c6f118}{Lefkowitz}{L\bibinitperiod}{Robert\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{uniquename=0,hash=b5cb25d1cb0ac0ccf2e7d10471a8d275}{Pierce}{P\bibinitperiod}{Kristen\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a0b29ed3da644651168e3480633e748e}{Premont}{P\bibinitperiod}{Richard\bibnamedelima T}{R\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ddf2117fdee0f3dfe5dda552f8c6f118}{Lefkowitz}{L\bibinitperiod}{Robert\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{fbfdb1628bb07880bc9298d60f4da1ac}
      \strng{fullhash}{6c8dd5cd8e2d647b63470ea3ceae0d5f}
      \field{sortinit}{P}
      \field{sortinithash}{b8af9282ac256b81613dc9012a0ac921}
      \field{labelyear}{2002}
      \field{datelabelsource}{}
      \field{labeltitle}{{Seven-transmembrane receptors.}}
      \field{abstract}{Seven-transmembrane receptors, which constitute the largest, most ubiquitous and most versatile family of membrane receptors, are also the most common target of therapeutic drugs. Recent findings indicate that the classical models of G-protein coupling and activation of second-messenger-generating enzymes do not fully explain their remarkably diverse biological actions.}
      \field{isbn}{1471-0072 (Print)$\backslash$n1471-0072 (Linking)}
      \field{issn}{14710072}
      \field{journaltitle}{Nat Rev Mol Cell Biol}
      \field{number}{9}
      \field{title}{{Seven-transmembrane receptors.}}
      \field{volume}{3}
      \field{year}{2002}
      \field{pages}{639\bibrangedash 650}
      \verb{doi}
      \verb 10.1038/nrm908
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2002/Pierce, Premont, Lefkowitz/Pierce, Premont, Lefkowitz - 2002 - Seven-transmembrane receptors.pdf:pdf
      \endverb
    \endentry
    \entry{Pin2007}{article}{}
      \name{labelname}{11}{}{%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c878ebd5d30c821c8c8544a67f380921}{Neubig}{N\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7ea48095889361f5fa9410c51a3acfa2}{Bouvier}{B\bibinitperiod}{Michel}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=69c83fc8ffb57435bd2d60cbc150b51e}{Devi}{D\bibinitperiod}{Lakshmi}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=caa7ad34df0c6628c95c1dbbf147fe90}{Filizola}{F\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e8062702653a27fc60dc0eb0ffc3c4e}{Javitch}{J\bibinitperiod}{Jonathan\bibnamedelima a}{J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=65ce19b54b395e37b896e60b30df47e9}{Milligan}{M\bibinitperiod}{Graeme}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=673b0f5d52008ad1441686dd78512e9a}{Palczewski}{P\bibinitperiod}{Krzysztof}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=30e885bad4cfa3a6da5ab1d66d31a1e8}{Parmentier}{P\bibinitperiod}{Marc}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=27e91a94c462aa7d77d536d19829ee02}{Spedding}{S\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{uniquename=0,hash=47e7de63efb23799ddebc7633df7863a}{Pin}{P\bibinitperiod}{Jean-Philippe}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c878ebd5d30c821c8c8544a67f380921}{Neubig}{N\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7ea48095889361f5fa9410c51a3acfa2}{Bouvier}{B\bibinitperiod}{Michel}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=69c83fc8ffb57435bd2d60cbc150b51e}{Devi}{D\bibinitperiod}{Lakshmi}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=caa7ad34df0c6628c95c1dbbf147fe90}{Filizola}{F\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e8062702653a27fc60dc0eb0ffc3c4e}{Javitch}{J\bibinitperiod}{Jonathan\bibnamedelima a}{J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d94e05a851b38dd515d071b4d96a08e}{Lohse}{L\bibinitperiod}{Martin\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=65ce19b54b395e37b896e60b30df47e9}{Milligan}{M\bibinitperiod}{Graeme}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=673b0f5d52008ad1441686dd78512e9a}{Palczewski}{P\bibinitperiod}{Krzysztof}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=30e885bad4cfa3a6da5ab1d66d31a1e8}{Parmentier}{P\bibinitperiod}{Marc}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=27e91a94c462aa7d77d536d19829ee02}{Spedding}{S\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{b8f82b442760c9922919faaad6e7a9e6}
      \strng{fullhash}{52573d4b898a094526ae34e43cbc7c1e}
      \field{sortinit}{P}
      \field{sortinithash}{b8af9282ac256b81613dc9012a0ac921}
      \field{labelyear}{2007}
      \field{datelabelsource}{}
      \field{labeltitle}{{International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers.}}
      \field{abstract}{G protein-coupled receptors (GPCRs) have long been considered to be monomeric membrane proteins. Although numerous recent studies have indicated that GPCRs can form multimeric complexes, the functional and pharmacological consequences of this phenomenon have remained elusive. With the discovery that the functional GABA(B) receptor is an obligate heterodimer and with the use of energy transfer technologies, it is now accepted that GPCRs can form heteromultimers. In some cases, specific properties of such heteromers not shared by their respective homomers have been reported. Although in most cases these properties have only been observed in heterologous expression systems, there are a few reports describing data consistent with such heteromultimeric GPCR complexes also existing in native tissues. The present article illustrates well-documented examples of such native multimeric complexes, lists a number of recommendations for recognition and acceptance of such multimeric receptors, and gives recommendations for their nomenclature.}
      \field{isbn}{0031-6997 (Print)$\backslash$r0031-6997 (Linking)}
      \field{issn}{0031-6997}
      \field{journaltitle}{Pharmacol Rev}
      \field{number}{1}
      \field{title}{{International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers.}}
      \field{volume}{59}
      \field{year}{2007}
      \field{pages}{5\bibrangedash 13}
      \verb{doi}
      \verb 10.1124/pr.59.1.5.5
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2007/Pin et al/Pin et al. - 2007 - International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature.pdf:pdf
      \endverb
    \endentry
    \entry{Rajapakse2010}{article}{}
      \name{labelname}{6}{}{%
        {{uniquename=0,hash=c3fc605cbb1c2bbcef24c79e9140f941}{Rajapakse}{R\bibinitperiod}{Harsha\bibnamedelima E}{H\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ac896705420cfe3f03e0639b776fa86d}{Gahlaut}{G\bibinitperiod}{Nivriti}{N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f27b6537d2039cb46c76861ae675248d}{Mohandessi}{M\bibinitperiod}{Shabnam}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=af9fa3bd3e2b4298536fdbcb709fefbc}{Yu}{Y\bibinitperiod}{Dan}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8601a973c66491c6302f5873a7e9ced7}{Turner}{T\bibinitperiod}{Jerrold\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0d3d3f23b0cab6fa5f323c2de42046d5}{Miller}{M\bibinitperiod}{Lawrence\bibnamedelima W}{L\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{uniquename=0,hash=c3fc605cbb1c2bbcef24c79e9140f941}{Rajapakse}{R\bibinitperiod}{Harsha\bibnamedelima E}{H\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ac896705420cfe3f03e0639b776fa86d}{Gahlaut}{G\bibinitperiod}{Nivriti}{N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f27b6537d2039cb46c76861ae675248d}{Mohandessi}{M\bibinitperiod}{Shabnam}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=af9fa3bd3e2b4298536fdbcb709fefbc}{Yu}{Y\bibinitperiod}{Dan}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8601a973c66491c6302f5873a7e9ced7}{Turner}{T\bibinitperiod}{Jerrold\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0d3d3f23b0cab6fa5f323c2de42046d5}{Miller}{M\bibinitperiod}{Lawrence\bibnamedelima W}{L\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{d696f458b91a489b355124c253141400}
      \strng{fullhash}{4a1395c3e883df7ec7b749bbb8e2a38c}
      \field{sortinit}{R}
      \field{sortinithash}{ff5a3533ecf9d5a03ff60b1e1389b63d}
      \field{labelyear}{2010}
      \field{datelabelsource}{}
      \field{labeltitle}{{Time-resolved luminescence resonance energy transfer imaging of protein-protein interactions in living cells.}}
      \field{abstract}{F{ö}rster resonance energy transfer (FRET) with fluorescent proteins permits high spatial resolution imaging of protein-protein interactions in living cells. However, substantial non-FRET fluorescence background can obscure small FRET signals, making many potential interactions unobservable by conventional FRET techniques. Here we demonstrate time-resolved microscopy of luminescence resonance energy transfer (LRET) for live-cell imaging of protein-protein interactions. A luminescent terbium complex, TMP-Lumi4, was introduced into cultured cells using two methods: (i) osmotic lysis of pinocytic vesicles; and (ii) reversible membrane permeabilization with streptolysin O. Upon intracellular delivery, the complex was observed to bind specifically and stably to transgenically expressed Escherichia coli dihydrofolate reductase (eDHFR) fusion proteins. LRET between the eDHFR-bound terbium complex and green fluorescent protein (GFP) was detected as long-lifetime, sensitized GFP emission. Background signals from cellular autofluorescence and directly excited GFP fluorescence were effectively eliminated by imposing a time delay (10 micros) between excitation and detection. Background elimination made it possible to detect interactions between the first PDZ domain of ZO-1 (fused to eDHFR) and the C-terminal YV motif of claudin-1 (fused to GFP) in single microscope images at subsecond time scales. We observed a highly significant (P<10(-6)), six-fold difference between the mean, donor-normalized LRET signal from cells expressing interacting fusion proteins and from control cells expressing noninteracting mutants. The results show that time-resolved LRET microscopy with a selectively targeted, luminescent terbium protein label affords improved speed and sensitivity over conventional FRET methods for a variety of live-cell imaging and screening applications.}
      \field{isbn}{1091-6490 (Electronic)$\backslash$n0027-8424 (Linking)}
      \field{issn}{1091-6490}
      \field{journaltitle}{Proc Natl Acad Sci U S A}
      \field{number}{31}
      \field{title}{{Time-resolved luminescence resonance energy transfer imaging of protein-protein interactions in living cells.}}
      \field{volume}{107}
      \field{year}{2010}
      \field{pages}{13582\bibrangedash 13587}
      \verb{doi}
      \verb 10.1073/pnas.1002025107
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2010/Rajapakse et al/Rajapakse et al. - 2010 - Time-resolved luminescence resonance energy transfer imaging of protein-protein interactions in living cells.pdf:pdf;:Users/ska/Documents/thesis/literature/2010/Rajapakse et al/Rajapakse et al. - 2010 - Time-resolved luminescence resonance energy transfer imaging of protein-protein interactions in living cell(2).pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pnas.org/content/107/31/13582.short
      \endverb
    \endentry
    \entry{Rashid2007}{article}{}
      \name{labelname}{8}{}{%
        {{uniquename=0,hash=c2074bcc5e89cd5f968021ef11bc50ab}{Rashid}{R\bibinitperiod}{Asim\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=19a577ae637b7ef85aae864132c513a7}{So}{S\bibinitperiod}{Christopher\bibnamedelima H}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ed8b6b5452903fb656519502eefd5050}{Kong}{K\bibinitperiod}{Michael\bibnamedelimb M\bibnamedelima C}{M\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a158696f8bd287e5ff1f7b54391ff0e5}{Furtak}{F\bibinitperiod}{Teresa}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=da39bccb20a7be06424c3a887b0e53a8}{El-Ghundi}{E\bibinithyphendelim G\bibinitperiod}{Mufida}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2a1b3e00170bc408b98908ceee076a46}{Cheng}{C\bibinitperiod}{Regina}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e57f4894466a9d847d1e45b5c7db77a4}{O'Dowd}{O\bibinitperiod}{Brian\bibnamedelima F}{B\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4f82f18c8d9bd65242153d4ce726b4c6}{George}{G\bibinitperiod}{Susan\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{uniquename=0,hash=c2074bcc5e89cd5f968021ef11bc50ab}{Rashid}{R\bibinitperiod}{Asim\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=19a577ae637b7ef85aae864132c513a7}{So}{S\bibinitperiod}{Christopher\bibnamedelima H}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ed8b6b5452903fb656519502eefd5050}{Kong}{K\bibinitperiod}{Michael\bibnamedelimb M\bibnamedelima C}{M\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a158696f8bd287e5ff1f7b54391ff0e5}{Furtak}{F\bibinitperiod}{Teresa}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=da39bccb20a7be06424c3a887b0e53a8}{El-Ghundi}{E\bibinithyphendelim G\bibinitperiod}{Mufida}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2a1b3e00170bc408b98908ceee076a46}{Cheng}{C\bibinitperiod}{Regina}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e57f4894466a9d847d1e45b5c7db77a4}{O'Dowd}{O\bibinitperiod}{Brian\bibnamedelima F}{B\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4f82f18c8d9bd65242153d4ce726b4c6}{George}{G\bibinitperiod}{Susan\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c139629bc1bf6bb0fa9f64df195488e6}
      \strng{fullhash}{0b9357e262c3b827ee14a7acfb7ed1ac}
      \field{sortinit}{R}
      \field{sortinithash}{ff5a3533ecf9d5a03ff60b1e1389b63d}
      \field{labelyear}{2007}
      \field{labelmonth}{01}
      \field{datelabelsource}{}
      \field{labeltitle}{{D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum}}
      \field{abstract}{We demonstrate a heteromeric D1-D2 dopamine receptor signaling complex in brain that is coupled to Gq/11 and requires agonist binding to both receptors for G protein activation and intracellular calcium release. The D1 agonist SKF83959 was identified as a specific agonist for the heteromer that activated Gq/11 by functioning as a full agonist for the D1 receptor and a high-affinity partial agonist for a pertussis toxin-resistant D2 receptor within the complex. We provide evidence that the D1-D2 signaling complex can be more readily detected in mice that are 8 months in age compared with animals that are 3 months old, suggesting that calcium signaling through the D1-D2 dopamine receptor complex is relevant for function in the postadolescent brain. Activation of Gq/11 through the heteromer increases levels of calcium/calmodulin-dependent protein kinase IIalpha in the nucleus accumbens, unlike activation of Gs/olf-coupled D1 receptors, indicating a mechanism by which D1-D2 dopamine receptor complexes may contribute to synaptic plasticity.}
      \field{isbn}{0027-8424 (Print)$\backslash$r0027-8424 (Linking)}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proc Natl Acad Sci}
      \field{month}{01}
      \field{number}{2}
      \field{title}{{D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum}}
      \field{volume}{104}
      \field{year}{2007}
      \field{pages}{654\bibrangedash 659}
      \verb{doi}
      \verb 10.1073/pnas.0604049104
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2007/Rashid et al/Rashid et al. - 2007 - D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq11 in the s.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pnas.org/cgi/doi/10.1073/pnas.0604049104
      \endverb
    \endentry
    \entry{Roed2014}{article}{}
      \name{labelname}{15}{}{%
        {{uniquename=0,hash=cc7082dde0e2c66f032c5fcdd59d6310}{Roed}{R\bibinitperiod}{Sarah\bibnamedelima Noerklit}{S\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=92a5542958a8b4c8691c0eeb87cfac05}{Wismann}{W\bibinitperiod}{Pernille}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9afe3d40305df23d67d20ba6d91ca135}{Underwood}{U\bibinitperiod}{Christina\bibnamedelima Rye}{C\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=be291367279add976aead2397a7b207d}{Kulahin}{K\bibinitperiod}{Nikolaj}{N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3160f6037d8d739bf67306e94ecf07be}{Iversen}{I\bibinitperiod}{Helle}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1a53279d14c533b6c87d7d2cb0c164ec}{Cappelen}{C\bibinitperiod}{Karen\bibnamedelima Arevad}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=505ce083ed82e707a534830af9524301}{Sch{ä}ffer}{S\bibinitperiod}{Lauge}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=dcb8bb14c6a8a753dfb32663dade8033}{Lehtonen}{L\bibinitperiod}{Janne}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=33f93d8130855ce3c656e2b3c28a4667}{Hecksher-Soerensen}{H\bibinithyphendelim S\bibinitperiod}{Jacob}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=18f38a4c478b45304903a18a31296c4a}{Secher}{S\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b5a6e5e3858418ac0623b0a557876e64}{Mathiesen}{M\bibinitperiod}{Jesper\bibnamedelima Mosolff}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c193eff61574bb3d7319dd97bb36baa1}{Br{ä}uner-Osborne}{B\bibinithyphendelim O\bibinitperiod}{Hans}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=85404252c5f3d7b9e718d16bdda2fb17}{Whistler}{W\bibinitperiod}{Jennifer\bibnamedelima L.}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=203896e0fc6e763a32af234e7a8f5d16}{Knudsen}{K\bibinitperiod}{Sanne\bibnamedelima Moeller}{S\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=28166a11401ef83caf0aacd03b3129ec}{Waldhoer}{W\bibinitperiod}{Maria}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{15}{}{%
        {{uniquename=0,hash=cc7082dde0e2c66f032c5fcdd59d6310}{Roed}{R\bibinitperiod}{Sarah\bibnamedelima Noerklit}{S\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=92a5542958a8b4c8691c0eeb87cfac05}{Wismann}{W\bibinitperiod}{Pernille}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9afe3d40305df23d67d20ba6d91ca135}{Underwood}{U\bibinitperiod}{Christina\bibnamedelima Rye}{C\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=be291367279add976aead2397a7b207d}{Kulahin}{K\bibinitperiod}{Nikolaj}{N\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3160f6037d8d739bf67306e94ecf07be}{Iversen}{I\bibinitperiod}{Helle}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1a53279d14c533b6c87d7d2cb0c164ec}{Cappelen}{C\bibinitperiod}{Karen\bibnamedelima Arevad}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=505ce083ed82e707a534830af9524301}{Sch{ä}ffer}{S\bibinitperiod}{Lauge}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=dcb8bb14c6a8a753dfb32663dade8033}{Lehtonen}{L\bibinitperiod}{Janne}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=33f93d8130855ce3c656e2b3c28a4667}{Hecksher-Soerensen}{H\bibinithyphendelim S\bibinitperiod}{Jacob}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=18f38a4c478b45304903a18a31296c4a}{Secher}{S\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b5a6e5e3858418ac0623b0a557876e64}{Mathiesen}{M\bibinitperiod}{Jesper\bibnamedelima Mosolff}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c193eff61574bb3d7319dd97bb36baa1}{Br{ä}uner-Osborne}{B\bibinithyphendelim O\bibinitperiod}{Hans}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=85404252c5f3d7b9e718d16bdda2fb17}{Whistler}{W\bibinitperiod}{Jennifer\bibnamedelima L.}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=203896e0fc6e763a32af234e7a8f5d16}{Knudsen}{K\bibinitperiod}{Sanne\bibnamedelima Moeller}{S\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=28166a11401ef83caf0aacd03b3129ec}{Waldhoer}{W\bibinitperiod}{Maria}{M\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier Ireland Ltd}%
      }
      \strng{namehash}{4842a8c1a554dd9133f3d9901e74f016}
      \strng{fullhash}{6916a63a7d87d177fd5b5f6826ffe0ff}
      \field{sortinit}{R}
      \field{sortinithash}{ff5a3533ecf9d5a03ff60b1e1389b63d}
      \field{labelyear}{2014}
      \field{datelabelsource}{}
      \field{labeltitle}{{Real-time trafficking and signaling of the glucagon-like peptide-1 receptor}}
      \field{abstract}{The glucagon-like peptide-1 incretin receptor (GLP-1R) of family B G protein-coupled receptors (GPCRs) is a major drug target in type-2-diabetes due to its regulatory effect on post-prandial blood-glucose levels. The mechanism(s) controlling GLP-1R mediated signaling are far from fully understood. A fundamental mechanism controlling the signaling capacity of GPCRs is the post-endocytic trafficking of receptors between recycling and degradative fates. Here, we combined microscopy with novel real-time assays to monitor both receptor trafficking and signaling in living cells. We find that the human GLP-1R internalizes rapidly and with similar kinetics in response to equipotent concentrations of GLP-1 and the stable GLP-1 analogues exendin-4 and liraglutide. Receptor internalization was confirmed in mouse pancreatic islets. GLP-1R is shown to be a recycling receptor with faster recycling rates mediated by GLP-1 as compared to exendin-4 and liraglutide. Furthermore, a prolonged cycling of ligand-activated GLP-1Rs was observed and is suggested to be correlated with a prolonged cAMP signal. © 2013 The Authors.}
      \field{issn}{03037207}
      \field{journaltitle}{Mol Cell Endocrinol}
      \field{number}{2}
      \field{title}{{Real-time trafficking and signaling of the glucagon-like peptide-1 receptor}}
      \field{volume}{382}
      \field{year}{2014}
      \field{pages}{938\bibrangedash 949}
      \verb{doi}
      \verb 10.1016/j.mce.2013.11.010
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2014/Roed et al/Roed et al. - 2014 - Real-time trafficking and signaling of the glucagon-like peptide-1 receptor.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.mce.2013.11.010
      \endverb
      \keyw{CAMP signaling,Fluorescent microscopy,Glucagon-like peptide-1,Real-time TR-FRET,Seven transmembrane-spanning receptors/G protein-c,Trafficking}
    \endentry
    \entry{Rosenbaum2009}{article}{}
      \name{labelname}{3}{}{%
        {{uniquename=0,hash=0828d953129b55f1f04d368185bc4a7d}{Rosenbaum}{R\bibinitperiod}{Daniel\bibnamedelima M}{D\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a3b965d18a54a31cb9e31c3c946397ab}{Rasmussen}{R\bibinitperiod}{S{ø}ren\bibnamedelimb G\bibnamedelima F}{S\bibinitperiod\bibinitdelim G\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=decc5062cdeca8b403aad00dc8d4ce14}{Kobilka}{K\bibinitperiod}{Brian\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{uniquename=0,hash=0828d953129b55f1f04d368185bc4a7d}{Rosenbaum}{R\bibinitperiod}{Daniel\bibnamedelima M}{D\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a3b965d18a54a31cb9e31c3c946397ab}{Rasmussen}{R\bibinitperiod}{S{ø}ren\bibnamedelimb G\bibnamedelima F}{S\bibinitperiod\bibinitdelim G\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=decc5062cdeca8b403aad00dc8d4ce14}{Kobilka}{K\bibinitperiod}{Brian\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9b50a06728b1772b4b51707bffeed9ce}
      \strng{fullhash}{143ed5213d6ccce4670bd51115ff312c}
      \field{sortinit}{R}
      \field{sortinithash}{ff5a3533ecf9d5a03ff60b1e1389b63d}
      \field{labelyear}{2009}
      \field{datelabelsource}{}
      \field{labeltitle}{{The structure and function of G-protein-coupled receptors.}}
      \field{abstract}{G-protein-coupled receptors (GPCRs) mediate most of our physiological responses to hormones, neurotransmitters and environmental stimulants, and so have great potential as therapeutic targets for a broad spectrum of diseases. They are also fascinating molecules from the perspective of membrane-protein structure and biology. Great progress has been made over the past three decades in understanding diverse GPCRs, from pharmacology to functional characterization in vivo. Recent high-resolution structural studies have provided insights into the molecular mechanisms of GPCR activation and constitutive activity.}
      \field{isbn}{9780123741455}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{number}{7245}
      \field{title}{{The structure and function of G-protein-coupled receptors.}}
      \field{volume}{459}
      \field{year}{2009}
      \field{pages}{356\bibrangedash 363}
      \verb{doi}
      \verb 10.1038/nature08144
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2009/Rosenbaum, Rasmussen, Kobilka/Rosenbaum, Rasmussen, Kobilka - 2009 - The structure and function of G-protein-coupled receptors.pdf:pdf
      \endverb
    \endentry
    \entry{Salahpour2004}{article}{}
      \name{labelname}{6}{}{%
        {{uniquename=0,hash=2d20845c786800e0e4a7539bb00916d5}{Salahpour}{S\bibinitperiod}{Ali}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9d32033589c02cfef3725bc02c4165d5}{Angers}{A\bibinitperiod}{St{é}phane}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e95ecfeb71c265b4af8202b2e580b182}{Mercier}{M\bibinitperiod}{Jean-Fran{ç}ois}{J\bibinithyphendelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=768b7bb395c862b1d0e16b79927a9cac}{Lagac{é}}{L\bibinitperiod}{Monique}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bc5ddd1bd419c9c57f7e3dd80489a3a3}{Marullo}{M\bibinitperiod}{Stefano}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7ea48095889361f5fa9410c51a3acfa2}{Bouvier}{B\bibinitperiod}{Michel}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{uniquename=0,hash=2d20845c786800e0e4a7539bb00916d5}{Salahpour}{S\bibinitperiod}{Ali}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9d32033589c02cfef3725bc02c4165d5}{Angers}{A\bibinitperiod}{St{é}phane}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e95ecfeb71c265b4af8202b2e580b182}{Mercier}{M\bibinitperiod}{Jean-Fran{ç}ois}{J\bibinithyphendelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=768b7bb395c862b1d0e16b79927a9cac}{Lagac{é}}{L\bibinitperiod}{Monique}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=bc5ddd1bd419c9c57f7e3dd80489a3a3}{Marullo}{M\bibinitperiod}{Stefano}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7ea48095889361f5fa9410c51a3acfa2}{Bouvier}{B\bibinitperiod}{Michel}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{dc74020f7331fc28ea9001166848c025}
      \strng{fullhash}{3a3fa5e4017a745455f0c5984e7898b0}
      \field{sortinit}{S}
      \field{sortinithash}{4125bb4c3a0eb3eaee3ea6da32eb70c8}
      \field{labelyear}{2004}
      \field{labelmonth}{08}
      \field{datelabelsource}{}
      \field{labeltitle}{{Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting.}}
      \field{abstract}{Although homodimerization has been demonstrated for a large number of G protein-coupled receptors (GPCRs), no general role has been attributed to this process. Because it is known that oligomerization plays a key role in the quality control and endoplasmic reticulum (ER) export of many proteins, we sought to determine if homodimerization could play such a role in GPCR biogenesis. Using the beta2-adrenergic receptor (beta2AR) as a model, cell fractionation studies revealed that receptor homodimerization is an event occurring as early as the ER. Supporting the hypothesis that receptor homodimerization is involved in ER processing, beta2AR mutants lacking an ER-export motif or harboring a heterologous ER-retention signal dimerized with the wild-type receptor and inhibited its trafficking to the cell surface. Finally, in addition to inhibiting receptor dimerization, disruption of the putative dimerization motif, 276GXXXGXXXL284, prevented normal trafficking of the receptor to the plasma membrane. Taken together, these data indicate that beta2AR homodimerization plays an important role in ER export and cell surface targeting.}
      \field{issn}{0021-9258}
      \field{journaltitle}{J Biol Chem}
      \field{month}{08}
      \field{number}{32}
      \field{title}{{Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting.}}
      \field{volume}{279}
      \field{year}{2004}
      \field{pages}{33390\bibrangedash 7}
      \verb{doi}
      \verb 10.1074/jbc.M403363200
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2004/Salahpour et al/Salahpour et al. - 2004 - Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/15155738
      \endverb
      \keyw{Adrenergic,Binding Sites,Biological Transport,Cell Fractionation,Cell Line,Cell Membrane,Cell Membrane: metabolism,Dimerization,Endoplasmic Reticulum,Endoplasmic Reticulum: metabolism,Energy Transfer,Enzyme-Linked Immunosorbent Assay,Fluorescent Antibody Technique,Gene Expression,Green Fluorescent Proteins,Hemagglutinins,Hemagglutinins: genetics,Luciferases,Luciferases: genetics,Luminescent Measurements,Luminescent Proteins,Luminescent Proteins: genetics,Mutagenesis,Polymerase Chain Reaction,Receptors,Recombinant Fusion Proteins,Structure-Activity Relationship,Transfection,beta-2,beta-2: chemistry,beta-2: genetics,beta-2: metabolism}
    \endentry
    \entry{Selvin1994}{article}{}
      \name{labelname}{2}{uniquelist=2}{%
        {{uniquename=0,hash=1a51cea15667ccdda2860c6816c2f70f}{Selvin}{S\bibinitperiod}{P\bibnamedelima R}{P\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=44aa651a30e82d53ac406f796e8044e8}{Hearst}{H\bibinitperiod}{J\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{uniquelist=2}{%
        {{uniquename=0,hash=1a51cea15667ccdda2860c6816c2f70f}{Selvin}{S\bibinitperiod}{P\bibnamedelima R}{P\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=44aa651a30e82d53ac406f796e8044e8}{Hearst}{H\bibinitperiod}{J\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{7b288e5436734f1460435902d6b4dcb4}
      \strng{fullhash}{7b288e5436734f1460435902d6b4dcb4}
      \field{sortinit}{S}
      \field{sortinithash}{4125bb4c3a0eb3eaee3ea6da32eb70c8}
      \field{labelyear}{1994}
      \field{labelmonth}{10}
      \field{datelabelsource}{}
      \field{labeltitle}{{Luminescence energy transfer using a terbium chelate: improvements on fluorescence energy transfer.}}
      \field{abstract}{We extend the technique of fluorescence resonance energy transfer (FRET) by introducing a luminescent terbium chelate as a donor and an organic dye, tetramethylrhodamine, as an acceptor. The results are consistent with a F{ö}rster theory of energy transfer, provided the appropriate parameters are used. The use of lanthanide donors, in general, and this pair, in particular, has many advantages over more conventional FRET pairs, which rely solely on organic dyes. The distance at which 50{\%} energy transfer occurs is large, 65 A; the donor lifetime is a single exponential and long (millisecond), making lifetime measurements facile and accurate. Uncertainty in the orientation factor, which creates uncertainty in measured distances, is minimized by the donor's multiple electronic transitions and long lifetime. The sensitized emission of the acceptor can be measured with little or no interfering background, yielding a > 25-fold improvements in the signal-to-background ratio over standard donor-acceptor pairs. These improvements are expected to make distances > 100 A measurable via FRET. We also report measurement of the sensitized emission lifetime, a measurement that is completely insensitive to total concentration and incomplete labeling.}
      \field{isbn}{0027-8424 (Print)}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proc Natl Acad Sci}
      \field{month}{10}
      \field{number}{21}
      \field{title}{{Luminescence energy transfer using a terbium chelate: improvements on fluorescence energy transfer.}}
      \field{volume}{91}
      \field{year}{1994}
      \field{pages}{10024\bibrangedash 10028}
      \verb{doi}
      \verb 10.1073/pnas.91.21.10024
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/1994/Selvin, Hearst/Selvin, Hearst - 1994 - Luminescence energy transfer using a terbium chelate improvements on fluorescence energy transfer.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pnas.org/cgi/doi/10.1073/pnas.91.21.10024
      \endverb
    \endentry
    \entry{Selvin2002}{article}{}
      \name{labelname}{1}{}{%
        {{uniquename=0,hash=54f5f259c2f8a54e5534fe50bfc54757}{Selvin}{S\bibinitperiod}{Paul\bibnamedelima R}{P\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{uniquename=0,hash=54f5f259c2f8a54e5534fe50bfc54757}{Selvin}{S\bibinitperiod}{Paul\bibnamedelima R}{P\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{54f5f259c2f8a54e5534fe50bfc54757}
      \strng{fullhash}{54f5f259c2f8a54e5534fe50bfc54757}
      \field{sortinit}{S}
      \field{sortinithash}{4125bb4c3a0eb3eaee3ea6da32eb70c8}
      \field{labelyear}{2002}
      \field{datelabelsource}{}
      \field{labeltitle}{{Principles and biophysical applications of lanthanide-based probes.}}
      \field{abstract}{Using luminescent lanthanides, instead of conventional fluorophores, as donor molecules in resonance energy transfer measurements offers many technical advantages and opens up a wide range of new applications. Advantages include farther measurable distances ( approximately 100 A) with greater accuracy, insensitivity to incomplete labeling, and the ability to use generic relatively large labels, when necessary. Applications highlighted include the study of ion channels in living cells, protein-protein interaction in cells, DNA-protein complexes, and high-throughput screening assays to measure peptide dimerization associated with DNA transcription factors and ligand-receptor interactions.}
      \field{isbn}{1056-8700 (Print)$\backslash$n1056-8700 (Linking)}
      \field{issn}{1056-8700}
      \field{journaltitle}{Annu Rev Biophys Biomol Struct}
      \field{title}{{Principles and biophysical applications of lanthanide-based probes.}}
      \field{volume}{31}
      \field{year}{2002}
      \field{pages}{275\bibrangedash 302}
      \verb{doi}
      \verb 10.1146/annurev.biophys.31.101101.140927
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2002/Selvin/Selvin - 2002 - Principles and biophysical applications of lanthanide-based probes.pdf:pdf
      \endverb
      \keyw{a wide range of,advantages and opens up,advantages include farther,as donor molecules in,fluorescence resonance energy transfer,instead of conventional fluorophores,lanthanide,lanthanides,luminescence,new applications,offers many technical,resonance energy transfer measurements,s abstract using luminescent}
    \endentry
    \entry{Soderberg2006}{article}{}
      \name{labelname}{11}{}{%
        {{uniquename=0,hash=69826f9b883427dd24c5d62afb56de25}{S{ö}derberg}{S\bibinitperiod}{Ola}{O\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=830e565be1aa21716fa2f78e90211670}{Gullberg}{G\bibinitperiod}{Mats}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6ad59584d77acfc81b387d3a454085ce}{Jarvius}{J\bibinitperiod}{Malin}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c3ecc02679f31bc6d72c2ac79bdbbb13}{Ridderstr{å}le}{R\bibinitperiod}{Karin}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=97785ff48f0e95739b6844469e914c5c}{Leuchowius}{L\bibinitperiod}{Karl-Johan}{K\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=77ba1fa3184365e780a8788438f85724}{Jarvius}{J\bibinitperiod}{Jonas}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7242b40ed1ed821052456d14f316f10c}{Wester}{W\bibinitperiod}{Kenneth}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0208b2cee6b710359e73d313d92bfb0f}{Hydbring}{H\bibinitperiod}{Per}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=941da1a68856077a6d677ca510074ae2}{Bahram}{B\bibinitperiod}{Fuad}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=41e047a30ee4dfabede72d6548b93205}{Larsson}{L\bibinitperiod}{Lars-Gunnar}{L\bibinithyphendelim G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d03048f54c00fc181a549267fe5bb3a1}{Landegren}{L\bibinitperiod}{Ulf}{U\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{uniquename=0,hash=69826f9b883427dd24c5d62afb56de25}{S{ö}derberg}{S\bibinitperiod}{Ola}{O\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=830e565be1aa21716fa2f78e90211670}{Gullberg}{G\bibinitperiod}{Mats}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=6ad59584d77acfc81b387d3a454085ce}{Jarvius}{J\bibinitperiod}{Malin}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c3ecc02679f31bc6d72c2ac79bdbbb13}{Ridderstr{å}le}{R\bibinitperiod}{Karin}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=97785ff48f0e95739b6844469e914c5c}{Leuchowius}{L\bibinitperiod}{Karl-Johan}{K\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=77ba1fa3184365e780a8788438f85724}{Jarvius}{J\bibinitperiod}{Jonas}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7242b40ed1ed821052456d14f316f10c}{Wester}{W\bibinitperiod}{Kenneth}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0208b2cee6b710359e73d313d92bfb0f}{Hydbring}{H\bibinitperiod}{Per}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=941da1a68856077a6d677ca510074ae2}{Bahram}{B\bibinitperiod}{Fuad}{F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=41e047a30ee4dfabede72d6548b93205}{Larsson}{L\bibinitperiod}{Lars-Gunnar}{L\bibinithyphendelim G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d03048f54c00fc181a549267fe5bb3a1}{Landegren}{L\bibinitperiod}{Ulf}{U\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{db6cd11d3d412b35656d19f1c8ddafa7}
      \strng{fullhash}{f492175778c77f3685ffe5453a02292f}
      \field{sortinit}{S}
      \field{sortinithash}{4125bb4c3a0eb3eaee3ea6da32eb70c8}
      \field{labelyear}{2006}
      \field{labelmonth}{12}
      \field{datelabelsource}{}
      \field{labeltitle}{{Direct observation of individual endogenous protein complexes in situ by proximity ligation}}
      \field{issn}{1548-7091}
      \field{journaltitle}{Nat Methods}
      \field{month}{12}
      \field{number}{12}
      \field{title}{{Direct observation of individual endogenous protein complexes in situ by proximity ligation}}
      \field{volume}{3}
      \field{year}{2006}
      \field{pages}{995\bibrangedash 1000}
      \verb{doi}
      \verb 10.1038/nmeth947
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2006/S{ö}derberg et al/S{ö}derberg et al. - 2006 - Direct observation of individual endogenous protein complexes in situ by proximity ligation.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/doifinder/10.1038/nmeth947
      \endverb
    \endentry
    \entry{Tanganelli2004}{article}{}
      \name{labelname}{10}{}{%
        {{uniquename=0,hash=02e89ebd949f1d4b23fcd5e18717219c}{Tanganelli}{T\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0609d7855e50b8ecaa92a44167f2ecf7}{{Sandager\bibnamedelimb Nielsen}}{S\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e6fc0a4e4c62590ae3127f242971a3c4}{Ferraro}{F\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b0a49472d23b0b07910507c461b2421c}{Antonelli}{A\bibinitperiod}{T}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3d076d649d686b60e1025ebdea9b029e}{Kehr}{K\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=db704d82e661984cef0d9b49bdd55bc4}{Franco}{F\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3f744a63ca07411116ce3244dbbb696a}{Ferr{é}}{F\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d41ece86096a17e5934a03c4e954d5b8}{Agnati}{A\bibinitperiod}{L\bibnamedelima F}{L\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c4b48e7715b5e6a77fb44f8c0dabaf97}{Fuxe}{F\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9ab82e2fc91331327092187eb98a2076}{Scheel-Kr{ü}ger}{S\bibinithyphendelim K\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{uniquename=0,hash=02e89ebd949f1d4b23fcd5e18717219c}{Tanganelli}{T\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=0609d7855e50b8ecaa92a44167f2ecf7}{{Sandager\bibnamedelimb Nielsen}}{S\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e6fc0a4e4c62590ae3127f242971a3c4}{Ferraro}{F\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b0a49472d23b0b07910507c461b2421c}{Antonelli}{A\bibinitperiod}{T}{T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3d076d649d686b60e1025ebdea9b029e}{Kehr}{K\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=db704d82e661984cef0d9b49bdd55bc4}{Franco}{F\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3f744a63ca07411116ce3244dbbb696a}{Ferr{é}}{F\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d41ece86096a17e5934a03c4e954d5b8}{Agnati}{A\bibinitperiod}{L\bibnamedelima F}{L\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c4b48e7715b5e6a77fb44f8c0dabaf97}{Fuxe}{F\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=9ab82e2fc91331327092187eb98a2076}{Scheel-Kr{ü}ger}{S\bibinithyphendelim K\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{47c415a2de1b7f5799d12bd07d0a9983}
      \strng{fullhash}{5ab07e6a13c52e489231d5bdf8ee522a}
      \field{sortinit}{T}
      \field{sortinithash}{9378dd666f3c24d81538df53aa99e23d}
      \field{labelyear}{2004}
      \field{labelmonth}{07}
      \field{datelabelsource}{}
      \field{labeltitle}{{Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.}}
      \field{abstract}{Behavioral and microdialysis studies have been performed on antagonistic A(2A)/D(2) interactions in animal models of Parkinson's Disease. The behavioral analysis involved studies on locomotor activity in reserpinized mice, haloperidol-induced catalepsy in rats and rotational behavior in rats with unilateral 6-OHDA lesions of the ascending DA pathways (Ungerstedt model). Dual probe microdialysis studies were indirectly performed on the striatopallidal GABA neurons by studying extracellular glutamate levels in the striatum and globus pallidus of the awake freely moving rat. The striatum was perfused with A(2A) and/or D(2) agonists via reverse microdialysis. The results show that the A(2A) antagonists SCH58261 and KF17837 can increase locomotor activity in reserpinized mice and produce contralateral rotational behavior only after administration of subthreshold doses of l-DOPA or the D(2) like agonist quinpirole. Furthermore, antagonizing the A(2A) receptor (R) reduced haloperidol induced catalepsy. The behavioral results underline the view that A(2A) antagonists act by blocking A(2A) R in A(2A)/D(2) heterodimers where A(2A) R inhibits the D(2) R transduction and D(2) inhibits the adenylate cyclase (AC) activated by A(2A) R. The microdialysis studies show that the A(2A) agonist CGS21680 striatally coperfused with the D(2) agonist quinpirole more potently counteract the D(2) agonist (quinpirole) induced reduction of pallidal glutamate levels in the DA denervated vs the control striatum indicating an enhancement of the inhibitory A(2A)/D(2) interaction. In the DA denervated but not in the control striatum the A(2A) agonist CGS21680 could strongly increase striatal glutamate levels, indicating an increased receptor signaling in the A(2A) R located on the striatal glutamate terminals, where also D(2) like R exist, here probably as D(4). Thus, the signaling of this A(2A) R may be set free by the loss of D(4) tone on the AC activated by A(2A) in this postulated A(2A)/D(4) heteromer on the glutamate terminals. Taken together, the results indicate that the antiparkinsonian actions of A(2A) antagonists probably are produced by blockade of A(2A) R in the A(2A)/D(2) heterodimers mainly located in the striatopallidal GABA neurons.}
      \field{issn}{1353-8020}
      \field{journaltitle}{Parkinsonism Relat Disord}
      \field{month}{07}
      \field{number}{5}
      \field{title}{{Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.}}
      \field{volume}{10}
      \field{year}{2004}
      \field{pages}{273\bibrangedash 80}
      \verb{doi}
      \verb 10.1016/j.parkreldis.2004.02.015
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/15196505
      \endverb
      \keyw{Adenosine A2 Receptor Antagonists,Animals,Corpus Striatum,Corpus Striatum: drug effects,Corpus Striatum: metabolism,Dopamine D2 Receptor Antagonists,Dose-Response Relationship,Drug,Female,Levodopa,Levodopa: pharmacology,Male,Mice,Nerve Net,Nerve Net: drug effects,Nerve Net: metabolism,Neuronal Plasticity,Neuronal Plasticity: drug effects,Neuronal Plasticity: physiology,Parkinson Disease,Parkinson Disease: metabolism,Pyrimidines,Pyrimidines: pharmacology,Rats,Rats,Sprague-Dawley,Rats,Wistar,Receptor,Adenosine A2A,Receptor,Adenosine A2A: metabolism,Receptors,Dopamine D2,Receptors,Dopamine D2: metabolism,Triazoles,Triazoles: pharmacology}
    \endentry
    \entry{Terrillon2004}{article}{}
      \name{labelname}{2}{}{%
        {{uniquename=0,hash=7b78b9de316c61bd35938fe2685e7334}{Terrillon}{T\bibinitperiod}{Sonia}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7ea48095889361f5fa9410c51a3acfa2}{Bouvier}{B\bibinitperiod}{Michel}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{uniquename=0,hash=7b78b9de316c61bd35938fe2685e7334}{Terrillon}{T\bibinitperiod}{Sonia}{S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7ea48095889361f5fa9410c51a3acfa2}{Bouvier}{B\bibinitperiod}{Michel}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ecdf528a1202d8c8f80a92e66156a9e9}
      \strng{fullhash}{934303f575e7936cf3295eb66dce7111}
      \field{sortinit}{T}
      \field{sortinithash}{9378dd666f3c24d81538df53aa99e23d}
      \field{labelyear}{2004}
      \field{labelmonth}{01}
      \field{datelabelsource}{}
      \field{labeltitle}{{Roles of G-protein-coupled receptor dimerization}}
      \field{abstract}{The classical idea that G-protein-coupled receptors (GPCRs) function as monomeric entities has been unsettled by the emerging concept of GPCR dimerization. Recent findings have indicated not only that many GPCRs exist as homodimers and heterodimers, but also that their oligomeric assembly could have important functional roles. Several studies have shown that dimerization occurs early after biosynthesis, suggesting that it has a primary role in receptor maturation. G-protein coupling, downstream signalling and regulatory processes such as internalization have also been shown to be influenced by the dimeric nature of the receptors. In addition to raising fundamental questions about GPCR function, the concept of dimerization could be important in the development and screening of drugs that act through this receptor class. In particular, the changes in ligand-binding and signalling properties that accompany heterodimerization could give rise to an unexpected pharmacological diversity that would need to be considered.}
      \field{isbn}{1469-221X (Print)$\backslash$n1469-221X (Linking)}
      \field{issn}{1469-221X}
      \field{journaltitle}{EMBO Rep}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Roles of G-protein-coupled receptor dimerization}}
      \field{volume}{5}
      \field{year}{2004}
      \field{pages}{30\bibrangedash 34}
      \verb{doi}
      \verb 10.1038/sj.embor.7400052
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2004/Terrillon, Bouvier/Terrillon, Bouvier - 2004 - Roles of G-protein-coupled receptor dimerization.pdf:pdf
      \endverb
      \verb{url}
      \verb http://embor.embopress.org/cgi/doi/10.1038/sj.embor.7400052
      \endverb
      \keyw{10,1038,2004,30,34,5,7400052,because it represents the,dimer,doi,embo reports,embor,g-protein-coupled receptor function,heterodimerization,homodimerization,oligomerization,refer systematically to the,regulation,sj,term}
    \endentry
    \entry{VonZastrow1994}{article}{}
      \name{labelname}{2}{}{%
        {{uniquename=0,hash=e271f90c50560c8b51e58eb906ac71db}{{Von\bibnamedelimb Zastrow}}{V\bibinitperiod}{Mark}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b4494fe9dadbd7bc3300ce3d94df9547}{Kobilka}{K\bibinitperiod}{Brian\bibnamedelima K.}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{uniquename=0,hash=e271f90c50560c8b51e58eb906ac71db}{{Von\bibnamedelimb Zastrow}}{V\bibinitperiod}{Mark}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b4494fe9dadbd7bc3300ce3d94df9547}{Kobilka}{K\bibinitperiod}{Brian\bibnamedelima K.}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{14fffd05b682b40bba67e21ab8c6e284}
      \strng{fullhash}{0ecedcc65aa9b34c3c00de172da9eab0}
      \field{sortinit}{V}
      \field{sortinithash}{63562d1af2cd68fb37e2e14e0c6d5c96}
      \field{labelyear}{1994}
      \field{datelabelsource}{}
      \field{labeltitle}{{Antagonist-dependent and -independent steps in the mechanism of adrenergic receptor internalization}}
      \field{abstract}{Epitope tagging and immunocytochemical techniques were used to examine the agonist-regulated internalization of human beta 2-adrenergic receptors in 293 cells. In the absence of agonist, receptors tagged with monoclonal antibody remain in the plasma membrane for > 1 h. In the presence of agonist, tagged receptors are endocytosed within 10 min. Endocytosed receptors are located in endosomes and can be recycled to the plasma membrane. In the prolonged presence of agonist, receptor endocytosis continues even after maximum sequestration of surface receptors (measured by radioligand binding to intact cells) has occurred. The process of receptor endocytosis requires cellular ATP and is temperature-dependent. At 4 degrees C, no agonist-induced redistribution of receptors located in the plasma membrane is observed. At 16 degrees C, agonist causes receptors to cluster in and around coated invaginations of the plasma membrane, but receptor endocytosis does not occur. Agonist treatment of cells at 16 degrees C, but not 4 degrees C, predisposes receptors to agonist-independent endocytosis upon warming to 37 degrees C. These studies suggest that: 1) beta 2-adrenergic receptors reside stably in the plasma membrane of untreated cells, while they continuously cycle between the plasma membrane and endosomes in the presence of agonist; 2) agonist regulates an early step in the endocytosis mechanism, which is associated with the redistribution of adrenergic receptors between distinct microdomains of the plasma membrane; and 3) later steps in the endocytosis mechanism do not require agonist and may utilize the same endocytic machinery that mediates the endocytosis of constitutively recycling receptors.}
      \field{issn}{00219258}
      \field{journaltitle}{J Biol Chem}
      \field{number}{28}
      \field{title}{{Antagonist-dependent and -independent steps in the mechanism of adrenergic receptor internalization}}
      \field{volume}{269}
      \field{year}{1994}
      \field{pages}{18448\bibrangedash 18452}
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/1994/Von Zastrow, Kobilka/Von Zastrow, Kobilka - 1994 - Antagonist-dependent and -independent steps in the mechanism of adrenergic receptor internalization.pdf:pdf
      \endverb
    \endentry
    \entry{Waldhoer2005}{article}{}
      \name{labelname}{8}{}{%
        {{uniquename=0,hash=28166a11401ef83caf0aacd03b3129ec}{Waldhoer}{W\bibinitperiod}{Maria}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ce6216867602fba133074f78688e93e3}{Fong}{F\bibinitperiod}{Jamie}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1e3e70839fbdf5c1454bd3539f713bbd}{Jones}{J\bibinitperiod}{Robert\bibnamedelima M}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d016a8fd379f4aa42152b2cc8020d4c6}{Lunzer}{L\bibinitperiod}{Mary\bibnamedelima M}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=51ad7991eef25ff9153820f5a50ab215}{Sharma}{S\bibinitperiod}{Shiv\bibnamedelima K}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=18394774de113a0b0cc4b820dbde1884}{Kostenis}{K\bibinitperiod}{Evi}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1b9ef4f82d1e8668afdb51c73d65e132}{Portoghese}{P\bibinitperiod}{Philip\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=68640b48e9db47feb12dbf5c18310fc6}{Whistler}{W\bibinitperiod}{Jennifer\bibnamedelima L}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{uniquename=0,hash=28166a11401ef83caf0aacd03b3129ec}{Waldhoer}{W\bibinitperiod}{Maria}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=ce6216867602fba133074f78688e93e3}{Fong}{F\bibinitperiod}{Jamie}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1e3e70839fbdf5c1454bd3539f713bbd}{Jones}{J\bibinitperiod}{Robert\bibnamedelima M}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d016a8fd379f4aa42152b2cc8020d4c6}{Lunzer}{L\bibinitperiod}{Mary\bibnamedelima M}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=51ad7991eef25ff9153820f5a50ab215}{Sharma}{S\bibinitperiod}{Shiv\bibnamedelima K}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=18394774de113a0b0cc4b820dbde1884}{Kostenis}{K\bibinitperiod}{Evi}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1b9ef4f82d1e8668afdb51c73d65e132}{Portoghese}{P\bibinitperiod}{Philip\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=68640b48e9db47feb12dbf5c18310fc6}{Whistler}{W\bibinitperiod}{Jennifer\bibnamedelima L}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{2be22361fbd960bedabc18c2655d46c3}
      \strng{fullhash}{04b2c124fbc19a23f1654fe7ca6b2710}
      \field{sortinit}{W}
      \field{sortinithash}{e560dae78a85a037c3da51c61467873a}
      \field{labelyear}{2005}
      \field{datelabelsource}{}
      \field{labeltitle}{{A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.}}
      \field{abstract}{There has been much speculation regarding the functional relevance of G protein-coupled receptor heterodimers, primarily because demonstrating their existence in vivo has proven to be a considerable challenge. Here we show that the opioid agonist ligand 6'-guanidinonaltrindole (6'-GNTI) has the unique property of selectively activating only opioid receptor heterodimers but not homomers. Importantly, 6'-GNTI is an analgesic, thereby demonstrating that opioid receptor heterodimers are indeed functionally relevant in vivo. However, 6'-GNTI induces analgesia only when it is administered in the spinal cord but not in the brain, suggesting that the organization of heterodimers is tissue-specific. This study demonstrates a proof of concept for tissue-selective drug targeting based on G protein-coupled receptor heterodimerization. Importantly, targeting opioid heterodimers could provide an approach toward the design of analgesic drugs with reduced side effects.}
      \field{isbn}{0027-8424 (Print)$\backslash$r0027-8424 (Linking)}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proc Natl Acad Sci U S A}
      \field{number}{25}
      \field{title}{{A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.}}
      \field{volume}{102}
      \field{year}{2005}
      \field{pages}{9050\bibrangedash 9055}
      \verb{doi}
      \verb 10.1073/pnas.0501112102
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2005/Waldhoer et al/Waldhoer et al. - 2005 - A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.pdf:pdf
      \endverb
    \endentry
    \entry{Ward2011}{article}{}
      \name{labelname}{3}{}{%
        {{uniquename=0,hash=5df662f6b64bb636e24a8eb01e0e456e}{Ward}{W\bibinitperiod}{Richard\bibnamedelima J.}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f8edde44ca16663957eb592175b17e54}{Pediani}{P\bibinitperiod}{John\bibnamedelima D.}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=65ce19b54b395e37b896e60b30df47e9}{Milligan}{M\bibinitperiod}{Graeme}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{uniquename=0,hash=5df662f6b64bb636e24a8eb01e0e456e}{Ward}{W\bibinitperiod}{Richard\bibnamedelima J.}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f8edde44ca16663957eb592175b17e54}{Pediani}{P\bibinitperiod}{John\bibnamedelima D.}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=65ce19b54b395e37b896e60b30df47e9}{Milligan}{M\bibinitperiod}{Graeme}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a844a7c2a4f7ea24f61d8a6b709b2b32}
      \strng{fullhash}{796bb4d3e7324cc3dd1d62524c170266}
      \field{sortinit}{W}
      \field{sortinithash}{e560dae78a85a037c3da51c61467873a}
      \field{labelyear}{2011}
      \field{labelmonth}{10}
      \field{datelabelsource}{}
      \field{labeltitle}{{Heteromultimerization of Cannabinoid CB1 Receptor and Orexin OX1 Receptor Generates a Unique Complex in Which Both Protomers Are Regulated by Orexin A}}
      \field{abstract}{Agonist-induced internalization was observed for both inducible and constitutively expressed forms of the cannabinoid CB(1) receptor. These were also internalized by the peptide orexin A, which has no direct affinity for the cannabinoid CB(1) receptor, but only when the orexin OX(1) receptor was co-expressed along with the cannabinoid CB(1) receptor. This effect of orexin A was concentration-dependent and blocked by OX(1) receptor antagonists. Moreover, the ability of orexin A to internalize the CB(1) receptor was also blocked by CB(1) receptor antagonists. Remarkably, orexin A was substantially more potent in producing internalization of the CB(1) receptor than in causing internalization of the bulk OX(1) receptor population, and this was true in cells in which the CB(1) receptor was maintained at a constant level, whereas levels of OX(1) could be varied and vice versa. Both co-immunoprecipitation and cell surface, homogenous time-resolved fluorescence resonance energy transfer based on covalent labeling of N-terminal "SNAP" and "CLIP" tags present in the extracellular N-terminal domain of the receptors confirmed the capacity of these two receptors to heteromultimerize. These studies confirm the capacity of the CB(1) and OX(1) receptors to interact directly and demonstrate that this complex has unique regulatory characteristics. The higher potency of the agonist orexin A to regulate the CB(1)-OX(1) heteromer compared with the OX(1)-OX(1) homomer present in the same cells and the effects of CB(1) receptor antagonists on the function of orexin A suggest an interplay between these two systems that may modulate appetite, feeding, and wakefulness.}
      \field{isbn}{0021-9258}
      \field{issn}{0021-9258}
      \field{journaltitle}{J Biol Chem}
      \field{month}{10}
      \field{number}{43}
      \field{title}{{Heteromultimerization of Cannabinoid CB1 Receptor and Orexin OX1 Receptor Generates a Unique Complex in Which Both Protomers Are Regulated by Orexin A}}
      \field{volume}{286}
      \field{year}{2011}
      \field{pages}{37414\bibrangedash 37428}
      \verb{doi}
      \verb 10.1074/jbc.M111.287649
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2011/Ward, Pediani, Milligan/Ward, Pediani, Milligan - 2011 - Heteromultimerization of Cannabinoid CB1 Receptor and Orexin OX1 Receptor Generates a Unique Complex in.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.jbc.org/cgi/doi/10.1074/jbc.M111.287649
      \endverb
    \endentry
    \entry{Wu2010}{article}{}
      \name{labelname}{15}{}{%
        {{uniquename=1,hash=73389fd2e38812db061609e401b90110}{Wu}{W\bibinitperiod}{B.}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a50c72551cd5be84679f08ac993e8423}{Chien}{C\bibinitperiod}{E.\bibnamedelimi Y.\bibnamedelimi T.}{E\bibinitperiod\bibinitdelim Y\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d55e789551e543d88b8e017e4872451d}{Mol}{M\bibinitperiod}{C.\bibnamedelimi D.}{C\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=653c39feff5845f2d58f1a5c3ab84d25}{Fenalti}{F\bibinitperiod}{G.}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3cb35c0c0a5778cada593535feadd516}{Liu}{L\bibinitperiod}{W.}{W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d664c39da296f6cc37c3cd1acfc4dff}{Katritch}{K\bibinitperiod}{V.}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e4b069074236f2c48ce691a65ce425c}{Abagyan}{A\bibinitperiod}{R.}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=17ec76ef56cf4fe55192f3f315cb4d94}{Brooun}{B\bibinitperiod}{A.}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c7cd5d9c7138b917e875118f601fbbd6}{Wells}{W\bibinitperiod}{P.}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2d63c72fab01d85483d6c19dc0503c55}{Bi}{B\bibinitperiod}{F.\bibnamedelimi C.}{F\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=853ec9958be20aa921c67565e682abea}{Hamel}{H\bibinitperiod}{D.\bibnamedelimi J.}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a4f39390dd318ac436b6f5eabf0ac2b1}{Kuhn}{K\bibinitperiod}{P.}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e9770b986a40614cd1fbc861bba9b0e3}{Handel}{H\bibinitperiod}{T.\bibnamedelimi M.}{T\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=213ea8b8ef8169222fd380505247be95}{Cherezov}{C\bibinitperiod}{V.}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a0b7fe261df2396ef762ae6192867317}{Stevens}{S\bibinitperiod}{R.\bibnamedelimi C.}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{15}{}{%
        {{uniquename=1,hash=73389fd2e38812db061609e401b90110}{Wu}{W\bibinitperiod}{B.}{B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a50c72551cd5be84679f08ac993e8423}{Chien}{C\bibinitperiod}{E.\bibnamedelimi Y.\bibnamedelimi T.}{E\bibinitperiod\bibinitdelim Y\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=d55e789551e543d88b8e017e4872451d}{Mol}{M\bibinitperiod}{C.\bibnamedelimi D.}{C\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=653c39feff5845f2d58f1a5c3ab84d25}{Fenalti}{F\bibinitperiod}{G.}{G\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=3cb35c0c0a5778cada593535feadd516}{Liu}{L\bibinitperiod}{W.}{W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4d664c39da296f6cc37c3cd1acfc4dff}{Katritch}{K\bibinitperiod}{V.}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e4b069074236f2c48ce691a65ce425c}{Abagyan}{A\bibinitperiod}{R.}{R\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=17ec76ef56cf4fe55192f3f315cb4d94}{Brooun}{B\bibinitperiod}{A.}{A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c7cd5d9c7138b917e875118f601fbbd6}{Wells}{W\bibinitperiod}{P.}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=2d63c72fab01d85483d6c19dc0503c55}{Bi}{B\bibinitperiod}{F.\bibnamedelimi C.}{F\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=853ec9958be20aa921c67565e682abea}{Hamel}{H\bibinitperiod}{D.\bibnamedelimi J.}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a4f39390dd318ac436b6f5eabf0ac2b1}{Kuhn}{K\bibinitperiod}{P.}{P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e9770b986a40614cd1fbc861bba9b0e3}{Handel}{H\bibinitperiod}{T.\bibnamedelimi M.}{T\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=213ea8b8ef8169222fd380505247be95}{Cherezov}{C\bibinitperiod}{V.}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a0b7fe261df2396ef762ae6192867317}{Stevens}{S\bibinitperiod}{R.\bibnamedelimi C.}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{366c38292456c2a73e7e703dbd8dcca6}
      \strng{fullhash}{77e9d221139432ed36e026357916fbd6}
      \field{sortinit}{W}
      \field{sortinithash}{e560dae78a85a037c3da51c61467873a}
      \field{labelyear}{2010}
      \field{labelmonth}{11}
      \field{datelabelsource}{}
      \field{labeltitle}{{Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists}}
      \field{issn}{0036-8075}
      \field{journaltitle}{Science (80- )}
      \field{month}{11}
      \field{number}{6007}
      \field{title}{{Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists}}
      \field{volume}{330}
      \field{year}{2010}
      \field{pages}{1066\bibrangedash 1071}
      \verb{doi}
      \verb 10.1126/science.1194396
      \endverb
      \verb{url}
      \verb http://www.sciencemag.org/cgi/doi/10.1126/science.1194396
      \endverb
    \endentry
    \entry{Wu2012}{article}{}
      \name{labelname}{16}{}{%
        {{uniquename=1,hash=ac0c6129cac5f6ed880a804a53c88505}{Wu}{W\bibinitperiod}{Huixian}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a938c8a8173b8ea4a55866a2ff8d05ef}{Wacker}{W\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e75d3b06a97af6f1a64ed79c1323c63}{Mileni}{M\bibinitperiod}{Mauro}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=beb06b53b5d9a31e80c094b12ba04f96}{Katritch}{K\bibinitperiod}{Vsevolod}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4a3bf88eae67a500af8e4b5c1ef58e71}{Han}{H\bibinitperiod}{Gye\bibnamedelima Won}{G\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=82241a0d0a30c9b099f09f879a936469}{Vardy}{V\bibinitperiod}{Eyal}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c0e0d23e2d09e45e6f51cc2bcea6d9f9}{Liu}{L\bibinitperiod}{Wei}{W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7697e7d5c5524c6cb608fab88a2e72b3}{Thompson}{T\bibinitperiod}{Aaron\bibnamedelima A}{A\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b1fb53b3cf40d964af67dd2479659fa1}{Huang}{H\bibinitperiod}{Xi-Ping}{X\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=805ea4c664aad86b8a79b48f3431806b}{Carroll}{C\bibinitperiod}{F\bibnamedelima Ivy}{F\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e2b01eae1ba6e1e78d9e31d88911597b}{Mascarella}{M\bibinitperiod}{S\bibnamedelima Wayne}{S\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=fef30b110e9281724afb93ee28fd9655}{Westkaemper}{W\bibinitperiod}{Richard\bibnamedelima B}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=788b9f4132c26fe3f9c4ccbc744eb373}{Mosier}{M\bibinitperiod}{Philip\bibnamedelima D}{P\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=85f25fba6066d253670f7e7018aec0ec}{Roth}{R\bibinitperiod}{Bryan\bibnamedelima L}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1a3634310c3b2b06eb166770ab5dda0e}{Cherezov}{C\bibinitperiod}{Vadim}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5e870ddd905b49881f1c106759b7acfc}{Stevens}{S\bibinitperiod}{Raymond\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{16}{}{%
        {{uniquename=1,hash=ac0c6129cac5f6ed880a804a53c88505}{Wu}{W\bibinitperiod}{Huixian}{H\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=a938c8a8173b8ea4a55866a2ff8d05ef}{Wacker}{W\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8e75d3b06a97af6f1a64ed79c1323c63}{Mileni}{M\bibinitperiod}{Mauro}{M\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=beb06b53b5d9a31e80c094b12ba04f96}{Katritch}{K\bibinitperiod}{Vsevolod}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=4a3bf88eae67a500af8e4b5c1ef58e71}{Han}{H\bibinitperiod}{Gye\bibnamedelima Won}{G\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=82241a0d0a30c9b099f09f879a936469}{Vardy}{V\bibinitperiod}{Eyal}{E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=c0e0d23e2d09e45e6f51cc2bcea6d9f9}{Liu}{L\bibinitperiod}{Wei}{W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=7697e7d5c5524c6cb608fab88a2e72b3}{Thompson}{T\bibinitperiod}{Aaron\bibnamedelima A}{A\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=b1fb53b3cf40d964af67dd2479659fa1}{Huang}{H\bibinitperiod}{Xi-Ping}{X\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=805ea4c664aad86b8a79b48f3431806b}{Carroll}{C\bibinitperiod}{F\bibnamedelima Ivy}{F\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=e2b01eae1ba6e1e78d9e31d88911597b}{Mascarella}{M\bibinitperiod}{S\bibnamedelima Wayne}{S\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=fef30b110e9281724afb93ee28fd9655}{Westkaemper}{W\bibinitperiod}{Richard\bibnamedelima B}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=788b9f4132c26fe3f9c4ccbc744eb373}{Mosier}{M\bibinitperiod}{Philip\bibnamedelima D}{P\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=85f25fba6066d253670f7e7018aec0ec}{Roth}{R\bibinitperiod}{Bryan\bibnamedelima L}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=1a3634310c3b2b06eb166770ab5dda0e}{Cherezov}{C\bibinitperiod}{Vadim}{V\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5e870ddd905b49881f1c106759b7acfc}{Stevens}{S\bibinitperiod}{Raymond\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{846a5b081604f2711620be9cc01005ed}
      \strng{fullhash}{ddf35a3cb499059ce372d76c86414fbe}
      \field{sortinit}{W}
      \field{sortinithash}{e560dae78a85a037c3da51c61467873a}
      \field{labelyear}{2012}
      \field{labelmonth}{05}
      \field{datelabelsource}{}
      \field{labeltitle}{{Structure of the human kappa-opioid receptor in complex with JDTic}}
      \field{annotation}{10.1038/nature10939}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{05}
      \field{number}{7398}
      \field{title}{{Structure of the human kappa-opioid receptor in complex with JDTic}}
      \field{volume}{485}
      \field{year}{2012}
      \field{pages}{327\bibrangedash 332}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature10939%20http://www.nature.com/nature/journal/v485/n7398/abs/nature10939.html%7B%5C#%7Dsupplementary-information
      \endverb
    \endentry
    \entry{Zhang2002a}{article}{}
      \name{labelname}{4}{}{%
        {{uniquename=0,hash=eb96d0b531eeac5c6b8b186634522d92}{Zhang}{Z\bibinitperiod}{Jin}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8c283cabb694a87cc95e2b6832d79bc7}{Campbell}{C\bibinitperiod}{Robert\bibnamedelima E}{R\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=90c65db5d1e5f033f50f25f0e08467a9}{Ting}{T\bibinitperiod}{Alice\bibnamedelima Y}{A\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=60bc2242671782c067c04f990be6ac64}{Tsien}{T\bibinitperiod}{Roger\bibnamedelima Y}{R\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{uniquename=0,hash=eb96d0b531eeac5c6b8b186634522d92}{Zhang}{Z\bibinitperiod}{Jin}{J\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=8c283cabb694a87cc95e2b6832d79bc7}{Campbell}{C\bibinitperiod}{Robert\bibnamedelima E}{R\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=90c65db5d1e5f033f50f25f0e08467a9}{Ting}{T\bibinitperiod}{Alice\bibnamedelima Y}{A\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=60bc2242671782c067c04f990be6ac64}{Tsien}{T\bibinitperiod}{Roger\bibnamedelima Y}{R\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{7acc8b64a1422194f4fffbaf725b68bb}
      \strng{fullhash}{2fa30f942daa0069dff68db974ca6668}
      \field{sortinit}{Z}
      \field{sortinithash}{9cca09897f0dfd9ed260e065f6d82cd6}
      \field{labelyear}{2002}
      \field{datelabelsource}{}
      \field{labeltitle}{{Creating new fluorescent probes for cell biology.}}
      \field{abstract}{Fluorescent probes are one of the cornerstones of real-time imaging of live cells and a powerful tool for cell biologists. They provide high sensitivity and great versatility while minimally perturbing the cell under investigation. Genetically-encoded reporter constructs that are derived from fluorescent proteins are leading a revolution in the real-time visualization and tracking of various cellular events. Recent advances include the continued development of 'passive' markers for the measurement of biomolecule expression and localization in live cells, and 'active' indicators for monitoring more complex cellular processes such as small-molecule-messenger dynamics, enzyme activation and protein-protein interactions.}
      \field{isbn}{1471-0072 (Print)$\backslash$r1471-0072 (Linking)}
      \field{issn}{14710072}
      \field{journaltitle}{Nat Rev Mol Cell Biol}
      \field{number}{12}
      \field{title}{{Creating new fluorescent probes for cell biology.}}
      \field{volume}{3}
      \field{year}{2002}
      \field{pages}{906\bibrangedash 918}
      \verb{doi}
      \verb 10.1038/nrm976
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2002/Zhang et al/Zhang et al. - 2002 - Creating new fluorescent probes for cell biology.pdf:pdf
      \endverb
    \endentry
    \entry{Zhu2002}{article}{}
      \name{labelname}{3}{}{%
        {{uniquename=1,hash=44dbb781507c37de3125e621b2882394}{Zhu}{Z\bibinitperiod}{Chang\bibnamedelima Cheng}{C\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5348a563a7b11bab31e4c86a27e3409f}{Cook}{C\bibinitperiod}{Laurie\bibnamedelima B.}{L\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f497e6dceacf761b52050fa3e3e6f7c3}{Hinkle}{H\bibinitperiod}{Patricia\bibnamedelima M.}{P\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{uniquename=1,hash=44dbb781507c37de3125e621b2882394}{Zhu}{Z\bibinitperiod}{Chang\bibnamedelima Cheng}{C\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=5348a563a7b11bab31e4c86a27e3409f}{Cook}{C\bibinitperiod}{Laurie\bibnamedelima B.}{L\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=f497e6dceacf761b52050fa3e3e6f7c3}{Hinkle}{H\bibinitperiod}{Patricia\bibnamedelima M.}{P\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8a9b109a34c02b0a717d328ec3ef809d}
      \strng{fullhash}{182156ae079f799c9fbcc0fd059b54b2}
      \field{sortinit}{Z}
      \field{sortinithash}{9cca09897f0dfd9ed260e065f6d82cd6}
      \field{labelyear}{2002}
      \field{datelabelsource}{}
      \field{labeltitle}{{Dimerization and phosphorylation of thyrotropin-releasing hormone receptors are modulated by agonist stimulation}}
      \field{abstract}{Dimerization and phosphorylation of thyrotropin-releasing hormone (TRH) receptors was characterized using HEK293 and pituitary GHFT cells expressing epitope-tagged receptors. TRH receptors tagged with FLAG and hemagglutinin epitopes were co-precipitated only if they were co-expressed, and 10-30{\%} of receptors were isolated as hemagglutinin/FLAG-receptor dimers under basal conditions. The abundance of receptor dimers was increased when cells had been stimulated by TRH, indicating that TRH either stabilizes pre-existing dimers or increases dimer formation. TRH increased receptor dimerization and phosphorylation within 1 min in a dose-dependent manner. TRH increased phosphorylation of both receptor monomers and dimers, documented by incorporation of (32)P and an upshift in receptor mobility reversed by phosphatase treatment. The ability of TRH to increase receptor phosphorylation and dimerization did not depend on signal transduction, because it was not inhibited by the phospholipase C inhibitor. Receptor phosphorylation required an agonist but was not blocked by the casein kinase II inhibitor apigenin, the protein kinase C inhibitor GF109203X, or expression of a dominant negative form of G protein-coupled receptor kinase 2. TRH receptors lacking most of the cytoplasmic carboxyl terminus formed dimers constitutively but failed to undergo agonist-induced dimerization and phosphorylation. TRH also increased phosphorylation and dimerization of TRH receptors expressed in GHFT pre-lactotroph cells.}
      \field{isbn}{0021-9258 (Print)}
      \field{issn}{00219258}
      \field{journaltitle}{J Biol Chem}
      \field{number}{31}
      \field{title}{{Dimerization and phosphorylation of thyrotropin-releasing hormone receptors are modulated by agonist stimulation}}
      \field{volume}{277}
      \field{year}{2002}
      \field{pages}{28228\bibrangedash 28237}
      \verb{doi}
      \verb 10.1074/jbc.M204221200
      \endverb
      \verb{file}
      \verb :Users/ska/Documents/thesis/literature/2002/Zhu, Cook, Hinkle/Zhu, Cook, Hinkle - 2002 - Dimerization and phosphorylation of thyrotropin-releasing hormone receptors are modulated by agonist stimulat.pdf:pdf
      \endverb
    \endentry
    \entry{Zhu1998}{article}{}
      \name{labelname}{2}{}{%
        {{uniquename=1,hash=a6ce5334b2c4a46c7f7d08b1b2f5bc23}{Zhu}{Z\bibinitperiod}{X}{X\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=319b80f0d13ed3ade6d6bad8caa65745}{Wess}{W\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{uniquename=1,hash=a6ce5334b2c4a46c7f7d08b1b2f5bc23}{Zhu}{Z\bibinitperiod}{X}{X\bibinitperiod}{}{}{}{}}%
        {{uniquename=0,hash=319b80f0d13ed3ade6d6bad8caa65745}{Wess}{W\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{e7d2e9369df8ce3c594dc388d1679123}
      \strng{fullhash}{d5414b8098f4625b4bdec91cbd20d5ed}
      \field{sortinit}{Z}
      \field{sortinithash}{9cca09897f0dfd9ed260e065f6d82cd6}
      \field{labelyear}{1998}
      \field{labelmonth}{11}
      \field{datelabelsource}{}
      \field{labeltitle}{{Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function.}}
      \field{abstract}{Accumulating evidence suggests that G protein-coupled receptors (GPCRs) can form dimeric or oligomeric arrays. Based on this concept, we have tested the hypothesis that truncated GPCRs can act as negative regulators of wild-type receptor function. Using the GS-coupled V2 vasopressin receptor as a model system, we systematically analyzed the ability of N- and C-terminal V2 receptor fragments to interfere with the activity of the wild-type V2 receptor coexpressed in COS-7 cells. Several N-terminal V2 receptor truncation mutants were identified that strongly inhibited the function (as determined in cAMP and radioligand binding assays) and cell surface trafficking of the coexpressed full-length V2 receptor. However, these truncation mutants did not interfere with the function of other GS-coupled receptors such as the D1 dopamine and the beta2-adrenergic receptors. Dominant negative effects were only observed with mutant receptors that contained at least three transmembrane domains. In addition, immunoblotting experiments showed that all V2 receptor truncation mutants displaying dominant negative activity (but not those mutant receptors lacking this activity) were able to form heterodimers with the full-length V2 receptor, suggesting that complex formation between mutant and wild-type V2 receptors underlies the observed inhibition of wild-type receptor function. Given the high degree of structural homology shared by all GPCRs, our findings should also be applicable to other members of this receptor superfamily.}
      \field{issn}{0006-2960}
      \field{journaltitle}{Biochemistry}
      \field{month}{11}
      \field{number}{45}
      \field{title}{{Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function.}}
      \field{volume}{37}
      \field{year}{1998}
      \field{pages}{15773\bibrangedash 84}
      \verb{doi}
      \verb 10.1021/bi981162z
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/9843382
      \endverb
      \keyw{Amino Acid Sequence,Animals,Antidiuretic Hormone Receptor Antagonists,Blotting,Western,COS Cells,Cell Membrane,Cell Membrane: genetics,Cell Membrane: metabolism,Dimerization,Down-Regulation,Down-Regulation: genetics,Humans,Ligands,Molecular Sequence Data,Mutagenesis,Insertional,Peptide Fragments,Peptide Fragments: antagonists {\&} inhibitors,Peptide Fragments: biosynthesis,Peptide Fragments: genetics,Peptide Fragments: metabolism,Protein Binding,Protein Binding: genetics,Receptors,Vasopressin,Receptors,Vasopressin: biosynthesis,Receptors,Vasopressin: genetics,Receptors,Vasopressin: metabolism,Signal Transduction,Signal Transduction: genetics,Transfection}
    \endentry
  \endsortlist
\endrefsection
\endinput

